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Abstract
The surgical removal o f primary tumours has been associated with the subsequent 
growth of previously dormant metastases. This accelerated growth has previously been 
ascribed to the removal o f the primary tumour and the anti-angiogenic factors they 
produce, such as angiostatin and endostatin. Endotoxin or lipopolysaccharide (LPS) is a 
cell wall constituent o f gram negative bacteria, ubiquitously present in air and 
endogenous gut bacteria, that may be introduced during surgery. LPS has been shown to 
be angiogenic and vascular endothelial growth factor (VEGF) is the most potent 
angiogenic cytokine identified to date. The role o f endotoxin in surgically induced 
metastatic tumour growth, the therapeutic use of anti-endotoxin agents in the peri­
operative period, the regulation o f VEGF expression by endotoxin and the effect of 
VEGF and endotoxin on tumour cell survival was examined.
A murine model of experimental metastasis was established where no primary 
tumour was present. This allowed the effect o f the surgical procedure on metastatic 
growth to be examined in the absence o f any possible angiostatin / endostatin effect. 
Animals undergoing open surgery or laparoscopy with air sufflation of the peritoneum 
displayed increased metastatic tumour burden, reflected in higher proliferation and 
lower apoptosis within the metastases. Circulating levels o f VEGF were also elevated in 
these groups and correlated with plasma levels of endotoxin. These changes were not 
observed in a group receiving laparoscopy with sterile C 0 2. Endotoxin injection resulted 
in similar effects, with increased metastatic burden and significantly higher serum 
VEGF levels than controls. The anti-endotoxin agent, rBPI21, reduced metastatic growth 
and serum VEGF levels in mice following LPS injection or open surgery, whereas the 
monoclonal antibody, E5, had no effect on tumour growth.
LPS increased tumour cell proliferation and VEGF production. Endotoxin also 
increased proliferation, decreased apoptosis and enhanced the production o f VEGF by 
endothelial cells and resulted in increased angiogenesis in vivo. LPS, through the 
induction o f VEGF, or VEGF alone increased Bcl-2 expression in tumour cells resulting 
in a significant decrease in tumour cell apoptosis. These results demonstrate that 
endotoxin plays a role in the enhanced growth o f metastases following surgical trauma 
by altering the critical balances governing tumour growth. Treatment with the anti­
endotoxin agent, rBPI2), blocked post-operative growth o f  metastases. Endotoxin 
regulates immune and tumour cell production o f VEGF. Furthermore, endotoxin, 
through the induction o f VEGF, or VEGF alone act as survival factors for tumour cells.
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Chapter 1
Introduction
1
Cancer is recognised as the second leading cause of death in modem society (21%), with 
only cardiovascular disease killing more people world-wide annually (35%) (WHO, 1998). 
Statistics from the World Health Organisation (WHO) report an estimated 10 million new 
cases yearly and 6.3 million world-wide deaths from cancer in 1996 alone (WHO, 1997). In 
Ireland there were over 20,800 cases of cancer with approximately 7,500 deaths in 1996 
(Irish Cancer Registry, 1999). Within Europe, Ireland has a relatively low incidence of male 
cancers, being 11th of the 20 countries assessed. Ireland ranked higher in the incidence of 
female cancers, being 4th of the 20. In Ireland, the risk of developing cancer before the age 
of 75 is 40% in men and 37% in women, while the risk of dying from the disease before the 
age of 75 is 17% in men and 12% in women.
World-wide, breast cancer is the most common malignancy in women with an 
incidence of 910,000 new cases in 1996, whereas lung cancer is the most common cancer in 
men with an incidence of 988,000 in 1996 (WHO). In Ireland, non-melanoma skin cancer is 
the most common cancer accounting for 30% of all cases. In women, breast cancer is the 
second most common accounting for 15%, whereas prostate is the second most common in 
men accounting for 11% of all cancers. With regard to breast cancer in Ireland, there were 
1695 new cases and 641 deaths in 1996 alone (Irish Cancer Registry, 1999). The risk of 
developing breast cancer before the age of 75 is 7.9% with an associated risk of death 
before the age of 75 at 2.8%. The mortality rate in patients diagnosed with breast cancer is 
currently 38%.
1.1 Cancer epidemiology
2
In every multi-cellular organism the cell numbers are tightly regulated by complex 
mechanisms that govern cellular proliferation, differentiation and the survival of individual 
cells. Deregulation of any of these processes results in alterations to the finite balances 
controlling cell numbers and consequently results in altered cellular growth (Holmgren et 
al., 1995). Cancer cells exhibit characteristics that indicate they have undergone extreme 
failure in the control of cellular growth at the genetic level. In such cases, changes in gene 
expression result in uncontrolled and disorganised cell growth. Numerous factors regulate 
the growth and development of cells. These include growth factors and growth factor 
inhibitors, their receptors, signal transduction proteins and nuclear proteins regulating 
cellular processes (Cox and Goding, 1991). Alterations in these growth control mechanisms 
have been attributed, at the genetic level, to changes in a subset of genes, oncogenes or 
tumour suppressor genes.
The development of cancer has been described as a two step process involving 
initiation and promotion. Initiation is described as mutations that occur facilitating 
cancerous growth at a later stage. Many factors such as ultraviolet (UV) radiation, cigarette 
smoke and free radical species are carcinogens that act as initiators causing DNA damage 
(Goldstein and Witz, 1990). Promotion occurs when the cell is triggered to grow in an 
uncontrolled fashion. Promotors can be factors causing similar DNA damage to that 
occurring in the initiation phase, or they may provide an environment that causes 
transformed cells to progress to form a tumour (Moustacchi, 1998). Either way the overall 
effect is for a single cell to be altered and proliferate rapidly. Over time, a hyperplastic 
lesion is formed which may or may not be further altered until its proliferative rate, state of 
differentiation and micro-environmental influences result in the development of a neoplasm
1.2 Development of cancer
which is capable of metastasising to distant organs. Uncoordinated growth of a 
heterogenous population of cancer cells results in organ destruction, loss of function and 
ultimately death.
Progression of the tumour is not controlled by genetic expression in the tumour cells 
alone. Solid tumours contain a variety of normal host cells including fibroblasts, smooth 
muscle cells, immune cells and endothelial cells (Foidart et al., 1994). Survival of the 
tumour is reliant on the support of these host cells, which the tumour can utilise to aid its 
growth, differentiation and subsequent spread.
1.3 Metastasis
The spread of tumours from the primary site to distant organs is the most clinically 
important property of malignant tumours and is termed metastasis. This process allows the 
cancer to survive surgical excision of the primary tumour, and forms the basis for geometric 
increases in tumour burden along with increasing the difficulty in its clinical management. 
Recurrence, as a consequence of metastases, is an alarming problem in all forms of cancer. 
Up to 50% of patients presenting with primary cancer are estimated to have established, but 
often clinically undetectable, metastatic deposits (Fidler and Ellis, 1994).
The formation of secondary deposits at distant sites is a complex multistep process. 
It begins with the emergence of a subpopulation of tumour cells within the primary tumour 
with increased metastatic potential which cross tissue boundaries and infiltrate 
neighbouring cellular populations. As the tumour grows, it requires a blood supply to 
provide fresh nutrients and remove harmful waste products, as diffusion alone becomes 
insufficient. Infiltrating blood vessels provide tumour cells with access to the circulation 
and thus a route to distant sites. Metastasising cells must leave the primary site, invading
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the extra-cellular matrix of adjacent tissues and migrate until they reach capillary or 
lymphatic linings. Then cells with the ability to penetrate basement membranes and 
insinuate between endothelial cells, intravasate and enter the circulation. At this point they 
are vulnerable to mechanical damage by shear forces and collisions as well as to 
immunesurveillance by the body’s defence mechanisms. Surviving cells must reattach to 
the interior of the blood vessel, extravasate, proliferate and develop a new vascular supply 
in order to form secondary tumours. Tumour cells unable to mobilise the appropriate 
biochemical and physiological responses at the correct moment in the metastatic process 
fail to progress any further in tumour dissemination. An overview of the main events in the 
metastatic spread of tumours is outlined in Fig. 1.1. The number of checkpoints illustrated 
here suggests why the majority of cells which are shed die in transit and how the process is 
highly selective for the cells which are most robust and suited to its demands. The lack of 
cells surviving the process is termed metastatic inefficiency. The evidence suggests that 
metastasis and metastatic inefficiency are determined by a series of random events, and that 
the presence of metastatic variants may alter the rate or efficiency with which metastasis 
occurs, but are not expected to determine whether they occur or not (Weiss, 1983). One 
example of the process of metastatic inefficiency was reported by Luzzi and colleagues 
after the intraportal injection of B16 melanoma cells in mice. Only 1 in 5,000 cells detected 
in the circulation after intra-portal injection progressed to form a macroscopic deposit 
(Luzzi et al., 1998). They reported that dormancy of solitary cells following successful 
extravasation, and limited survival of early micrometastases were responsible for the 
metastatic inefficiency observed in their study.
Studies on the pattern of secondary tumour growth have shown that the growth and 
development of metastases relies not only on the intrinsic properties of the disseminating
tumour cells described previously (i.e. the ‘seed’), but also on whether they arrive in a 
congenial tissue or organ (i.e. the ‘soil’). This ‘seed and soil’ hypothesis was originally 
proposed by Stephen Paget in 1889 following his observations on the distribution of 
metastases in breast cancer patients (Paget, 1889). The underlying mechanisms responsible 
for the distribution of metastases are not properly understood, however some evidence from 
clinical studies indicates that vascular drainage patterns and organ-specific factors may also 
be involved (Willis, 1973). The frequency of metastases in the lungs of patients with 
primary tumours draining into the pulmonary veins (incidence of approximately 40%) 
supports the vascular drainage mechanism. However, other patterns of metastases cannot be 
explained purely by circulatory anatomy. The high incidence of brain metastases in patients 
with carcinoma of the lung (approximately 30% compared to an overall incidence of 
approximately 5% in carcinomas generally) (Willis, 1973) and of bone deposits in breast 
cancer patients (approximately 70% compared to 20% for malignant tumours overall) 
(Paget, 1889; Lee, 1983) cannot be explained by vascular drainage patterns. These 
observations indicate that organ-specific factors, perhaps local paracrine hormones or other 
micro-environmental conditions at the secondary site, affect the survival and growth of 
metastatic cells and ultimately the pattern of metastases seen clinically.
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Fig. 1.1 : The multistep process o f metastasis.
1. A subset o f cells within the primary tumour acquire the metastatic phenotype.
2. Vascularisation o f the tumour occurs.
3. Invasion of the blood vessel.
4. Circulating tumour cells evade immune surveillance and mechanical destruction.
5. Arrest and extravasation o f the tumour cell in downstream organs.
6. Multiplication and vascularisation o f the secondary deposit at the distant site. 
(Fidler and Ellis, 1994)
Blood vessels are an essential requirement for any living tissue, providing a constant 
supply o f oxygen and nutrients and removing the harmful waste products o f  cellular 
metabolism. Angiogenesis is the process o f generating new capillaries from a pre­
existing blood supply (Folkman, 1982). In the developed adult, angiogenesis is the sole 
method for the formation o f new blood vessels (Tischer et al., 1991). The process is 
fundamental to healing, reproduction and embryonic development. The proliferation 
rate o f endothelial cells is very low compared to many other cells in the body. More 
than 1012 endothelial cells line the interior o f blood vessels covering an area o f 1000 m2 
in a 70 Kg adult (Jaffe, 1987). The turnover o f these cells can exceed 1000 days. Under 
normal physiological circumstances there is little need for new vessel formation, 
however the vasculature retains the ability to form new vessels if  necessary, for 
example following injury (Edgington, 1995).
Because angiogenesis is crucial to a number o f physiological processes it is 
tightly regulated. Angiogenesis is required within the female reproductive system for 
the development o f the corpus luteum, the endometrium during the menstrual cycle and 
the placenta throughout gestation (Reynolds et al., 1992; Wilting and Christ, 1996). 
Angiogenesis is also an essential component o f wound healing, delivering nutrients and 
immune cells to the wound site as well as removing wound debris (Arbiser, 1996). In 
both o f these circumstances angiogenesis is switched on for a brief period and is then 
completely inhibited.
Pathological angiogenesis occurs when the body loses its control over 
angiogenesis, resulting in either excessive or insufficient blood vessel growth. For 
instance, conditions such as venous ulcers, strokes and heart attacks may result from an 
absence o f angiogenesis that is normally required for natural healing (Szabo and
1.4 Angiogenesis
Vincze, 2000; Marti and Risau, 1999). On the other hand excessive angiogenesis is a 
feature o f a number o f pathological conditions including rheumatoid arthritis, diabetic 
retinophathy and psoriasis (Koch, 1998; Folkman and Shing, 1992; Malhotra et al., 
1989). However, the most serious consequence o f pathological angiogenesis is 
observed in tumour growth.
1.5 Tumour angiogenesis
Accumulating evidence indicates that progressive tumour growth is dependent on 
angiogenesis. Tumours can remain in situ for long periods o f time in an avascular, 
quiescent state. During this stage, the tumour may contain only a few million cells. 
Growth o f these avascular deposits require a subset o f the cells within the tumour to 
switch to an angiogenic phenotype. This switch to the angiogenic phenotype occurs 
when the local equilibrium between positive and negative regulators o f angiogenesis is 
tipped in favour o f blood vessel growth (Hanahan and Folkman, 1996). New blood 
vessels provide nutrients to proliferating cancer cells, thereby favouring tumour growth. 
On the other hand, capillaries provide a route for the delivery o f anti-neoplastic drugs, 
thus allowing the chemotherapeutic treatment o f cancer patients. Unfortunately, these 
new capillaries have incomplete basement membranes and as such are ‘leaky’, causing 
increases in interstitial pressure that limits drug diffusion within the tumour and favours 
tumour cell dissemination in the blood stream (Yuan, 1998).
There is substantial evidence that tumour growth is angiogenesis dependent 
(Folkman, 1990). The requirement o f angiogenesis for tumour growth was noted over 
50 years ago in a mouse sarcoma model. Tumours implanted sub-cutaneously in 
transplant chambers did not grow until the development o f new blood vessels was 
observed, after which growth was almost exponential (Algire et al., 1945). In another
experiment, a rat sarcoma in the chick chorioallantoic membrane (CAM) did not grow 
for 72 hours when no blood vessel supply was visible. However, tumour growth rapidly 
increased within 24 h o f the in-growth o f capillaries (Ingber et al., 1986). Similarly, 
homologous tumour implants grown in the anterior chamber o f the rabbit eye formed 
dormant spheroids because angiogenesis doesn’t occur at this site. The tumours 
remained viable for 34 days after which, when they were placed on the iris where 
vascularistaion could occur, they grew rapidly reaching 16,000 times their original size 
within 2 weeks and became locally invasive (Gimbrone et al., 1972). These 
experiments provide direct evidence that the acquisition o f a vascular supply from the 
host is essential for the local establishment o f a tumour.
The relationship between tumour angiogenesis and malignancy has also been 
investigated in an experimental model where diploid mouse fibroblasts were passaged 
subcutaneously and then separately assessed for their angiogenic potential using the 
CAM assay (Ziche and Gullino, 1982). Fibroblasts could initiate angiogenesis by 
passage 5, but malignancy began at passage 15, indicating that angiogenesis preceded 
the development o f the malignant phenotype. Recent evidence shows that angiogenesis 
suppression within tumours leads to a clinically dormant state where cellular 
proliferation is balanced by cell death enabling the tumours to reach an equilibrium 
with deposits limited to 2 mm3 (Holmgren et a l,  1995). There is evidence that 
angiogenesis occurs at an even earlier stage in tumour growth. In a study by Li et al. 
40-50 4T1 mammary carcinoma cells were injected into dorsal chambers in mice. 
Modification of the host vasculature was observed when tumour mass reached 
approximately 60-80 cells, and functional new blood vessels were seen when the 
tumour mass reached as little as 100-300 cells (Li et al., 2000).
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The use o f microvessel quantitation or extent o f  angiogenesis in solid tumours as a 
prognostic indicator in cancer has been the subject of intense investigation. The extent 
o f angiogenesis within tumour sections can be measured by staining the tumours for 
endothelial cell specific markers and then counting the number of blood vessels 
manually or estimating the percentage o f endothelial cells using an interactive image 
analysis system. The endothelial cell specific markers commonly used to date include 
factor VUI-related antigen, platelet endothelial cell adhesion molecule (PECAM or 
CD31) and CD34 antigen (Weidner et al., 1991; Horak et al., 1992; Goulding et al.,
1995). A number o f studies have demonstrated that breast tumours are significantly 
more vascularised than normal breast tissue or benign tumours (Horak et al., 1992; 
Goede et al., 1998). Increased vessel density within tumours has been associated with 
various clinical outcomes. Horak et al. (1992) found that the number o f vessels in 
primary breast tumours was associated with nodal metastases, as well as tumour size 
and grade. Microvessel counts and density grades have also been associated with 
metastatic disease and increased tumour aggressiveness in cancer o f the breast 
(Weidner et al., 1991; Bosari et al., 1992), non-small-cell lung cancer (Macchiarini et 
al., 1992), prostate cancer (Fregene et al., 1993) and squamous cell carcinoma of the 
head and neck (Albo et al., 1994). Recently, a study o f 531 breast cancer patients, with 
a follow-up greater than 6 years, reported microvessel density (MVD) to be a 
significant prognostic indicator for relapse-free and overall survival using multivariate 
models (Gasparini el al., 1998). However a number o f reports have disagreed with 
these findings, suggesting that MVD counts may be highly variable and of no 
prognostic significance (Goulding et al., 1995; Costello et al., 1995). Indeed, results 
from our laboratory suggest that the measurement o f VEGF as an indicator of
1.6 Tumour vascularisation
angiogenesis is more reliable prognostically than the measurement o f microvessel 
density (Callagy et al., 2000). In order for tumour vascularity to be used clinically as a 
reliable prognostic factor in cancer, standardisation o f quantitation methods needs to 
occur. Recent developments in technology in the area o f automated image analysis 
systems could provide the standardisation required to address these issues.
1.7 Steps in angiogenesis
In order to support continued tumour growth, the tumour vasculature constantly 
remodels itself and as such angiogenesis is an ongoing process continuing indefinitely 
until the tumour is removed or killed, or the host dies. The angiogenic process can be 
divided into four sequential steps:
1) Release o f tumour angiogenic factors (TAFs) and endothelial cell activation
2) Endothelial cell migration
3) Endothelial cell proliferation
4) Microvessel differentiation and lumen formation
A simplified version o f the process is shown in figure 1.2. The process of 
angiogenesis begins with the release o f tumour angiogenic factors (TAF) which diffuse 
into the surrounding tissue. Many o f these factors have been identified to date and a list 
o f some o f the most common is outlined in table 1.1. The release o f these factors is 
provoked by factors both endogenous and exogenous to the tumour cells including local 
environmental conditions, such as hypoxia (Battegay, 1995). The site o f action for these 
TAFs can vary considerably, some acting nearly exclusively on endothelial cells such 
as vascular endothelial growth factor (VEGF) (Jakeman et al., 1992), while others such 
as basic fibroblast growth factor (bFGF) act on fibroblasts, endothelial and smooth 
muscle cells (Gospodarowicz, 1990). Some angiogenic factors, such as bFGF, lack
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signal peptides necessary for extracellular secretion but are released from extracellular 
matrix and basement membranes by enzymatic cleavage (Klagsbrun and D ’Amore, 
1991). Other factors such as transforming growth factor-(31 (TGF(31) (Frater-Schroder 
et al., 1987), tumour necrosis factor-a (TNF-a) (Leibovich et al., 1987) and IL-6 
(Motro et al., 1990) inhibit the proliferation o f endothelial cells in vitro. They have 
been suggested to have an indirect mechanism o f action, such as the stimulation of 
other cells (e.g. macrophages) to release angiogenic factors. Alternatively, they may 
promote angiogenesis by causing endothelial cell differentiation (e.g. tube formation or 
matrix production) rather than endothelial proliferation (Klagsbrun and D ’Amore,
1991).
Each o f these angiogenic factors act with varying degrees o f potency with 
VEGF being the most potent identified to date. The relative importance o f each o f the 
angiogenic peptides as mediators o f tumour angiogenesis is uncertain. The majority of 
these factors are produced by tumour cells while others are released by immune cells in 
the tumour micro-environment following signals from the tumour cells. The first 
reaction to these tumour derived angiogenic factors is the activation of quiescent 
endothelial cells in the neighbouring vessels. The morphology o f the endothelial cells is 
altered in response to these factors, increasing their relative amounts o f endoplasmic 
reticulum, Golgi apparatus and mitochondria and the cells form protrusions on the 
abluminal side (Fox et al., 1996).
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Fig. 1.2 : Sequential steps in angiogenesis.
(A) Tumour or immune cells release tumour angiogenic factors (TAFs) which bind to 
receptors on endothelial cells. (B) Activated endothelial cells release proteolytic 
enzymes which degrade the extracellular matrix and migrate along a chemotactic 
gradient. (C) Endothelial cells proliferate at the base forming a capillary sprout. (D) 
Capillaries mature and a functional lumen allows the delivery o f oxygen and nutrients to 
support tumour expansion.
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Factor Endothelial Cell 
Mitogen
Reference
Acidic fiboblast growth factor 
(aFGF)
Positive (Thomas et al., 1985)
Angiogenin no effect (Kurachi et al., 1985)
Basic fibroblast growth factor 
(bFGF)
Positive (Gospodarowicz, 1990)
Colony stimulating factor (CSF) Positive (Bussolino et a l,  1991)
Epidermal growth factor (EGF) Positive (Stewart et al., 1989)
Insulin-like growth factor I 
(IGF-I)
n/a (Grant et al., 1993)
Interleukin-8 (IL-8) Positive (Strieter et al., 1992)
Platelet-derived endothelial cell 
growth factor (PD-ECGF)
Positive (Ishikawa et al., 1989)
Platelet-derived growth factor 
(PDGF)
Positive (R isaueia /., 1992)
Transforming growth factor-a 
(TGFa)
Positive (Schreiber et al., 1986)
Transforming growth factor-(3 
(TGF-p)
Inhibitor (Roberts et al., 1986)
Tumour necrosis factor-a 
(TNF-a)
Inhibitor (Frater-Schroder et al., 
1987)
Vascular endothelial growth 
factor (VEGF)
Positive (Connolly et al., 1989)
Table 1.1 : Endogenous protein angiogenic factors. [n/a= not assessed]
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In order for new vessel invasion to occur, degradation o f the extracellular matrix must 
happen. This is facilitated by the production of proteolytic enzymes including 
plasminogen activators (urokinase plasminogen activator (uPA) and tissue plasminogen 
activator (tPA)) and metalloproteinases (MMPs) secreted by endothelial, immune or 
tumour cells (Bacharach et al., 1992; Hiraoka et al., 1998). Urokinase plasminogen 
activator generates the broad spectrum protease plasmin which is capable o f degrading 
most matrix components (Fox et al., 1996). Inhibition o f this factor inhibited 
angiogenesis and tumour growth of B16 melanoma cells in a murine model (Brock et 
al., 1991). uPA receptors on endothelial cells may be increased by VEGF, and therefore 
VEGF can aid in the co-ordination of matrix degradation (Mandriota et al., 1995). 
Matrix degradation and remodelling is carefully controlled by alterations in the 
proteolytic balance (Pepper and Montesano, 1990).
Degradation o f the basement membrane allows the endothelial cells to 
accumulate in the region where the concentration o f angiogenic factors has first reached 
a threshold level. The endothelial cells from the capillary venules migrate and form 
sprouts. The capillary sprouts begin to grow by recruiting endothelial cells from the 
parent vessel. The endothelium initially forms a tube-like solid cord, but eventually 
intra- and inter-cellular spaces appear to form lumina (Folkman and Haudenschild, 
1980). The sprouting vessel is elongated by endothelial cell proliferation some distance 
from the top o f the sprout. The proliferation rate o f endothelial cells is some 40 times 
faster in tumours than in normal tissue where they are normally quiescent (Vartanian 
and Weidner, 1994).
Neighbouring sprouts eventually fuse together at their tips to form loops or 
anastomoses (Polverini, 1995). The looped vessels may bud or fuse with other vessels 
until a complex vascular network develops. These newly formed capillaries have wide
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cell junctions, numerous trans-endothelial channels and an irregular basement 
membrane (Fox et a l ,  1996). Vascular endothelial growth factor, also known as 
vascular permeability factor (VPF) causes hyper-permeability o f blood vessels within 
the tumour (Senger et a l,  1983). The capillary networks within tumours are therefore 
‘leaky’ due to their structure and the action of VEGF. These events are constant within 
the growing tumour, with new vessels being constantly recruited, therefore the tumour 
vasculature is highly unstable (Fox et a l ,  1996).
1.8 Vascular Endothelial Growth Factor
Vascular endothelial growth factor is the most potent directly acting angiogenic 
cytokine identified to date. Also known as vascular permeability factor (VPF), it was 
originally isolated from guinea pigs with hepatocellular carcinomas as a factor 
regulating permeability (Senger et a l,  1983). It was independently discovered as a 
soluble factor produced by bovine pituitary folliculo stellate cells that stimulated the 
growth o f adrenal endothelial cells (Ferrara and Henzel, 1989). Vascular permeability 
factor was subsequently found to be an angiogenic endothelial cell mitogen, and 
structural analysis by protein sequencing and cDNA cloning showed that the two 
proteins were identical (Connolly et al., 1989).
VEGF is an approximately 46-kDa homodimeric protein with heparin binding 
activity (Connolly et al., 1989). Molecular cloning has revealed at least 5 different 
isoforms containing 121, 145, 165, 189, and 206 amino acids respectively. All are 
encoded on a single gene and are generated by alternative splicing of the mRNA 
(Tischer et al., 1991; Poltorak et al., 1997). These isoforms differ in their properties due 
to the presence o f different exons. VEGF121 fails to bind heparin whereas VEGF|g9 and 
VEGF206 readily bind it (Houck et al., 1992). VEGF165 has weak heparin binding
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activity. These heparin binding affinities reflect their bioavailability, with VEGFt2l 
being secreted freely as a soluble protein, VEGFlgy and VEGF206 retained at the cell 
surface or extracellular matrix, and VEGF165 displaying intermediate behaviour, some 
being freely secreted and some apparently bound to the cell surface (Houck et al., 1992). 
VEGF145 is the most recently discovered isoform, with heparin binding activity that 
keeps it bound to the cell surface upon secretion (Poltorak et al., 1997). All iso forms 
contain glycosylation sites that are essential for efficient secretion but not for their 
biological activity.
All of the VEGF isoforms contain 8 cysteine residues required for both homo 
and hetero-dimerisation of the protein. They have a low overall homology with platelet 
derived growth factor (PDGF), another endothelial growth factor, but the location o f the 
cysteine residues is particularly conserved. Other members o f the same family of 
endothelial growth factors include, placenta growth factor (P1GF), PDGF-A and PDGF- 
B, VEGF-B, VEGF-C, VEGF-D, and VEGF-E (Maglione et al., 1991; Olofsson et al., 
1996; Joukov et al., 1996; Yamada et al., 1997; Ogawa et al., 1998). VEGF-B shares 
approximately 45% homology with VEGF and is expressed in a variety o f human 
tumours including melanomas, sarcomas, breast, and head and neck tumours (Salven et 
al., 1998). The remaining members vary in their degree of homology from 20-45%.
1.9 Regulation of VEGF
VEGF expression is regulated by a variety o f factors both intrinsic and extrinsic to the 
tumour cells. P1GF can significantly enhance the activity o f low levels o f VEGF by its 
binding to the VEGF type 1 receptor, Flt-1 (Park et al., 1998). PDGF has a more direct 
effect by enhancing the transcription of the VEGF gene (Finkenzeller et al., 1992). 
Epidermal growth factor (EGF) and transforming growth factor beta (TGFP) have also
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been shown to have similar effects in human malignant glioma cells, vascular smooth 
muscle cells and the monocyte like U937 cells, with TGFpi inducing a 1.8 fold increase 
in VEGF expression in the U937s (Goldman et ah, 1993; Brogi et ah, 1994; Dolecki 
and Connolly, 1991; Donovan et al., 1997). Other factors that can potentiate VEGF 
production include fibroblast growth factor 4 (FGF-4) (Deroanne et ah, 1997), tumour 
necrosis factor a  (Ryuto et al., 1996), keratinocyte growth factor (KGF) (Frank et ah,
1995), IGF-I (Goad et al., 1996), interleukin ip  (IL-ip) (Li et ah, 1995) and IL-6 
(Cohen et ah, 1996). Increased VEGF expression has also been reported following 
stimulation o f hormone receptors. Both oestrogen and progesterone have been shown to 
considerably increase VEGF mRNA expression (Cullinan-Bove and Koos, 1993). The 
prostaglandins E, and E2, which stimulate bone formation, a process strongly reliant on 
angiogenesis, have also been shown to increase VEGF mRNA and protein levels in an 
oesteoblastic cell line (Harada et al., 1994).
Hypoxia and hypoglycemia also stimulate VEGF expression (Shweiki et ah, 
1992; Harmey et ah, 1998). Hypoxia-induced transcription o f VEGF mRNA is 
mediated in part by the binding of hypoxia-inducible factor 1 (HIF-1) to a binding site 
in the VEGF promoter (Levy et ah, 1996; Liu et ah, 1995). This factor can also be 
induced by the oncogene v-src thereby overriding the hypoxia sensing mechanism and 
ultimately leading to increased VEGF expression (Jiang et ah, 1997). Hypoxia also 
promotes the stabilisation of VEGF mRNA by proteins that bind to sequences located in 
the 3’ untranslated region of the VEGF mRNA (Stein et ah, 1995; Claffey et ah, 1998).
Inactivation o f tumour suppressors is another mechanism whereby VEGF may 
be constitutively upregulated in tumour cells. The von Hippel Landau (vHL) suppressor 
gene has been shown to inhibit the production of many hypoxia-regulated proteins 
including VEGF (Siemeister et ah, 1996). This effect was shown to be mediated at both
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the transcriptional and post-transcriptional level, by SP1 binding and inhibition o f 
protein kinase C (PKC) activity, respectively (Mukhopadhyay et al., 1997; Iliopoulos et 
al., 1996). Binding o f the transcription factor SP-1 by von Hippel-Lindau protein has 
been shown to inhibit SP-1 mediated VEGF expression, and inhibition o f PKC results in 
decreased stability o f the VEGF mRNA as active PKC mediates the interaction of 
stabilising proteins with VEGF mRNA (Mukhopadhyay et ah, 1997; Levy et ah, 1996). 
P53 tumour suppressor gene can also regulate VEGF expression. Loss o f wild-type P53 
is associated with increased angiogenesis (Vanmeir et ah, 1994) and wild-type P53 was 
identified as an inhibitor o f VEGF (Mukhopadhyay et ah, 1995), while mutated P53 
potentiated its expression, mediated again by PKC (Kieser et ah , 1994)
1.10 VEGF receptors
The biological effects associated with VEGF are mediated by its binding to one of at 
least two receptors. The first, VEGFR-1, is fms-like tyrosine kinase (fit-1) and was 
shown to be a high-affinity receptor (KD ca. 20pM) for VEGF (DeVries et ah, 1992). 
The second one, VEGFR-2, fetal liver kinase 1 (flk-1) also known as kinase insert- 
domain receptor (KDR), has a lower binding affinity for VEGF with a KD of 75mM 
(Terman et ah, 1992). Both receptors are type III receptor tyrosine kinases containing 
seven immunoglobulin-like domains in their extracellular region, a transmembrane 
domain and two kinase domains separated by an interkinase linker (Terman et ah,
1992). Both receptors are predominantly expressed on endothelial cells (Peters et ah, 
1993; Quinn et ah, 1993), although some additional types of cells express one or both of 
the receptors. VEGFR-1 has been shown to be expressed on trophoblast cells 
(Chamockjones et ah, 1994), monocytes (Barleon et ah, 1996) and renal mesangial cells 
(Takahashi et al., 1995), while VEGFR-2 is also expressed on hematopoietic stem cells,
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megakaryocytes, and retinal progenitor cells (Katoh et al., 1995; Yang and Cepko, 
1996). They are reported to have different signal transduction properties resulting in 
different patterns o f responses (Waltenberger et al., 1994; Seetharam et al., 1995).
Both receptors are glycosylated, but in cells only expressing VEGFR-1, 
stimulation with VEGF induces no significant receptor autophosphorylation and no 
mitogenic response (Waltenberger et al., 1994). In contrast, VEGFR-2 can 
autophosphorylate upon stimulation with VEGF and is capable o f mediating a 
mitogenic response. In an experiment by Seetharam et al., NIH3T3 cells expressing 
recombinant VEGFR-2 phosphorylated phospholipase Cy (PLCy), GTP-ase activating 
protein (GAP) and mitogen activated protein kinase (MAPK) following treatment with 
VEGF, and a mitotic response was observed (Seetharam et al., 1995). When VEGFR-1 
was transfected into the same cells MAP kinase was not activated. It is therefore 
possible that VEGFR-1 does not induce cellular proliferation because it fails to activate 
MAP kinase.
Recently neuropilin-1, a receptor for the collapsin/semaphorin family that 
mediate neuronal cell guidance was identified as an iso form specific receptor for 
VEGF165 (Soker et al., 1998). It was previously recognised that these receptors existed 
and were not related to the VEGFR-1 or VEGFR-2 receptors, which bind both isoforms 
VEGF121 and VEGFI65 (Gitay-Goren et al., 1996). These receptors are expressed in 
unusually high amounts by many types o f prostate and breast cancer cells, including the 
MDA-MB-231 cell line (Soker et al., 1996; Soker et al., 1998). These neuropilin 
receptors, so called because receptors expressed on the MDA-MB-231 cells were found 
to be encoded by neuropilin-1, have short intracellular domains and are therefore 
unlikely to function as independent receptors. When cells expressing neuropilin-1, but 
no other VEGF receptor, were stimulated with VEGF no mitogenic activity or VEGF
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mediated chemotaxis in endothelial cells was observed (Soker et al., 1998). However, it 
has been shown to be crucial to blood vessel development as mouse embryos lacking a 
functional neuropilin-1 gene fail to develop a functional cardiovascular system and die 
(Kitsukawa et al., 1997). Recent studies have shown that neuropilin-1 acts as a VEGF,65 
co-receptor for VEGFR-2 potentiating its binding to the receptor and increasing the 
subsequent migratory response o f the cell (Soker et al., 1998). The identification of the 
neuropilin-1 receptor may explain why the VEGF12I isoform, which does not bind to 
this receptor, does not appear to be as strong a mitogen as VEGF165. Indeed more 
interestingly perhaps, is why there are substantial amounts of the receptor on tumour 
cells which appear to not express substantial amounts, if  any, o f the other VEGF 
receptors. Perhaps they may act as receptors for autocrine regulation of tumour cells by 
VEGF, or as mediators o f cross-talk between the tumour and endothelial cells, similar to 
that observed between inflammatory and endothelial cells (Krishnaswamy et al., 1999).
VEGF signalling in tumours requires the presence o f VEGF receptors in the 
vasculature adjacent to the tumour. For colon carcinoma it was shown that only the 
endothelial cells of nearby stromal blood vessels expressed the mRNA for both VEGF 
receptors. Endothelial cells located some distance from the tumour did not stain for 
either receptor (Brown et al., 1993a). Similarly in renal cell carcinoma, endothelial cells 
o f small tumour vessels stain strongly for the mRNA o f the two receptors (Brown et al., 
1993b). These data suggest that receptor expression is observed in vessels penetrating 
the tumour or adjacent to it, and is absent from endothelial cells of normal blood 
vessels. This implies that the tumour may secrete factors that are capable of 
upregulating the expression o f the VEGF receptors on endothelial cells, making them 
more susceptible to VEGF activation. One factor capable of inducing VEGF receptor 
expression is bFGF, which has been shown to up-regulate the mRNA for both receptors
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in human vascular endothelial cells (Barleon et al., 1994). Another factor capable of up- 
regulating VEGF receptor expression is heparin (Gitay-Goran et al., 1992; Terman et 
al., 1994). In addition to inducing receptor expression, low concentrations (0.1 - 1 
pg/ml) o f heparin can enhance the binding of VEGF to both receptors in bovine aortic 
endothelial cells (Gitay-Goren et al., 1992). Other micro-environmental factors such as 
hypoxia can induce VEGF receptor expression. This was shown in a cerebral slice 
culture system, where hypoxia increased VEGFR-2 expression (Kremer et al., 1997). In 
the same system addition o f VEGF increased VEGFR-2 expression, an effect that was 
lost by the addition of anti-VEGF antibodies. Recently VEGF has been shown to 
upregulate the expression o f KDR in human endothelial cells (Shen et al., 1998), 
indicating that VEGF can regulate its own receptor expression. The importance of the 
VEGF signalling system for its biological effects make it an attractive target for novel 
therapeutic strategies. Indeed the VEGF signal may be regulated by the production of a 
soluble VEGFR-1 binding VEGF with high affinity (Kendell and Thomas, 1993). 
Transfection of this soluble VEGFR-1 into human fibrosarcoma cells inhibited tumour 
growth, metastasis and mortality when implanted into nude mice (Goldman et al.,
1998). On the basis o f the body of knowledge available regarding the VEGF receptor 
system, many inhibitory compounds have been developed as a mechanism of regulating 
tumour angiogenesis, such as PTK inhibitors developed by Novartis.
1.11 Role of VEGF in tumour growth
VEGF is a potent mitogen for vascular endothelial cells, but it is devoid of mitogenic 
activity for other cell types (Ferrara and Henzel, 1989; Ferrara et al., 1992). It also 
promotes the migration o f endothelial cells, their invasion into collagen gels and their
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formation into tube-like structures. It has also been widely reported that VEGF 
specifically induces the formation and growth o f new blood vessels in the chick 
chorioallantoic membrane (CAM), the mesentery of the small bowel and comeal 
implants (Oh et a l,  1997; Norrby, 1996; Kenyon et al., 1996). Studies have shown that 
when VEGF signalling is inhibited, tumour angiogenesis and, consequently, tumour 
growth are impaired (Kim et al., 1993; Millauer et al., 1994). The angiogenesis- 
inducing activity of VEGF is accompanied by an increase in vascular permeability 
(Keck et al., 1989). This function o f VEGF may be implicated in the mechanism 
whereby tumour cells enter and leave the circulation to facilitate metastases.
At the cellular level, VEGF can increase the mRNA levels of plasminogen 
activators and plasminogen activator inhibitor-1 (PAI-1) in endothelial cells (Olofossen 
et al., 1996). It has also been shown to induce interstitial collagenase expression (Wang 
and Keiser, 1998). The induction o f plasminogen activators and collagenases promotes a 
pro-degradative environment that is necessary for the migration o f endothelial cells, 
whereas PAI-1 can serve to regulate and balance the process. Therefore it is obvious that 
VEGF can regulate multiple steps involved in the development of metastasis, and as 
such is more than just an endothelial cell specific mitogen.
The essential role o f VEGF in vessel formation can be seen as early as the 
development of the embryo. In mice embryos containing a homozygous VEGF 
deficiency (VEGF -/-) there was massive impairment o f vascular and cardiovascular 
development resulting in the death o f the embryos mid-gestation (Carmeliet et al.,
1996). Evidence for its role in the regulation o f tumour growth is strong. Embryonic 
murine stem cells with homozygous deficiencies for VEGF display dramatically 
reduced ability to form tumours in nude mice compared to normal stem cells, and the 
tumours that do form have significantly reduced blood vessel density (Ferrara et al.,
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1996). In addition administration o f monoclonal antibodies directed against VEGF 
inhibited the growth of a variety o f experimental tumours in mice including human 
rhabdomyosarcoma, glioblastoma and fibrosarcoma (Kim et al., 1993; Asano et al., 
1995; Borgstrom et al., 1996). VEGF is therefore a crucial factor in both the spread and 
development of tumours, and a potential target for tumour therapies.
1.12 Role of cell death in tissue maintenance
Cancer may be described as a net accumulation of mutated cells, which is generally 
attributed to excessive cellular proliferation. However, the overall size of cell 
populations is governed, not only by cellular proliferation, but by the homeostatic 
balance between cell production and cell death. Factors which interfere with the fine 
physiological tuning process regulating cell numbers could contribute to the 
development o f a neoplastic phenotype either by promoting cell proliferation and/or 
inhibiting cell death.
Cell death can occur by one of two processes. Necrosis is a result of acute, non- 
physiological injury (such as that following oxygen deprivation, a physical blow or at 
the site o f toxic action). This sort o f cell death is characterised by swelling o f the cell, its 
subsequent rupture and the release of the intercellular contents into the surrounding 
milieu, thus sparking an inflammatory response. Under normal circumstances 
inflammation limits infection and aids in the clearance of cellular debris. However, in 
extreme cases, the activities and secretions of white blood cells may result in damage to 
normal healthy tissue in the vicinity o f the original injury.
The second fonn o f cell death was discovered by Kerr et al. over 20 years ago 
and is termed ‘apoptosis’ (derived from the Greek word meaning ‘falling o ff)  (Kerr et 
al., 1974). This form of cell death, also termed ‘cellular suicide’, is a purposeful, self­
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destruction mechanism in which the cell plays an active role. Cells undergoing the 
‘programmed’ form o f cell death rapidly shrink, losing normal intercellular contact and 
subsequently exhibit chromatin condensation, nuclear fragmentation, cytoplasmic 
blebbing and cellular fragmentation into small apoptotic bodies (Wyllie, 1992). Unlike 
necrosis, the cytosolic contents are not released into the intercellular milieu and 
therefore no inflammation is triggered. Apoptotic cells are removed rapidly (within 
hours) by scavenging cells in the vicinity such as macrophages, thereby preventing 
either direct damage to neighbouring tissue and avoiding the possible adverse side 
effects of an inflammatory response.
Apoptotic cell death is an integral part of tissue modelling in vertebrate 
development (Duke et al., 1996). In general unwanted, injured, or virus-infected cells 
are eliminated by apoptosis. When this process is disturbed, severe diseases can result. 
Perhaps the most critical discovery was that o f the importance o f apoptosis in the 
pathogenesis of many fonns o f cancers and their likelihood to form resistance to many 
conventional apoptosis-inducing forms of therapy.
1.13 Regulation of apoptosis
Apoptosis is regulated by a number o f genes that influence cellular susceptibility to 
enter the process. The p53 gene is the most common gene associated with apoptosis. 
Mutations in the p53 gene and its regulators are very common, occurring in 50-70% of 
human cancers (Levine, 1997). p53 protein acts by inducing cell cycle arrest and 
apoptosis in response to DNA damage. In many tumours, genetic damage fails to induce 
apoptosis because the cells have an inactivated p53 gene. Loss of functional p53 
correlates well with tumour aggressiveness in a variety o f tumours. In addition, people 
carrying defects in either 1 or 2 o f the genes coding for p53 are clinically diagnosed
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with Li-Fraumeni syndrome and develop cancer at a much higher rates and incidence 
than the normal population (Hetts, 1998)
The p53 protein induces apoptosis by acting as a transcription factor, regulating 
many other apoptosis mediating genes. One of these mechanisms is through p53 
suppression o f Bcl-2 expression. Bcl-2 is an anti-apoptotic protein whose over­
expression has been reported in many forms of malignancy (Reed, 1994). The function 
o f this survival protein is thought to be in the protection o f cells whose loss would be 
detrimental to the body. Many normal cells, such as melanocytes, express relatively 
high levels o f  Bcl-2 and are subsequently more likely to give rise to aggressive tumours 
when they become cancerous (Solary et al., 1996). While Bcl-2 acts by suppressing 
apoptosis, other members of this family of proteins serve to induce apoptosis, working 
in conjunction with the anti-apoptotic members to regulate the process. Bcl-2 family 
members are capable o f forming dimers, often including homodimer and heterodimer 
pairs. When Bcl-2 is heterodimered with a pro-apoptotic member o f the family, Bax, its 
anti-apoptotic action is lost and apoptosis is induced. Interestingly, p53 has been shown 
to upregulate the expression of Bax in lung cancer cells and this is another possible 
mechanism whereby p53 induces apoptosis in cells (Pearson et al., 2000). In a study by 
Yin et al. it was reported that mice lacking the Bax gene developed fast growing 
tumours with 50% fewer apoptotic cells compared to similar tumours in non knock-out 
mice.
Other apoptosis-regulating genes include abl, c-myc and ras. Hence, it appears 
that even within cancer cells there are many different regulators of apoptosis. This in 
itself creates a further problem when designing treatments aimed at inducing apoptosis 
by disrupting the homeostatic balances regulating cancer growth.
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In many forms of cancer, secondary tumours may remain clinically asymptomatic and 
undetectable for months or years after primary tumour resection, only to reappear at a 
later date. The lag time between treatment and recurrence varies widely, and led to the 
speculation that the tumours undergo a dormant or ‘sleepy’ state with growth restraint 
for prolonged periods (Wheelock et al., 1981). Little is known about the cellular or 
molecular mechanisms controlling the fate o f these tumour cells during dormancy. It 
was initially viewed as a state in which tumour cells remained in Go and was 
characterised clinically as a state of remission. The long disease free survival associated 
with recurrence may be explained by one of two mechanisms. The first is founded on 
uninterrupted tumour growth, where tumour growth starts at the time o f seeding and 
continues until clinical recurrence is documented. In this scenario considerable 
interpatient variability is suggested and late recurrence denotes slower growing tumours. 
However, when the interval between excision and reappearance of the tumour as 
secondary foci exceeds periods such as 5 years, as it often does, it becomes increasingly 
difficult to believe that cellular proliferation in the residual tumour fragments has been 
continuous and uninterrupted.
Clinical studies o f tumour resection in melanoma and breast cancer patients 
dispel this theory and actually show that tumour cells can undergo a period of 
quiescence or dormancy followed by rapid growth during relapse (Crowley & Seigler, 
1992; Demicheli et al., 1994). This hypothesis claims that tumour deposits can remain 
‘dormant’ for prolonged periods and then resume their growth at a later date presumably 
following some critical event. Recent evidence and the discovery of the homeostatic 
balance governing cell growth lends credibility to this hypothesis. In such case, a 
population of cells may be considered dormant if  the net rate o f increase in tumour cell
1.14 Tumour dormancy
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numbers is equalled by the rate of cell loss. Recently Holmgren et al. (1995) linked the 
concept o f balanced proliferation and cell death with angiogenesis suppression into a 
unified hypothesis o f tumour dormancy in three experimental models. In addition, in the 
case o f dormant tumours the vast majority of cells may lack the angiogenic phenotype. 
Therefore, the reawakening of dormant cells may be explained by events leading to 
deregulated apoptosis, localised increases in survival or growth factors or induced 
neovascularisation.
1.15 Cancer treatment
Over the past couple o f decades significant progress has been made in the treatment of 
most forms o f cancer. These treatments have led to improvements in the survival of 
patients and consequent reductions in mortality rates. In the case of breast cancer, as 
with most other cancers, the choice o f systemic treatment depends on the tumour 
characteristics and stage o f the disease. Additional factors such as the patients age, state 
o f health, menopausal status and oestrogen receptor (ER) status also influence the 
modality o f treatment used in breast cancer. At present the main treatment options 
include surgery, chemotherapy, radiation therapy and endocrine therapy. Traditionally, 
endocrine therapy has been reserved for post-menopausal women, whereas combination 
chemotherapy is more commonly used in premenopausal women. Surgical removal of 
the tumour is the most common treatment for primary disease and is usually followed 
by adjuvant endocrine, radiation or chemotherapy.
A variety of chemotherapeutic drugs have been shown to induce extensive 
apoptosis in rapidly proliferating normal cells, lymphoid tissue and tumours. Thus, 
enhanced apoptosis is responsible for many of the adverse effects associated with 
chemotherapy such as alopecia, low blood count and infertility. However, induced
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apoptosis also occurs within the tumours and this is the ultimate aim of the 
chemotherapy or radiation therapy. Understanding that anti-cancer regimes mediate 
their therapeutic effects by triggering apoptosis explains some o f the possible 
mechanisms responsible for failed therapy. Apoptosis is a tightly regulated process that 
is capable o f being inhibited or activated. The failure of chemotherapy is due to the fact 
that in tumour cells the death program is often deregulated as described previously and 
therefore only a subset o f tumour cells are chemosensitive (Kerr, 1994). Thus the 
development of resistance to chemotherapy is a major clinical problem. Patients 
presenting with recurrent disease usually have tumours more resistant to chemotherapy 
than the primary tumour due to natural selection. In order to obtain successful 
antitumour therapy in all forms of cancer the self destruction mechanisms within 
tumours have to be activated in the tumour itself or in any remaining cells following 
radical tumour resection.
1.16 Anti-angiogenic therapy
As angiogenesis is essential for progressive tumour growth it constitutes a very 
promising therapeutic target. Successfully inhibiting tumour angiogenesis may represent 
a potential strategy to circumvent the problem of acquired therapeutic resistance to more 
'direct' anti-cancer agents caused by the genetic instability o f tumour cells (Kerbel, 
1991), as endothelial cells are less heterogenous and are therefore more stable targets. 
Angiogenesis is regulated at a number o f checkpoints and can be inhibited by 
decreasing the levels or effects o f angiogenesis factors, increasing levels of angiogenesis 
inhibitors, inhibiting the action o f proteases or by inhibiting endothelial cell 
proliferation, migration or tube formation. There is considerable evidence suggesting 
that targeting VEGF and/or its receptors can serve as an effective way of inhibiting
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tumour associated angiogenesis (Ferrara et al., 1996; Kim et a l ,  1993). Injection of 
tumour bearing mice with neutralising antibodies to VEGF inhibited tumour growth and 
resulted in the reversion o f growing malignancies to dormant micro-colonies (Ferrara et 
al., 1996; Borgstrom et al., 1996). Other tumour derived angiogenesis factors (TAFs) 
capable o f  stimulating angiogenesis in vivo, such as bFGF, have also been successfully 
targeted by using neutralising antibodies (Hori et al., 1991). Many other factors have 
shown promise as angiogenic inhibitors. Thrombospondin inhibits endothelial cell 
migration in vitro, and therefore can act as an angiogenesis inhibitor (Good et al., 1990). 
Linomide has been shown to be both cytostatic and inhibitory to endothelial 
chemotaxis, suggesting that its anti-angiogenic properties may account for its anti­
tumour effects observed in mice and rats (Vukanovic et al., 1995). Antibodies to a vp3- 
integrin inhibited angiogenesis in the CAM assay by inducing apoptosis in endothelial 
cells (Brooks et al., 1994).
To date more than 200 compounds have been reported to have anti-angiogenic 
properties (Holmgren and Bicknell, 1997). Two of the most recently identified o f these 
are angiostatin and endostatin. Produced by the cleavage o f plasminogen and collagen 
XVIII respectively, both are endogenous inhibitors o f tumour-related angiogenesis 
selectively inhibiting endothelial cell growth (O'Reilly et al., 1994; O'Reilly et al.,
1997). They have been shown to act by increasing apoptosis within endothelial cells, 
and angiogenesis suppression has been associated with tumour dormancy. Anti- 
angiogenesis strategies are numerous, reflecting the complexity of the process and the 
number o f levels at which intervention is possible. The list of agents is rapidly 
expanding and includes agents whose mechanism of action is as yet unidentified. As 
yet, success with this approach has been limited and confined to the experimental and 
clinical trial setting. However, it is very likely that anti-angiogenics will form an
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integral part of cancer treatment either alone or in combination with more conventional 
treatments.
1.14 Surgical removal of tumours
Surgery still remains the predominant method o f limiting the progression of solid 
tumour growth. However, at the time o f diagnosis, up to 50 % of cancer patients already 
have metastatic deposits (Fidler and Ellis, 1994). While the surgical procedure may 
prove beneficial in the removal o f macroscopic disease, there is evidence to suggest that 
the surgery may induce the rapid growth o f microscopic deposits (Arai et ah, 1992; 
Kodoma eta l., 1992).
Surgical removal o f the tumour may be associated with immunosuppression, 
tumour cell spill or alterations in the physiological balances that govern tumour growth 
and angiogenesis. Many studies detail suppressive effects o f surgery or trauma on host 
immune function. One such study outlined the effects o f surgical operations on the 
immune system in 35 patients with benign disease. Circulating lymphocyte sub­
populations fell significantly following surgery and the magnitude and duration of the 
reduction was related to the degree o f surgical trauma (Lennard et ah, 1985). Arai et ah 
(1992) reported modulation o f macrophage function following manipulation of primary 
melanoma in mice. Following the removal of the primary tumour, the growth of 
pulmonary metastases were enhanced significantly and this was related to a reduction in 
macrophage cytotoxicity and increases in prostaglandin E2 secretion by macrophages 
(Arai et ah, 1992). It is recognised that patients with advanced malignancy already 
suffer from depressed immune function as a consequence o f their disease (Angevin et 
ah, 1993). Surgical trauma may therefore further deplete an already depressed immune 
system resulting in ideal conditions for tumour growth (Lennard et ah, 1985).
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Tumour manipulation per se during surgery may increase tumour cell 
dissemination into the blood stream resulting in the seeding o f tumour cells in distant 
organs and the establishment of secondary deposits directly. In a study o f 61 patients 
undergoing a variety o f oncological operations, tumour cells were detected in the blood 
shed during surgery in 93% of patients, whereas 20% had circulating tumour cells at the 
end o f the surgical procedures (Hansen et al., 1995). Multiple local, systemic, host and 
tumour-related factors determine the fate o f these circulating tumour cells and whether 
they will ultimately seed and present clinically as metastatic lesions.
The concept o f minimally invasive surgery with its associated reduction in 
inflammatory responses stimulated by minimal trauma appeared to be a promising 
development. However, more recently, work has suggested that metastasis to wound 
sites following laparoscopic procedures may present real problems in minimally 
invasive cancer surgery (Bouvy et a l,  1996), whereas other reports suggest no benefit 
(Lacy et a l,  1998). In the first years o f laparoscopic surgery, incidences o f portal-site 
metastases as high as 21% were quoted for resection o f colorectal cancer, diagnostic 
laparoscopy for digestive cancer or laparoscopic removal o f gall bladders with occult 
cancer (Wexner and Cohen, 1995). These rates were probably due to poor surgical 
technique during early experience because more recent studies on larger patient bodies 
have documented incidences of port-site metastases as low as 2% (Ballantyne, 1995; 
Lord et a l,  1996). It has been suggested that insufflating gas into the peritoneal cavity 
augments the growth of cancer cells at portal sites. This has been attributed to gas 
turbulence increasing the transport of cells to the portal site and leakage o f gas around 
the trocar causing a 'chimney effect' and accumulation o f cancer cells (Kazemier et al., 
1995). However a growing body of evidence suggests that the minimally invasive 
laparoscopic procedures are associated with significant reductions in post operative
tumour growth (Allendorf et al., 1998; DaCosta et al., 1998). In a study by Allendorf et 
al. (1998), murine mammary carcinomas were more easily established and grew to 1.5 
times the size o f tumours in open cecectomy groups compared to controls receiving 
anaesthesia only. This was confirmed in another study by DaCosta et al. (1998) in 
which B16 melanomas grew significantly larger following open laparotomy compared 
to laparoscopy. These effects were suggested to be mediated at least in part by immune 
function, however other reports show that open surgery leads to translocation of 
abdominal bacterial endotoxin (Watson et al., 1995), which has been associated with 
increased tumour growth previously (Kawai et al., 1993).
In the light of restraints in the development of other therapies, it is likely that 
surgery will remain the primary treatment modality for most cancers and therefore 
research developments into its immunological and biological implications for the host 
may lead to better survival statistics in oncology patients.
1.15 Endotoxin
Septic shock is a clinical condition commonly occurring in post-operative patients in 
response to severe overwhelming infections with gram-negative organisms such as 
E.coli, P.aeruginosa, Klebsiella or Proteus. Characteristic clinical manifestations of the 
condition include fever and/or hypothermia, hypotension, cachexia and multiple organ 
failure, with an associated mortality o f greater than 50% (Brun-Buisson, 2000). The 
poor prognosis associated with septic shock has been attributed to the role o f endotoxin, 
or lipopolysaccharide (LPS).
Endotoxin, or lipopolysaccharide, is a cell wall constituent of most gram- 
negative, and some gram-positive bacteria that is capable of stimulating a wide variety 
of cell types including macrophages, polymorphonuclear leukocytes and endothelial
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cells (Ulevitch and Tobias, 1994). The stimulation of these cells initiates a cascade of 
events involving the release o f a number o f cytokines including TNF-a, IL-1 and IL-6 
that mediate a plethora o f  effects including changes to the micro-vasculature (Rietschel 
et al., 1994; Ulevitch and Tobias, 1994; Raetz, 1991). The overall result is an 
uncontrolled amplification o f the inflammatory response contributing to gram negative 
septic shock, characterised by increased vascular permeability (Brandtzaeg et al., 1995) 
and ultimately leading to organ failure, adult respiratory distress syndrome (ARDS) and 
death.
Endotoxin from Enterobacteria consist o f three structurally similar regions: the 
O antigen (a highly variable region), a core consisting primarily o f heptose and 2-keto- 
3-deoxyoctane (kdo) (a relatively conserved region) and the lipid A moiety (Raetz et al.,
1991). The majority o f biological activities associated with LPS have been attributed to 
the lipid A region. Recent studies have shown it to be the endotoxically active centre, as 
the deleterious effects observed with LPS are equally elicited by polysaccharide- 
deprived free lipid A (Galanos et al., 1984). The general structure o f lipopolysaccharide 
is outlined in Fig. 1.3. The initiation o f septic shock may be attributed to the binding of 
lipid A to its receptor (CD 14) on the surface o f a variety o f host cells leading to the 
production and release o f excess immunomodulatory proteins / cytokines. The CD 14 
receptor is a cell-
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Fig. 1.3 : Schematic representation of the structure o f endotoxin / lipopolysaccharide 
(LPS). [Reproduced from Raetz et al., 1991]
36
surface, 55-kDa phosphatidylinositol-linked protein on macrophages, monocytes and 
neutrophils (Schumann et al., 1990; Wright et al., 1990). The receptor recognises and 
binds complexes formed between LPS and circulating LPS binding protein (LBP) and 
septins. The LBP forms a complex with LPS and enhances the binding to CD 14 
manyfold. One molecule o f LBP is capable o f forming multiple LPS-CD14 complexes, 
therefore it acts as a lipotransferase (Tobias et al., 1989), meaning even small amounts 
of LPS are capable o f stimulating monocytes / macrophages.
Following binding to CD14, LPS activates a number o f protein tyrosine kinases 
(PTKs) such as p56, lyn, p58 and mitogen-activated protein kinase A (MAPK A) and 
leads to the mobilisation o f the ubiquitous transcription factor NF-kB (Weinstein el al.,
1992). This leads to the triggering o f  a wide range o f parallel signalling pathways 
resulting in the production o f a wide variety of cytokines, each capable o f binding to 
different receptors on cell surfaces and stimulating the production o f further chemicals 
and/or cytokines (Sweet and Hume, 1996).
1.16 Role of endotoxin in tumour growth / angiogenesis
Chronic inflammation has been implicated in the pathogenesis o f many forms o f cancer 
including gastric cancer following atrophic gastritis (Correa, 1992) and squamous 
carcinoma in draining sinuses o f chronic osteomyelitis (Schiller, 1988). Indeed, an 
epidemiological study on 2,982 bladder cancer patients in the US reported that a 
previous history o f urinary tract infection was a significant causal factor in their disease 
(Kantor et al., 1984). More recent studies on rats have taken these obsevations a step 
further by relating the development o f neoplasia with bacterial infections. Infection with 
heat killed E.coli significantly enhanced the growth of N-methyl-N-nitrosourea induced 
tumours in rats (Yamamoto et al., 1992). This increased growth was characterised by 6-
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40 fold increases in the number o f tumour nodules and marked capillary proliferation in 
the tumour stroma. In another study by Davis et a l,  long term infection with E.coli was 
associated with hyperplastic alterations, dysplasia and early lesions consistent with 
neoplasia (Davis et a l, 1984). Similar results have been reported by other authors, and 
the enhanced tumorigenesis associated with urinary tract infection has been shown to be 
due to lipopolysaccharide / endotoxin (Kawai et a l,  1993; Johansson et al., 1987). 
Higher tumour burden in these studies was associated with increased angiogenesis in the 
tumour stroma, suggesting a possible angiogenic mechanism of action for LPS.
Recent reports have shown that endotoxin is angiogenic, inducing 
neovascularisation in the rabbit corneal implant model (Li et a l ,  1991; BenEzra et al.,
1993) as well as in the rat mesentery (Mattsby-Baltzer et al., 1994). The latter report 
concluded that endotoxin mediated neovascularisation could be a component of 
inflammation and wound healing , as the doses used were realistic in the clinical setting 
(2ng/ml - 20(j.g/ml). Endotoxin may mediate its angiogenic activity through the 
induction of macrophages to secrete cytokines such as TNF-a, IL-1, IL-6 and bFGF, all 
o f which have previously been shown to promote angiogenesis (Austgulen & Nissen- 
Meyer, 1988; Motro et a l ,  1990; Fajardo et al., 1992). However, endotoxin can also 
stimulate human pulmonary arteiy endothelial cells to produce PDGF mRNA and 
PDGF-like protein (Albeda et a l,  1989). LPS has also been shown to upregulate the 
expression o f VEGF in pulp cells, through a sCD14 mechanism (Matsushita et al.,
1999). Therefore, LPS is capable o f stimulating the production o f multiple cytokines 
and angiogenic factors that may work alone or in parallel to mediate endotoxin induccd 
angiogenesis.
1.17 Anti-endotoxin strategies
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With the recognition that there was an unacceptably high mortality rate associated with 
sepsis, many anti-endotoxin strategies have been developed to block endotoxins 
activation o f cellular responses. These approaches include neutralising endotoxin before 
it interacts with the cell receptors, competition for the receptors, inhibition o f LPS 
induced signal transduction and reduction o f the inflammatory mediators produced 
following stimulation. With the realisation of a possible role for endotoxin in both 
tumour growth and angiogenesis, it is feasible that these strategies could be utilised in 
the inhibition o f endotoxin induced effects on tumour growth.
One molecule that has been given a lot o f attention is bactericidal permeability 
increasing protein (BPI) which is released from polymorphonuclear leukocytes with 
unique antibacterial activity to specifically kill and permeabilise gram-negative bacteria 
(Marra et a l ,  1992). Its specificity results from avid binding o f the protein to the LPS 
constituent o f the bacterial wall and it also shares striking homology (45%) to the LPS- 
binding protein LBP (Abrahamson et a l,  1997). This homology suggests that BPI is 
part o f the mechanism whereby the human host regulates its response to bacterial 
endotoxin. BPI blocks LPS by binding with a high affinity and preventing the LBP-LPS 
interaction which is required before binding to the CD 14 receptor. BPI has been shown 
to inhibit endotoxin induced TNF-a secretion both in-vivo and in-vitro in human 
macrophages (Marra et al., 1992) and to significantly reduce the LD50 in mice (Marra 
et a l ,  1994). LPS binding is a property o f the N-terminal fragment o f BPI and LBP, 
while the C-terminal region o f LBP is required for its interaction with CD 14 
(Abrahamson et al., 1997). The N-terminal fragment o f BPI has been isolated and 
characterised (Elsbach, 1994) and is up to 30 times more potent than holo-BPI, 
possessing essentially all o f BPI’s endotoxin-neutralising activity. The mechanism 
whereby BPI interferes with LPS mediated effects is outlined in Fig. 1.4.
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Another method of neutralising endotoxin is by targeting its active Lipid-A 
moiety. Recently a new lipid A antagonist termed E5531 has been synthesised that is 
non-toxic, derived from the lipopolysaccharide o f Rhodobacter capsulatus (Christ et al., 
1995). This compound proved therapeutic in mice, reducing the lethality to E.coli under 
antibiotic treatment. Another lipid A binding murine monoclonal antibody, E5, had been 
shown to have some promise in humans reducing morbidity and mortality in sepsis 
patients (Greenman et al., 1991; Greenberg et a l,  1992). However, other reports found 
both HA-1A and E5, two monoclonal antibodies directed against the lipid A moiety, to 
have unsatisfactory endotoxin-neutralising activity in vivo (Baumgartner et a l,  1991; 
Warren et al., 1993; Young et a l, 1989). Indeed the latest comparative study comparing 
E5, HA-1 A and BPI reported that neither monoclonal antibody was as effective as BPI 
at binding or neutralising the effects o f LPS in vitro or in vivo (Marra et al., 1994), and 
since then E5 has been removed from clinical trials.
As membrane CD 14 is required for the myeloid cell responses to LPS it is 
feasible that a soluble form of the receptor may inhibit LPS activation o f cells and 
therefore thus may be an effective therapeutic target for endotoxin shock. A 
recombinant form of the soluble receptor, rsCD14, was produced using a Baculovirus 
expression system and was effective in inhibiting TNF-a release by human 
mononuclear cells (Haziot et al., 1994). It was also found that mice treated with this 
rsCD14 and LPS had 100% survival compared to mice receiving saline and LPS (100 
f ig ) , in which there was a 60%  mortality rate. At present the clinical use o f anti­
endotoxin agents is still being assessed. Whether any of these agents may prove 
effective in reducing endotoxin induced angiogenesis and subsequent tumour growth is 
as yet undetermined.
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Fig. 1.4 : Mechanism whereby BPI and LBP regulate LPS activity.
1.18 Aim
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The surgical removal o f a primary tumour is often associated with a subsequent growth 
o f previously dormant metastases. The growth o f  these tumour deposits is regulated by 
the balances governing proliferation and apoptosis within the cellular population, as 
well as those regulating angiogenesis within the metastases. Endotoxin or 
lipopolysaccharide, a cell wall constituent o f gram-negative bacteria, is ubiquitously 
present in air and may be introduced during surgery. Having previously been shown to 
induce angiogenesis, endotoxin is a potential angiogenic and metastatic candidate in 
cancer. Vascular endothelial growth factor is the most potent pro-angiogenic factor 
identified to date and is regulated by a number o f factors. The aims o f this thesis were as 
follows:
• Determination o f the effect o f surgery on metastatic tumour growth by examining the 
balances governing their growth and the levels of post-operative serum VEGF and 
plasma endotoxin in a murine model o f experimental metastasis.
• Determination o f the effect o f endotoxin on metastatic tumour growth and 
angiogenesis in a murine model, and the examination o f the potential therapeutic use 
of anti-endotoxins to reduce endotoxin- and surgically-induced metastatic tumour 
growth.
• Elucidating the role o f endotoxin in the regulation o f VEGF and examination of 
endotoxin’s angiogenic potential in vivo.
• Examination o f the role o f VEGF and endotoxin as survival factors for tumour cells.
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Chapter 2
Materials and Methods
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2.1 Preparation and handling of reagents
General lab chemicals were o f analytical grade and were purchased from Sigma Chemical 
Company (St. Louis, Mo, USA) and BDH Chemicals Ltd. (Poole, UK) unless otherwise 
stated. All chemicals and reagents were stored according to the manufacturers instructions. 
Solid chemicals were weighed using a Sartorius analytical AC 1215 electronic balance 
(Gottingen, Germany) and prepared in sterile distilled water (SDW) with a conductivity of 
greater than 18 m il The pH of solutions was measured using a radiometer PHM82 pH 
meter (Copenhagen, Denmark). Following preparation, solutions were autoclaved within a 
few hours. Liquid transfer for volumes less than and including 1 ml were carried out using a 
designated set o f Gilson pipettes and for volumes greater than 1 ml an electronic pipette aid 
was used (Drummond, Broomall, PA, USA) with plastic pipettes (Sarsedt, Wicklow, 
Ireland).
2.2 Cell Culture
All cell culture work was carried out in an aseptic manner within a grade II laminar air flow 
cabinet (Holten LaminAir HB2436, Allerod, Denmark). The cabinet was switched on at 
least 20 min prior to use. The cabinet was sanitised thoroughly using 70% (v/v) isopropyl 
alcohol (IPA). All equipment and reagents were sanitised in a similar manner before being 
brought into the cabinet. Disposable gloves and a clean lab coat with elasticated cuffs were 
worn at all times. Following completion o f work, the cabinet was cleaned again and air 
allowed to circulate for at least 20 min.
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2.2.1 Breast Cancer Cell lines
Two breast cancer cell lines were used for the duration o f this project. Murine mammary 
metastatic 4T1 cells were a gift from Mr. E. Coveney (Waterford Regional Hospital, 
Ireland) and Fred Miller (Duke Univ. Ms, US). Human mammary metastatic MDA-MB- 
231 (ECACC92020424) cells, isolated from a pleural effusion, were purchased from the 
European Cell and Culture Collection (ECACC). 4T1 cells were maintained in Roswell 
Park Memorial Institute medium (RPMI) 1640 supplemented with 10% (v/v) heat- 
inactivated foetal calf serum (FCS), 100 U/ml penicillin and 100 fjg/ml streptomycin 
sulfate in 25 cm2 or 75 cm2 vented flasks at 37°C in a humidified atmosphere of 5% C 0 2 
(Forma Scientific 3193 Water Jacket Incubator, Ohio, USA). MDA-MB-231 cells were 
maintained in Leibovich L-15 medium supplemented with 10% (v/v) heat-inactivated FCS 
with antibiotics at 37°C. L I5 is a C 0 2 independent medium and therefore sealed flasks were 
used. FCS was heat inactivated by incubating at 56°C for 15 min and stored in 50 ml 
aliquots at -20°C. For experiments requiring cells to be plated in 12, 24 or 96-well plates 
MDA-MB-231 cells were cultured in Dulbelco’s Modified Eagle’s Medium (DMEM) with 
no loss of viability or obvious morphological changes. RPMI, LI 5, DMEM and FCS were 
obtained from Gibco-BRL (Paisley, Scotland). Tissue culture flasks were from Sarsedt 
(Wicklow, Ireland).
2.2.2 Cell Subculture
Cells were examined daily using an inverted phase contrast microscope (Nikon TMS, 
Tokyo, Japan) and sub-culturing was performed when the cells reached 80-90% confluency. 
Both cell lines in this study grew in an anchorage dependent manner forming a monolayer
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of cells. Cells were detached by trypsinastion for subculturing. Growth medium was 
decanted and cells were washed with 5 mis o f 0.01M phosphate buffered saline (13.8 mM 
NaCl, 2.7 mM KC1, pH 7.4) (PBS) to remove residual FCS. 1 ml (25 cm2 flasks) or 2.5 mis 
(75 cn r flasks) o f trypsin-ethylenediamine tetracetic acid (EDTA) (0.05% (w/v) trypsin, 
0.02% (w/v) EDTA) (Gibco BRL, Paisley, Scotland) was added to the flasks. Flasks were 
incubated at 37°C for approximately 5 min when the cells had clearly detached from the 
flask surface. 10 mis o f complete medium (medium containing 10% FCS) was added and 
cells were transferred to a sterile tube and pelleted by centrifugation (MSE Instruments 
Mistral 2000, London, UK) at 300 X g for 5 min. Following centrifugation, the supernatant 
was discarded and the cell pellet resuspended in 5 - 10 ml o f complete medium and this 
suspension was used to seed fresh flasks at a ratio between 1:6 and 1:12. 5 ml or 10 ml of 
complete medium was added to the cells in 25cm2 and 75cm2 flasks respectively. Cells were 
then maintained as described (2.2.1).
2.2.3 Preparation of frozen cell culture stocks
Cell stocks were stored frozen under liquid nitrogen in a cryofreezer (L ’air Liquide 
RCB40A. Champigny, France). The stocks were prepared from cells growing in log phase 
at less than 80% confluency. When frozen stocks were being prepared cells were washed 
with 5 ml PBS and trypsinised as above (2.2.2). Trypsinised cells were layered carefully on 
a cushion o f 2 - 3 ml FCS and pelleted by centrifugation at 300 X g for 5 min. FCS was 
decanted and the cell pellet was resuspended in 2 ml of FCS. An equal volume of 10% (v/v) 
dimethyl sulfoxide (DMSO) in FCS was added dropwise to the cell suspension mixing 
between each addition. 1.5 ml aliquots were added to cryo vials and placed in a styrofoam
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rack at - 80°C for 24 h. Following this, the vials were transferred to the liquid nitrogen tank 
for long term storage.
2.2.4 Revival of stored cells
Cryovials were removed from liquid nitrogen and placed at 37°C to thaw rapidly. Cells 
were transferred to a centrifuge tube and 10 mis o f complete medium was added. The cells 
were pelleted by centrifugation at 300 X g for 5 min. The supernatant was decanted and the 
pellet o f cells resuspended in 7 ml of complete medium and transferred to a 25cm2 flask. 
Cells were moved to the incubator and stored at 37°C for 24 h. The medium was replaced 
the following day to remove any dead cells, and the flasks maintained and passaged as 
previously described (2.2.2).
2.2.5 Human Umbilical Vein Endothelial Cells
Human Umbilical Vein Endothelial Cells (HUVECs) were isolated from fresh human 
umbilical cords by an experienced technician and used in experiments over a maximum of 4 
passages. In brief, fresh cords were thoroughly cleaned using 70% alcohol in a laminar air 
flow cabinet. A sterile catheter was inserted and the cord was flushed with PBS buffer 
containing penicillin (250(j,g/ml), streptomycin sulfate (250pg/ml) and fungizone 
(0.625fjg/ml). Thereafter the cord was filled with 20 ml o f 0.1% collagenase I until 
distended, tied off and incubated at 37°C for 20 min. Following this the cord was massaged 
lightly to free cells from underlying collagen / smooth muscle layer. This was continued by 
pinching and stripping down the length o f the cord. The contents o f the cord were then 
emptied into a Falcon tube and 20 ml o f M199 medium containing 20% FCS was added to
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inactivate the collagenase. The suspension was centrifuged at 300 x g for 10 min and 
resuspended in 5 ml of M199 containing 20% FCS. The cells were transferred to a culture 
flask coated with gelatin and 150 ml o f endothelial cell growth factor (ECGF) was added. 
Cells were incubated at 37°C in a 5% C 0 2 atmosphere and subcultured as described 
previously, however a 0.1% trypsin solution was used and all plastics were coated in gelatin 
prior to seeding the HUVECs.
2.2.6 Cell Counting
Suspensions of cells were counted using a Neubauer haemocytometer slide. Viability of 
cells was examined using a trypan blue dye exclusion assay. 20 pi o f the cell suspension 
was added to 180 pi of trypan blue dye. The mixture was allowed to stand for 1 min and 
then approximatey 10 pi added to the counting chamber o f the slide (enough to fill the 
compartment fully). Viable cells had an intact cellular membrane and appeared white while 
dead cells appeared blue due to a damaged cell membrane. The four comer squares o f the 
grid, each 1mm2 in size, were counted and the number o f viable cells calculated using the 
following equation:
„ , , No.Cells Counted x 10,000x lO(dilutionfactor)
cells / ml =   ---------
4
2.2.7 Mycoplasma testing of cells
When first receiving cell cultures all stocks were examined for mycoplasma contamination. 
Thereafter all cell lines were routinely examined for mycoplasma every 6 months. A 
commericial PCR ELISA (Boehringer Mannheim, Mennheim, Germany) was used for
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mycoplasma testing according to the manufacturers instructions. However the ELISA part 
of the test was omitted. In brief, 1 ml o f medium from the flask o f cells to be tested was 
taken. Cellular debris was removed by centrifugation at 300 X g for 5 min. The supernatant 
was removed and mycoplasma were pelleted by centrifugation at 13,000 X g for 10 min. 
The supernatant was decanted and the pellet was resuspended in 10 jo.1 o f sterile distilled 
water (SDW). A positive control (supplied with the kit) and a negative control (SDW) was 
also included with each batch of samples. 10 jj.1 of lysis reagent was added and the mixture 
was incubated for 1 h at 37°C. 30 fil of neutralisation buffer was added per tube. Thereafter 
10 [¿1 o f this sample was mixed with 25 fil o f PCR ready-to-go solution and 10 (il of SDW 
in a PCR thermo-tube. The tubes were transferred to a PCR thermal cycler machine (PTC 
2000 Peltier Thermal Cycler, MJ Research, MA, USA) and the required product was 
amplified using the following program:
5 min at 95°C, 40 cycles o f 95°C for 30 sec, 62°C for 30 sec, 72°C for 1 min and a final 
extension o f 10 min at 72°C. The resulting PCR product was visualised on a 1.2% agarose 
gel with ethidium bromide staining following electrophoresis (2.3.6).
2.2.8 Isolation of monocytes
30 ml of blood was removed from human volunteers into hcparinised tubes (Sarsedt, 
Wicklow, Ireland). A density gradient was prepared by layering 10 ml Histopaque 1077 
carefully over 10 ml Histopaque 1199 (Sigma, St. Louis, Mo, USA). The 30 ml of blood 
was layered carefully onto the gradient. Cells were separated out by density centrifugation 
at 400 X g for 30 min. Different layers o f cells were clearly visible following centrifugation 
as seen in figure 2.1. The top plasma layer was removed and filtered through a 0.2 /am
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syringe filter (Gelman, Ann Arbor, MI, USA). The layer containing lymphocytes and 
monocytes was then collected and washed with approximately 30 ml DMEM by 
centrifugation at 300 X g for 10 min. Following this the cell pellet was washed twice with 
30 ml PBS, collecting with centrifugation between washes. After the final wash the cell 
pellet was resuspended in 2 ml o f DMEM and counted (2.2.5). The percentage o f 
monocytes in the cell suspension was determined using Flow Cytometry staining for 
CD14/CD45 (2.2.10). The cells were finally resuspended at a concentration equivalent to 1 
X 106 monocytes / ml in DMEM containing 20% (v/v) autologous plasma. Cells were 
plated into tissue culture plates and monocytes were allowed to adhere by incubating at 
37°C for 3 h. Non-adherent lymphocytes were removed by washing twice with sterile PBS. 
Fresh DMEM containing 20% (v/v) autologous plasma was added to the monocytes.
Before Centrifugation Following Centrifugation
Fig. 2.1 : Cell layers formed before and after density centrifugation o f whole blood through 
a Histopaque gradient.
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2.2.9 Preparation of monocyte derived macrophages
Monocytes isolated according to the procedure outlined in 2.2.7 were matured for 3 or 5 
days in 12-well or 96-well plates respectively in DMEM containing 20% autologous 
plasma. During this maturation period cells were seen to enlarge. Following this, the cells 
were washed with sterile PBS and activated for 24 h with 100 ng/ml recombinant interferon 
y (rhLFNy 103 units/ml ) (Gibco-BRL, Paisley, Scotland) in DMEM with 10% (v/v) FCS. 
Following activation monocytes appeared to attain spindle like appearance and macrophage 
like morphology. This method was developed previously in the laboratory (Harmey et al.,
1998)
2.2.10 CD14/CD45 Flow cytometry
The percentage of monocytes present in cell samples was determined using flow cytometry 
counting cells expressing the cell surface receptors CD 14 and CD45. CD45 is present on 
the majority o f leukocytes whereas CD14 is a specific marker for monocytes. A 100 (J.1 
aliquot o f cell suspension (1 x 105 cells) was incubated with 10 p.1 of CD14/CD45 labeled 
monoclonal antibodies (Becton Dickenson, San Jose, CA, US). The sample was carefully 
mixed, protected from light exposure with foil and incubated for 30 min at 4°C. Cells were 
washed with 2 ml o f cold PBS and centrifuged at 300 x g for 5 min. Supernatant was 
carefully removed and cells resuspended in FACS fluid and analysed (FACScan, Becton 
Dickenson, San Jose, CA, US). The percentage o f CD14 positive leukocytes was 
calculated. A sample dot plot for CD14/CD45 flow cytometric analysis is shown in Fig.
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Fig. 2.2 : Sample dot plot for CD14/CD45 flow cytometric analysis.
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2.2.11 Preparation of cells
Cells required for experiments were obtained by trypsinisation and counted. When 
measuring VEGF protein production, 200 (j,l o f cells were seeded into 96-well plates at a 
density of 50,000 cells/ml (tumour cells) or 25,000 cells/ml (HUVEC). For proliferation 
experiments cells were seeded at a concentration o f 5,000 cells/ml in 96-well plates. For 
reverse transcription polymerase chain reaction (RT-PCR) 1 ml o f cells at 200,000 
cells/well were seeded into 12-well plates. For apoptosis assays, cells were seeded at a 
concentration of 50,000 cells/chamber. Cells were allowed to recover after trypsinisation 
for approximately 16 h in RPMI or DMEM with 10% (v/v) FCS. Treatment with 
lipopolysaccharide or cytokines was carried out by preparing the reagents in the appropriate 
medium with 10% (v/v) FCS. In the proliferation experiments the lipopolysaccharide was 
prepared with and without 10% (v/v) FCS for comparison. In the case o f VEGF protein 
analysis medium was removed following the incubation period and stored at -80°C. 100 ul 
of sterile PBS was added per well and the plates were stored at -80°C for total cell protein 
determination as described in section 2.4.2.
2.2.12 Proliferation Assays
Cells at a concentration of 5 x 103 / well were seeded into 96-well plates in RPMI (4T1) or 
DMEM (MDA-MB-231 and HUVEC) with 10% (v/v) FCS and incubated for 18 - 24 h. 
Lipopolysaccharide (Sigma, St. Louis, MO, US) or recombinant bactericidal permeability 
increasing protein rBPI (Xoma Co., Berkley, CA,US) was added at various concentrations 
in 100 (J.1 of complete medium and incubated for 48 h. Cell proliferation was assessed using 
one o f two proliferation assays. The first was a Cell Titre 96 Non-Radioactive Cell
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Proliferation Assay (Promega, Madison, WI, US) based on cellular metabolism and was 
used according to manufacturers instructions. In brief, cells were incubated with 15 pi o f 
tétrazolium dye for 4 h and living cells metabolise the tétrazolium dye to a coloured 
formazan product. 100 pi o f solubilisation solution was added to the wells and incubated 
overnight at 37°C to solubilise the formazan product. Absorbance was measured at 570 nm 
in a plate reader. The colour and absorbance reading were directly proportional to the 
number of cells present in the wells. The proliferation o f control cells (medium only) was 
expressed as 100% and proliferation in treated cells expressed as % o f control.
The second assay was a BrDU 96 well proliferation assay. The assay was performed 
according to manufacturers instructions (Boehringer Mannheim, UK). 10 pi o f labeling 
solution was added to each well for 6 h at 37°C. Cells were washed with wash medium 
containing 10% bovine serum. Cells were then fixed with 200 pi o f fixative solution for 30 
min at -20°C. Cells were washed again and incubated with 100 pi o f nuclease solution for 
30 min at 37°C. Thereafter cells were washed again and 100 pi o f the anti-BrDU antibody 
was added for 30 min. Cells were washed and finally 100 pi o f peroxidase substrate 
solution was added for 15-30 min (until strong colour change was apparent). Absorbance 
was measured at 405 nm with reference wavelength at 490 nm. In a similar way to the first 
assay, the proliferation of controls was set to 100% and treated cells expressed as % of 
controls.
2.2.13 Apoptosis assay in culture chamber slides
4T1, MDA-MB-231 or HUVEC cells were trypsinised as outlined in section 2.2.2 and 
2.2.5. Cells were counted and a solution of 50,000 cells / ml was prepared in DMEM
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containing 10% FCS. 1 ml o f this solution was added to each chamber o f Falcon glass 
culture slides (Becton Dickinson, NJ., US). Plastic culture slides were used for 4T1 cells, as 
these cells did not adhere properly to glass slides. Following 24 h, different treatments were 
added to the cells prepared in DMEM containing 10% for HUVECs. In the case of the 
tumour cells the FCS was reduced to 1% to induce a higher rate o f apoptosis within the 
cells and treatments were prepared in this. Cells were incubated for 24 h at 37°C. The 
medium was then removed and the slides were fixed in 100% acetone. Following this 
slides were stained using the TUNEL procedure as outlined in section 2.8.2.
2.3 RNA Extraction and Reverse Transcriptase Polymerase Chain Reaction (RT- 
PCR)
2.3.1 Isolation of total RNA from cultured cell monolayers
As RNA is readily degraded by ubiquitous RNase enzymes a number of precautions were 
taken when isolating RNA. Gloves, filter-tips and a clean lab coat were used at all times. 
RNA was isolated from cell cultures growing in 12-well plates. Cells were washed with 
sterile PBS. 800 ^1 o f TRIzol ® LS (Gibco-BRL, Paisley, Scotland) was added to each well 
for 5 min at room temperature and transferred to a clean eppendorf tube. 300 fil of 
chloroform was added per tube. Tubes were vigorously shaken for approximately 20 
seconds and allowed to stand at room temperature for 10 min. Phases were separated by 
centrifugation at 12,000 X g for 15 min (Eppendorf Centrifuge 5417, Hamburg, Germany). 
Approximately 300 jil of the top aqueous phase was removed to a new eppendorf and the 
RNA precipitated with 1 ml o f isopropyl alcohol (IPA) for 10 min at room temperature. 
RNA was pelleted by centrifugation at 12,000 X g for 10 min. The supernatant was
55
aspirated and the pellet washed in 1 ml of 70% (v/v) ethanol. RNA was pelleted by 
centrifugation at 7,500 X g for 5 min. Ethanol was carefully aspirated and the pellet air 
dried over 2-4 min. Pellets were resuspended in 20 fil o f Diethylpyro-carbonate (DEPC) 
treated water (water treated with 0.01% DEPC overnight and then autoclaved to deactivate 
DEPC) and immediately placed on ice. The concentration and purity o f the RNA was 
assessed spectrophotometrically as outlined in 2.3.2.
2.3.2 Quantification of RNA
RNA was assessed by measuring the optical densiy at 260 nm, the Amax for nucleic acids, 
using a Genequant spectrophotometer (Pharmacia, Cambridge, UK). A 40 (ig/ml sample of 
RNA yields an absorbance value of 1 at 260 nm. The purity o f RNA was calculated by 
measuring the ratio o f the sample absorbance at 260 nm relative to the absorbance at 280 
nm, the Amax for proteins. Pure RNA yields a A260/A280 ratio o f 1.6 - 1.8. Lower ratios 
were an indication o f the presence of protein in the samples. Absorbance was measured in a 
clean quartz cuvette following a 1:500 dilution in SDW.
2.3.3 Reverse Transcription-Polymerase Chain Reaction
RT-PCR was used to examine mRNA levels o f VEGF, TGF-(3, and bFGF in cells. P-actin, 
a constitutively expressed gene, was also amplified in each experiment to act as an internal 
control for cDNA starting quantities and loading differences. The ratio o f the target mRNA 
to P-actin allows semi-quantitative comparison between samples. The conditions used for 
amplification of VEGF and P-actin have previously been shown by our laboratory to allow 
semi-quantitative analysis (Harmey et al., 1998).
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2.3.4 Reverse Transcription
1 pg of total RNA was used for the reverse transcription reaction. DNase I treatment was 
carried out to remove any contaminating DNA. 1 pi containing 1 U o f DNase I (Gibco- 
BRL, Paisley, Scotland) was added to 1 pg o f total RNA in 10 pi of 1 X DNase buffer in 
DEPC water and the mixture incubated at room temperature for 15 min. The DNase I was 
inactivated by adding 1 pi o f 25 mM EDTA and heating to 70°C for 10 min. 1 pi o f random 
primers (Promega, Madison, WI, US) (500 pg/ml) was added and the samples incubatcd at 
70°C for 10 min and then immediately placed on ice. An RT mastermix was prepared and 
added to the samples containing the following components: 0.5 pi DEPC water, 0.5 pi 
RNasin (Promega, Madison, WI, US), 1 pi 5 mM dNTP’s (1:1:1:1 dATP, dCTP, cGTP, 
dTTP) (Promega, Madison, WI, US) (19 U), 4 pi 5X RT buffer (Gibco-BRL, Paisley, 
Scotland), 2 pi 0.1 M DTT, 1 pi Superscript IID Reverse Transcriptase (200 U) (Gibco- 
BRL, Paisley, Scotland). cDNA synthesis was performed for 16 h at 37°C and the cDNA 
amplified by PCR thereafter or stored at -20°C.
2.3.5 Polymerase Chain Reaction
The PCR components were prepared as a mastermix and added to 1.5 pi o f cDNA. Each 50 
pi reaction contained the following: 5 pi 10 x buffer (supplied by the manufacturers with 
Taq polymerase enzyme), 2 pi 25 mM MgCl2, 2 pi 5 mM dNTPs, 1 pi o f forward and 
reverse primers (50 pmol) (VEGF: Genosys, Cambridge, UK; Bcl-2 and Bax: R&D 
systems, Kent, UK), 0.5 pi Taq DNA polymerase (2.5U) (Promega, Madison, WI, US) and 
DEPC water to a final volume of 48.5 pi. Samples were placed in the PCR thermal cycler
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(PTC 2000 Peltier Thermal Cycler, MJ Research, MA, US) and amplification was carried 
out using the appropriate cycle.
The cycle used for the amplification of human VEGF was 30 cycles o f 94°C for 1 min, 
55°C for 2 min, and 72°C for 1.5 min using the following primers: 
forward: 5 ’- CGC AAG CTT AGG AGT ACC CTG ATG AG - 3’ 
reverse: 5 ’- CCG TCT AGA ACA TTT GTT GTG CTG T - 3 ’
These primers amplify a 204 bp fragment.
The cycle used to amplify (3-actin was 32 cycles o f 94°C for 45 sec, 60°C for 45 sec, and 
72°C for 1.5 min using a commercial actin primer mix that amplifies both human and 
mouse [3-actin (Strategene, La Jolla, CA, US) resulting in a 661 bp fragment.
PCR products were visualised on a 1.5% agarose gel as outlined in section 2.3.6.
2.3.6 Agarose gel electrophoresis of DNA
Products were visualised on agarose gels prepared by boiling an appropriate amount of 
agarose in 50 - 100 ml o f 1 X TAE buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA; 
pH 8.0) in a 650 watt microwave. 1.5% (w/v) gels were the most commonly used. The 
solution was allowed to cool to approximately 60°C (warm to the hand) and then poured 
into a level gel mold of Easi-E-Cast Gel System (Hybaid, Middlesex, UK). Bubbles were 
carefully removed and combs placed into the gel and the gel allowed to set. Once set the gel 
was transferred to the electrophoresis tank filled with 1 X TAE. Samples were prepared by 
adding a suitable volume of 6 X loading dye (30% (v/v) glycerol, 0.01% (w/v) 
bromophenol blue) to give a final cocentration o f 1 X. Approximately 20 p.1 of samples or 
DNA marker was added to each well and the gel run at a constant voltage o f 80 V (E-C
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Apparatus Corporation EC 105, FL, US) until the bromophenol front approached the edge 
o f the gel. Subsequent bands were visualised using a transilluminator (Syngene, 
Cambridge, UK).
2.4 Protein electrophoresis
2.4.1 Protein isolation from cell cultures
Following treatment, cell monolayers were washed twice with PBS. In the case of samples 
for analysis of the apoptosis regulating proteins the supernatant was decanted first and 
centrifuged at 300 x g for 10 min to collect floating (apoptotic) cells. Cells were lysed in 1 
ml of lysis buffer prepared as 1 x TNE (5 mM Tris-HCl, pH 7.4, 0.15 M NaCl, 5 mM 
EDTA) containing 0.5% (w/v) SDS, 0.5% (v/v) Triton X-100, 0.005% (w/v) deoxycholic 
acid and 1 mM phenylmethylsufonyl fluoride (PMSF). Flasks or tubes containing the lysis 
buffer were kept on ice for 30 min. The lysate was passed through a 20 gauge insulin 
syringe 1 0 - 1 5  times to shear DNA and then boiled for 10 min. Debris was pelleted by 
centrifugation at 15,000 x g for 10 min. 500 (J.1 o f the cleared lysate was added to 3.5 ml 
methanol and stored at -80°C overnight to precipitate protein. Protein was recovered by 
ultra centrifugation at 50,000 x g for 30 min at 4°C and resuspended in 2 x Llaemmli buffer 
(0.03 M Tris-HCl, pH 7.4, 5% (w/v) SDS, 20% (v/v) glycerol, 10% (v/v) 2- 
mercaptoethanol) at a concentration o f 5 |ag/fil.
2.4.2 Protein determination
For the determination o f total protein in samples the bichinoic acid (BCA) protein assay 
(Pierce, Rockford, IL, US) was used. The principle behind the assay is that in the presence
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of protein Cu++ is oxidised to Cu+ which reacts with the BCA reagent under alkaline 
conditions to yield a coloured product. The commercially available kit is provided as two 
reagents; A, an alkaline bicarbonate solution and B, a copper sulphate solution, which were 
mixed in a 50:1 ratio prior to use. 200 jal o f this working reagent was added to 10 )j,l of 
protein standard or sample to be tested in a 96 well plate and incubated at 37°C for 30 min. 
The absorbance of each well was read at 570 nm (Bio-Tek Microplate Autoreader EL311, 
VT, US). The protein concentration was determined by extrapolation from a standard curve 
of known concentrations of BSA between 0 and 1000 pg/ml.
2.4.3 Denaturing polyacrylamide gel electrophoresis (SDS-PAGE)
A 12% (w/v) gel was routinely used for Western blot analysis. Samples for PAGE were run 
in the presence o f SDS and 2-mercaptoethanol to denature the proteins. Separating gel was
prepared by mixing the following solutions.
Separating gel: 12%
acrylamide : bisacrylamide (37.5:1) 9.2 ml
1.875 M Tris-HCl, pH 8.8 4.5 ml
Sterile distilled water (SDW) 8.3 ml
10% (w/v) SDS 176 *il
10% (w/v) ammonium persulphate 120 |al
N,N,N’,N’-tetramethyl-ethylenediamine (TEMED) 10 (il
The solutions were mixed and approximately 7 ml were cast in vertical gel plates (Atto 
Corporation AE-6450 mini-slabs, Tokyo, Japan). A small volume of ethanol was added to
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the gel to aid polymerisation by excluding oxygen, removing bubbles and leveling the top 
of the gel. Once the gel had set the ethanol was poured off and the top o f the gel rinsed with 
distilled water. Following this the stacking gel was prepared and added on top of the 
resolving gel and 12 well combs inserted.
Stacking gel: 1.7 ml acrylamide:bisacrylamide (37.5:1), 2 ml 0.6 M Tris-HCl, pH 6.8, 6 ml 
SDW, 100 jil 10% (w/v) SDS, 150 jj.1 10% (w/v) ammonium persulphate, 10 \i\ TEMED. 
Samples were prepared by mixing an equal volume of sample in 2 X Llaemmli with SDW. 
Samples were denatured by boiling for 10 min. Protein markers were prepared in a similar 
way by mixing with 2 X Llaemmli. Samples and markers were added to the wells and 
electrophoresed at 25 mA / gel in electrode buffer (50 mM Tris base, 384 mM glycine and 
0.1% (w/v) SDS) for approximately 1 h 30 min until the dye front approached the bottom of 
the gel.
2.4.4 Staining with Coomassie brilliant blue
Following electrophoresis gels were stained for protein by immersion in Coomassie 
brilliant blue (50% (v/v) methanol, 10% (v/v) glacial acetic acid, 0.25% (w/v) Coomassie 
brilliant blue G250) for 30 min on a shaking table. Gels were destained with 50% (v/v) 
methanol, 10% (v/v) glacial acetic acid until background cleared and bands were clearly 
visible.
2.5 Western Blotting
Following electrophoresis gels were overlaid with pre-wetted 0.2 p,m nitrocellulose 
membranes and a layer o f Whatman blotting paper. Bubbles were carefully removed and
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proteins transferred for 16 h at 80 mA in transfer buffer (0.15 M glycine, 20 rnM Tris, 0.1% 
(w/v) SDS, 20% (v/v) methanol) using a Bio-Rad Trans Blotter (Hercules, CA., USA). 
During transfer the temperature was maintained at 4°C using a cooling apparatus (Medingen 
KK5E, Bonn, Germany). Following transfer, membranes were blocked for 1 hour using 5% 
(w/v) dried milk (Marvel) in TBST (25mM Tris-HCl, pH 7.6, 150mM NaCl, 0.05% (v/v) 
Tween 20). Thereafter a 1:200 dilution of anti-Bcl-2 (Santa Cruz, CA. USA) was added for 
1 hour. Following incubation with the primary antibody the membranes were washed 3 
times for 10 min each in TBST. A 1:2000 dilution o f anti-rabbit IgG horseradish peroxidase 
(HRP) conjugate (Dako, Cambridge, UK) was then added to the membrane for 1.5 h with 
gentle agitation. Following this the membranes were washed six times for 5 min each in 
TBST. The horseradish peroxidase (HRP) signal was detected using a chemiluminescent 
substrate (Pierce, Rockford, IL, USA). The working reagent was prepared just prior to use 
by mixing two solutions in equal volumes and adding to the blot for 5min. Following 
incubation the solution was poured off and the membrane enclosed in plastic and exposed 
to X-ray film (Kodak) in a dark room and developed. Exposure times varied between a few 
seconds to several minutes depending on the protein concentration and age of the antibody 
used.
2.6 Densitometry
Blots and gels were recorded using a computerised Syngene UV transilluminator and white 
box in a syngene darkroom with camera. The software utilised was GeneSnap version 2.6. 
Dcnsitometric analysis was carried out using GeneTools version 2.1 assigning bands as 
PCR boxed manual areas.
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2.7.1 Animals
Male six to eight week old BALB/c mice (Charles River Institute, Margate, Kent, UK) were 
used throughout the course of the study. The mice were acclimatised for one week before 
experimentation and caged in groups of five or less in an air conditioned room at ambient 
temperature o f 21-22°C and 50% relative humidity under a 12 h light-dark cycle (lights on 
at 8am). The animals were housed in a licensed biomedical facility (RCSI Department o f 
Surgery, Beaumont Hospital) and all procedures were carried out under animal licence 
guidelines o f the Ministry o f Health, Ireland. Animals had ad libitum access to animal chow 
(W.M. Connolly & Sons Ltd., Kilkenny, Irl.) and water.
2.7.2 Establishment of Pulmonary metastases by tail vein injection
4T1 cells at 80% confluency were removed by trypsinisation as outlined in section 2.2.2. 
The cells were washed three times in Ca++/Mg' free Phosphate Buffered Saline (PBS), 
counted (as described in section 2.2.6) and resuspended at a final concentration o f 5 X 
1OVml in PBS. 200 pi o f this solution was injected into each mouse via the lateral tail vein 
following intramuscular administration o f 200 pi of 10% (v/v) solution of the anaesthetic 
and vasodilator Hypnorm™ (Janssen, Buckinghamshire, UK) in the left hind limb. Initially 
animals were sacrificed at intervals of two days and the lungs removed and processed by 
histology to examine for visible metastases. The livers and brains o f mice were also 
removed and processed by histology to ensure that no metastases were present in these 
organs.
2.7 In-Vivo Experiments
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Two weeks following tumour cell injection mice were randomised into four groups. A 
control group received the anaesthetic Halothane™ (Rhone-Poulenc Rorer Ltd., Dublin, 
Irl.) for 30 min with oxygen at a flow rate o f 4L/min. A second group underwent 
laparotomy following the preparation of their abdomen with ethanol. Under anaesthesia a 
mid-line xiphoid to pubis incision was made with a sharp scissors through the skin, 
subcutaneous tissues and peritoneum. The peritoneal contents were exposed and agitated 
for a period o f 25 min (replacing the contents at 10 min intervals) before closure (5 min) 
with a continuous nylon suture (Ethicon, UK) (Figure 2.3a). Animals were returned to their 
cages thereafter and allowed to recover under a heat lamp.
A third group underwent laparoscopy with sterile carbon dioxide. Under Halothane 
anaesthesia, after preparation o f the abdomen with ethanol, an 18-guage cannula (Venflon, 
UK) was placed in the epigastrium. A sterile C 02 pneumoperitoneum was established and 
maintained for 30 min by passing the C 0 2 through a 0.2pm acrodisc PF filter (Gelman 
sciences, Ann Arbor, MI, USA) at 4-6 mmHg. A second 18-guage cannula was then 
inserted in the midclavicular line to serve as an outlet port, and the cannula was loosely 
sealed (Figure 2.3b). This method o f trocar insertion was necessary to enable the insertion 
of the second cannula once the bowel contents were safely separated from the anterior 
abdominal wall by the pneumoperitoneum. Following this the port-sites were closed by 
pressure using a sterile metal forceps. Throughout this time the peritoneal cavity was not 
exposed to any atmospheric air, only to sterile C 0 2 used to insufflate the peritoneum.
The final surgical group received laparoscopy with air. The surgical model was identical to 
that outlined above except for the fact that room air was used to insufflate the peritoneum
2.7.3 Surgical treatment
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A. B.
Loosely sealed 
outlet-port
Diaphragm
CO2 gas / 
inlet port
Fig. 2.2 : A. Diagrammatic representation of a mouse undergoing open laparotomy with 
intestinal agitation. B. Diagrammatic representation of a mouse undergoing laparoscopy 
with sufflation o f the peritoneal cavity with either sterile CO2 gas or room air.
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instead of sterile carbon dioxide. In order to deliver the same volume of air a 50 ml syringe 
was attached to a hypochondrial cannula and the peritoneal cavity insufflated for 30 min 
with non-sterile room air. Following this time the portal sites were closed as previously 
described. Following the laparoscopy procedures all animals were returned to their cages 
and allowed to recover as before under a heat lamp.
2.7.4 Intra-peritoneal injection of mice
Two weeks following tail-vein injection of tumour cells animals were separated into one of 
two groups. The first group served as a control and received a 200 jj,1 intra-peritoneal 
injection of sterile saline, while the second group received a 200 f.il intra-peritoneal 
injection of 50 (.ig/ml (10jo.g/mouse) commercial LPS derived from E.coli (serotype 055:B5 
Sigma Corp., Dublin, Irl.) in saline.
2.7.5 Anti-endotoxin intervention
To determine if  anti-endotoxin treatment could reduce endotoxin or surgically induced 
tumour growth the above experiments were repeated in conjuction with a regime of anti­
endotoxin treatment. The murine monoclonal antibody E5, recombinant bactericidal 
permeability increasing protein (rBPI21) and thaumatin were a gift from Xoma Corporation, 
Berkely, CA., US. Animals underwent anaesthesia or laparotomy, saline or endotoxin 
injection injection as outlined in sections 2.7.3 and 2.7.4 respectively. Animals were then 
further separated to receive a 200 p.1 intra-peritoneal injection o f 0.4 mg/ml rBPI21, E5, 
thaumatin (a control peptide o f 21 KD with no endotoxin neutralising activity) or in the 
case o f controls 200 (il formulation buffer. Animals received further injections o f the same
treatment at two hourly intervals for a total of 4 injections and then were allowed to recover 
overnight. 24 h later the animals received a final injection and were then allowed to recover 
in their cages.
2.7.6 Blood collection
Mice were anaesthetised with Halothane and their chests cleaned with ethanol. Blood was 
obtained via closed cardiac puncture by means of a 22-gauge hypodermic needle and a sub- 
xiphoid approach. Blood was transferred to 1.5 ml capacity serum tubes (Sarstedt, 
Germany) and allowed to clot for 1-2 h at room temperature. Tubes were centrifuged for 20 
min at 1200 X g. Serum was removed, filtered through a 0.22 (im filter and stored in 
aliquots at -80°C.
For endotoxin analysis, blood was removed as described above 4 h after surgical treatment 
via closed cardiac puncture. Blood was transferred into pyrogen free Coatex Endo tubes 
(Chromogenix AB, Molndal, Sweden). Plasma was separated by centrifugation at 2,200 X 
g for 15 min and samples were analysed for plasma endotoxin levels immediately using the 
Limulus Amebocyte Lysate assay (Chromogenix AB, Molndal, Sweden).
2.7.7 Sacrificing of animals, metastatic burden and tissue processing
Five days after surgical treatment or intra-peritoneal injection the animals were 
anaesthetised again under Halothane. The animals were weighed and thereafter returned to 
anaesthetic where blood was removed. Following this the animals were sacrificed by 
cervical dislocation. The chest cavity was cleaned using ethanol and opened using a sharp 
scissors. The lungs were carefully excised and weighed immediately. Following this the
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lungs were fixed in a 10% formalin solution and processed into paraffin embedded blocks 
by the histology department. The percentage lung weight : body weight (lung weight/body 
weight X 100) was used as an indicator o f metastatic burden, similar to the method used 
previously to assess metastatic burden in murine tumour metastases following 
cytomegalovirus infection (Olson et al., 1980).
2.8 Immunohistochemistry
2.8.1 Preparation of sections from paraffin embedded tissue
Paraffin embedded blocks were cut into 4 micron sections using a Microm HM325 (MSc., 
Dublin Irl.) microtome. Blocks were cooled on an ice-block and then secured in place in the 
microtome. The block was brought close to the blade and sections were cut until a full face 
was taken. A ribbon of approximately 5 to 8 sections was taken at a time and transferred to 
a clean water bath containing a few drops of ethanol. Sections were taken onto pre-treated 
glass slides and then wrinkles were removed by dipping the section into a heated water bath 
(MSc., Dublin, Irl.). The sections were allowed to dry overnight at 37°C and then baked for 
3 - 4  hours at 50°C prior to staining.
2.8.2 TUNEL immunohistochemical staining
The number o f apoptotic cells within metastases was estimated by labelling apoptotic cells 
with the TUNEL kit (Boehringer Mannheim, East Sussex, UK). Sections to be stained were 
re-hydrated by bringing the sections through graded solutions of xylene, 100% ethanol and 
70% ethanol, before rinsing in running water. Sections were then treated with proteinase K 
(20 pg/ml) for 30 min at 37°C. Following this endogenous peroxide activity was blocked by
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incubating the slides in a 3% (v/v) solution of hydrogen peroxide. Thereafter ice-cold 
permeabilisation solution (0.1% (v/v) Triton-X-100, 0.1% (w/v) sodium citrate) was added 
for 3 min. Following this samples were rinsed in TBS and 50 jj,1 o f the working TUNEL 
reaction mix was added (prepared by mixing two reagents provide in the kit). A negative 
was included in each batch of samples by adding 50 jal of only one o f the working TUNEL 
mixture components. A cover slip was added to ensure even distribution of the labelling 
mixture and the slides were incubated at 37°C for 1 hour in a humidified chamber (prepared 
by placing soaked tissue paper in a sealed plastic tip box below the level at which the slides 
were kept). Thereafter slides were rinsed with TBS and placed in a TBS bath for 5 min. 
Following this 50 pi of the converter-POD mixture was added to each section and again a 
cover slip was added. Slides were returned to the humidified chamber and incubated for a 
further 1 hour at 37°C. Slides were rinsed again with TBS and placed in a TBS bath for 5 
min. Peroxidase activity was visualised by the precipitation o f 3, 3’ diaminobenzidene 
(DAB) (Sigma, Dublin, Irl.) for 15 min. Sections were lightly counterstained in 
haematoxylin, rinsed in running water and then dehydrated by bringing the section through 
graded alcohol and finally into xylene. Apoptotic cells stained brown against a blue 
background and were counted using a 1mm3 grid counting an average of 500 tumour cells / 
mm3 at a magnification x 400. Only cells which stained brown and had the morphological 
appearance o f an apoptotic cell were counted. Necrotic cells were easily distinguished and 
were not counted. 10 fields were scored and inter-person variation checked by an 
independent observer. The apoptotic index (AI) was calculated as the mean number of 
positively stained cells in 10 fields.
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The extent o f angiogenesis within matrigels was estimated by staining gels with anti-CD31 
(PECAM) antibody (Santa Cruz, CA., USA). Sections to be stained were re-hydrated by 
brining the sections through graded solutions of xylene, 100% ethanol and 70% ethanol, 
before rinsing in running water. Endogenous peroxide activity was blocked by incubating 
the slides in a 3% (v/v) solution o f hydrogen peroxide. Thereafter unspecific binding sites 
were blocked by the addition of 10% normal goat serum for 30 min. Following this samples 
were rinsed in TBS and a 1:100 dilution of the goat anti-CD31 primary antibody was 
applied to the sections for 1 h. A negative was included in each batch o f staining by 
addition o f TBS only in place of the primary antibody. Thereafter slides were rinsed with 
TBS and placed in a TBS bath for 5 min. Following this a 1 TOO dilution of rabbit anti-goat 
biotinylated secondary antibody (Santa Cruz, CA., US) was added for 30 min. Slides were 
rinsed again with TBS and placed in a TBS bath for 5 min. A 1:100 dilution of strepavidin 
and biotin (Dako, Dublin, Irl.) in TBS was applied to amplify the signal from the 
biotinylated antibody. Peroxidase activity was visualised by the precipitation of 3, 3’ 
diaminobenzidene (DAB) (Sigma, Dublin, Irl.) for 15 min. Sections were lightly 
counterstained in haematoxylin, rinsed in running water and then dehydrated by bringing 
the section through graded alcohol and finally into xylene. Endothelial cells within 
matrigels stained brown following CD31 immunostaining and the number o f vessels within 
the matrigels was determined using a 1mm3 grid, counting an average o f 5 fields.
2.9 VEGF ELISA
VEGF protein levels were determined using ELISA. For human cell culture supernatants a
sandwich ELISA that was developed previously in our laboratory was used (Donovan, PhD
2.8.3 CD31 Immunohistochemistry
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thesis, 1999). Plates were prepared by adding 100 jal o f the coating antibody (R&D 
systems, UK, anti-human VEGF neutralising antibody) at a concentration o f 0.7 (ig/ml in 
PBS and incubating at room temperature overnight in sealed plates. The following day 
plates were washed with wash buffer (0.05% (v/v) Tween-20 in PBS, pH 7.4) four times 
and blocked by incubating with blocking buffer (1% (w/v) BSA and 5% (w/v) sucrose in 
PSS) for 1 h at room temperature. Following blocking plates were washed again. Samples 
or standards were prepared in diluent (0.1% (w/v) BSA, 0.05% (v/v) Tween-20 in TBS, pH 
7.3) and 100 fil added to the wells for 2 h at room temperature. The plates were mixed 
gently on a shaking table over this two hour period. Following this the wells were washed 4 
times with wash buffer and 100 jj.1 of biotinylated detection antibody (R&D systems, 
Biotinylated anti-human VEGF antibody) at a concentration of 500 ng/ml in dilution buffer 
was added for 2 h at room temperature with gentle agitation as before. The plate was 
washed 4 more times and 100 (4,1 o f streptavidin HRP (Zymed Laboratories, San Francisco, 
CA, USA) was added for 30 min at room temperature. Following a further set of 4 washes 
100 jil o f substrate was added (0.1 mg tetramethylbenzidine (TMB), 10% (v/v) DMSO, 
0.045 M phosphate-citrate buffer, 0.006% (v/v) hydrogen peroxide, pH 5.0) per well for 40 
min at room temperature in the dark. Thereafter the reaction was stopped by adding 50 ml 
of 0.5 M H2S 0 4. Absorbance was read at 450 nm with a correction wavelength of 570 nm to 
correct for impurities on the plate. VEGF levels in samples were determined from a 
standard curve constructed from known standards. A sample standard curve is provided 
(Appendix 1A).
For murine serum and cell culture samples a mouse-specific commercial ELISA 
was used in accordance with manufacturers instructions (R&D systems, Abington, UK). In
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brief, 50 pi of assay diluent was added to each well, followed by 50 pi o f standard or 
sample prepared in calibrator diluent and the plates incubated for 2 h at room temperature. 
The contents of the wells were aspirated and the plates washed five times with 400 pi of 
wash buffer. Following this, 100 pi o f prepared conjugate was added per well and incubated 
at room temperature for further 2 h. Wells were aspirated and washed again as before, and 
100 pi of substrate solution was added for 30 min. Thereafter 100 pi o f stop solution was 
added and the absorbance read at 450 nm with a correction wavelength o f 570 nm. VEGF 
levels in samples were determined from a standard curve constructed from known 
standards. A sample standard curve is provided in the appendix (Appendix IB).
2.10 Limulus Amebocyte Lysate assay
Plasma endotoxin levels were determined using the limulus amebocyte lysate (LAL) assay 
according to the manufacturers instructions (Chromogenix AB, Molndal, Sweden). In brief, 
samples or standards were diluted 1:10 with LPS free water in sterile falcon plasma tubes in 
a laminar air flow cabinet. Samples or standards were heated to 75°C in a water bath for 5 
min. 50 pi of sample or standard was then added to a 96 well plate, followed by 50 pi of the 
LAL solution and the plate was incubated for 16 min at 37°C. 100 pi of previously heated 
(37°C) substrate solution was then added to each well and the plates incubated at 37°C for a 
further 10 min. Following this 100 pi of 20% acetic acid was added to each well to stop the 
reaction and the plates were read at 405 nm single wavelength. A standard curve was 
constructed from known standards and plasma endotoxin levels in samples read from the 
curve. A sample standard curve is provided in the appendix (Appendix 1C).
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2.11.1 Matrigel preparation and implantation
Matrigel basement membrane matrix (Becton Dickinson, MA, US) is a solubilised 
basement membrane preparation extracted from Engelbreth-Holm-Swarm (EHS) mouse 
sarcoma, containing laminin, collagen IV, heparin sulfate proteoglycans and many growth 
factors occurring naturally in the EHS tumour. It was prepared for use by placing at 4°C 
overnight at which it became liquid. In a laminar air flow cabinet different solutions of 
matrigel were prepared in falcon tubes held on ice. 100 ng/ml VEGF, 10 (.ig/ml LPS or 
saline control solutions were prepared in matrigel. 500 (0,1 o f each o f these solutions was 
drawn into 1 ml insulin syringes and the syringes laid flat on crushed ice to ensure the 
matrigel did not set.
Mice were anaesthetised as outlined in section 2.7.3 and placed on their stomachs. Using a 
clean metal forceps the skin above their left hind limb was lifted and 500 (il o f the prepared 
matrigel solution was injected slowly in one continuous motion. Following injection the gel 
solidified rapidly and a clear implant was visible to the left side o f each mouse. Mice were 
returned to their cages and allowed to recover.
2.11.2 Extraction and processing of matrigels
5 days after matrigel implantation mice were sacrificed by cervical dislocation. Matrigels 
were located and an incision was made to the right o f the implant with clean sterile metal 
scissors. The whole matrigel implant along with skin was carefully removed by cutting 
around the implant initially and then trimming the appropriate perimeter. Skin was pinned 
to small pieces of cork and the implants and skin were floated (implant down) in 10%
2.11 In-Vivo angiogenesis assay
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formalin solution overnight, before being processed into paraffin embedded blocks for 
immunohistochemistry.
2.12 Statistical analysis
Data is graphically represented as mean ± standard error o f mean (SEM). Normal 
probability plots were prepared to determine if  the data was normally distributed. For 
normally distributed data, statistical significance was determined using students t-test or 
ANOVA for samples comparing more than 2 groups. A Scheffe post-hoc test was used with 
the ANOVA to determine differences between the groups. Data that was not normally 
distributed was analysed using Wilcoxon signed rank in place o f paired t-test and a Mann- 
Whitney U for a students t-test. Correlation coefficients were determined using Pearson 
product moment correlation for normally distributed data, or a Spearman rank for 
abnormally distributed data. Data was taken to be significant where p<0.05. All data was 
analysed using DataDesk 5.1 for a Macintosh computer (Data Description Inc., Itheca, NY, 
US).
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Chapter 3
Effect of Surgery on Metastatic Tumour Growth
Published : Pidgeon, G.P., Harmey, J.H., Kay, E., DaCosta, M., Redmond, H.P., 
Bouchier-Hayes, D.J. (1999) The role of endotoxni/lipopolysaccharide in 
surgically-induced tumour growth in a murine model o f metastatic disease. 
Br.J. Cancer 81, 1311-1317.
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Rapid growth of previously dormant métastasés following the surgical removal of a 
primary tumour is well documented (Arai et al, 1992; Kodama et al, 1992). A 
generalised state of immune-suppression prevails in the postoperative period. While 
tumour resection may be the only curative measure available to some patients, the 
procedure itself may compromise host defences and therefore create a permissive 
environment for the seeding and growth o f any circulating tumour cells or 
micrometastascs remaining after the surgery.
Surgical trauma modulates immune cell populations and their function, and may 
influence metastasis directly by mechanical spillage of tumour cells during resection. 
Recently, however, there is growing evidence to suggest that the removal o f a primary 
tumour alters the balances governing tumour growth and angiogenesis. In animal tumour 
models, primary tumours have been shown to inhibit the growth o f their own métastasés 
by the secretion of angiogenesis inhibitors, such as angiostatin and endostatin, formed by 
enzymatic cleavage of plasminogen and collagen XVIII, respectively (O’Reilly et al, 
1994; O’Reilly et al, 1997). Within five days of removal of the primary tumour these 
angiogenesis inhibitors disappear from the circulation permitting new vessel growth 
within previously dormant métastasés.
A universal factor associated with surgery is the healing wound. Clinical 
experience has shown that the healing wound provides a favourable environment for 
metastatic tumour growth (Abramovitch et al., 1998; Bogden et al., 1997, Skipper et al.,
1988). It has been reported in rats that when radiolabelled MC28 sarcoma cells reach a 
healing colonic anastamosis or laparotomy wound within 2 hours of its formation, there 
is a 1000 fold increase in the probability of the cells forming a viable metastatic deposit
3.1 Introduction
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compared to normal tissue (Skipper et al., 1988). Following surgical trauma the cytokine 
environment within the body is altered to influence the healing process and limit 
infection (Reid et al., 1996). However, this environment can facilitate tumour recurrence 
by promoting a pro-angiogenic climate altering the equilibrium which would otherwise 
maintain micrometastases in a state o f dormancy (Holmgren et al, 1995). Vascular 
endothelial growth factor (VEGF) is one possible mediator o f tumour recurrence 
following surgery as it is essential for wound healing but may encourage the growth of 
micrometastases via its potent angiogenic activity. There are a limited number of clinical 
studies demonstrating elevated VEGF in the post-operative period in both cancer and 
non-cancer patients (Harmey, un-published observations).
In addition to removing angiogenic inhibitors, depressing immune function and 
altering the cytokine balance, surgery is also associated with the introduction of factors 
that may promote tumour growth. Endotoxin or lipopolysaccharide (LPS) is a cell wall 
constituent of gram negative bacteria that is present ubiquitously in the atmosphere at 
concentrations of approximately 1 ^g/m3 (Rylander et al, 1989). Another major source of 
endotoxin is derived from endogenous gut bacteria and significant translocation of 
endotoxin into the peritoneal cavity and systemic circulation following open surgery or 
laparoscopy with air-sufflation has been reported (Watson et al, 1995). Endotoxin is 
angiogenic at clinically relevant doses, inducing angiogenesis in a number of 
experimental animal models (Li et al, 1991, Mattsby-Baltzer el al, 1994; BenEzra et al, 
1993).
The aim of this chapter was to investigate the effect o f surgical procedures on 
metastatic tumour growth in a murine experimental metastasis model where no primary 
tumour was established. In this model, alterations in tumour growth can not be attributed 
to the removal of angiogenesis inhibitors, such as angiostatin and endostatin derived
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from primary tumours. The effects o f open surgery on metastatic growth was compared 
with a minimally invasive laparoscopic technique performed with either sterile C 0 2, 
containing no endotoxin, or normal room air containing ubiquitous endotoxin. The 
numbers o f proliferating and apoptotic tumour cells were assessed within metastases as 
these are the ultimate processes governing tumour expansion. Circulating levels o f VEGF 
were measured to determine if  an angiogenic mechanism was activated by the surgical 
procedure. Plasma endotoxin levels were also examined following the different surgical 
procedures and compared to VEGF to examine the relationship between levels of 
endotoxin and circulating VEGF.
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3.2.1 4T1 cell line
Figure 3.1 is a representative photograph of cultured 4T1 cells. The 4T1 cell line is a 6- 
thioguanine-resistant variant of 410.4, a spontaneously arising mammary 
adenocarcinoma from BALB/c mice. This tumour shares many characteristics with 
human mammary cancers, closely mimicking their immunogenicity, metastatic 
properties, and growth characteristics (Pulaski et al, 1998). The 4T1 cell line 
spontaneously metastasises to the lungs early, and the liver and brain later, as indicated 
by the formation of visible nodules in these organs in mice bearing subcutaneous 
tumours.
3.2.2 Mycoplasma testing of cell cultures
Mycoplasma is a very common infection contaminating cultured cell lines. All cell lines 
used in the laboratory were examined for mycoplasma contamination on arrival and 
every six months thereafter as described (2.2.7). Any cell lines testing positive for 
mycoplasma were discarded. Culture supernatants were centrifuged to pellet 
mycoplasma, the resuspended pellet was lysed and mycoplasma DNA amplified by PCR. 
Figure 3.2 shows a representative agarose gel of PCR products following amplification 
for mycoplasma-specific DNA. Lane 1 shows molecular weight markers, <j>X174 digested 
with HaeIII. A negative control (no template) and a positive control (mycoplasma DNA) 
were included in each batch o f samples to be tested for PCR. No amplified product is 
visible in the negative control (lane 2) indicating that no contamination of samples 
occurred. A 660 bp PCR product was amplified from the positive control (lane 3). 
Smearing of the sample indicates some degradation o f the template and is likely to be
3.2 Results
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due to repeated freeze-thawing of the control DNA. Mycoplasma specific PCR reactions 
for 4T1 cells are shown in lanes 4 and 5, and MDA-MB-231 cells in lane 6. The absence 
o f any amplified PCR product indicates that these samples are free from mycoplasma 
contamination. Lane 7 shows a PCR reaction for a cell line obtained from an outside 
laboratory. It is clear that this cell line was contaminated with mycoplasma and therefore 
was discarded.
3.2.3 Development of experimental metastasis model
An initial pilot study was carried out to establish the growth kinetics of 4T1 cells in 
BALB/c mice. 105 4T1 cells were injected into the lateral tail vein of BALB/c mice as a 
single cell suspension in Ca2+ and Mg2+ free PBS. 7 days later mice were sacrificed (n=3/ 
timepoint) to examine organ metastases and every second day thereafter. Lungs were 
removed and weighed and a lung : body weight index recorded as outlined (2.7.7). The 
liver and brain of any mice containing visible tumour nodules in the lungs was also 
removed and all organs were examined by histology for the presence of micro- 
metastases. Fig 3.3 shows the lung : body weight index over time following the tail-vein 
injection o f the 4T1 cells. There is no significant change in lung : body weight index over 
the first two weeks following tumour injection. At two weeks small nodules were visible 
in the lungs, and by day 19 these nodules were large enough (minimum 500 tumour 
cells) to allow histological examination of their mitotic and apoptotic indices. By day 19 
there was a significant (p<0.05) increase in metastatic burden (0.926+0.03) as indicated 
by lung : body weight index relative to day 0 (0.592+0.051). Figure 3.4 shows 
representative H + E stained sections from the lungs (3.4.A), liver (3.4.B) and brain 
(3.4.C) of mice on day 19. No visible metastases were recorded in the liver or brain of 
any mice at this time.
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Fig. 3.1 : Monolayer culture o f  4 T 1 cells.
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Fig 3.2: Mycoplasma testing of cell lines. Mycoplasma DNA was amplified by PCR. 
PCR products were resolved on a 1.5% (w/v) agarose gel and photographed under UV 
light. Lane 1 shows molecular weight markers, <j>X174 digested with HaeIII. Lanes 2 and 3 
show negative and positive controls, respectively. Lanes 4 - 6  contain samples from two 
4T1 samples and MDA-MB-231 cells, respectively. Lane 7 shows a mycoplasma positive 
sample. A mycoplasma specific band of 660 bp is indicated.
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Fig 3.3: Metastatic burden in mice following tail vein injection of 4T1 tumour cells. 10' 
4T1 mammary adenocarcinoma cells were injected and animals sacrificed at the time 
points shown and lungs were removed and weighed. Tumour burden is expressed as 
lung weight/body weight x 100 (mean ±  S.E.M., n=3). Statistical analysis was by 
ANOVA, with Scheffe post-hoc correction * (p<0.05 vs day 0).
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Fig 3.4: Histological sections o f lung (A), liver (B) and brain (C) tissue o f mice 19 days 
after tail-vein injection o f 105 4T1 cells. Sections were stained with haematoxylin and eosin 
(original magnification X 200). Metastatic deposits containing at least 500 tumour cells are 
noted by an arrow in the lung section (a).
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3.2.4 Effect of surgery on metastatic tumour burden
The effect o f different surgical procedures on metastatic tumour growth was examined. 
105 4T1 cells were injected into the lateral tail vein o f mice as a single cell suspension in 
Ca2+ and Mg2+ free PBS. Two weeks later the mice underwent a designated surgical 
procedure (n=8/group). 5 days later animals were sacrificed, lungs removed and weighed 
and a lung : body weight index recorded as outlined (2.7.7). There was no significant 
difference between body weights in any o f the groups (Fig. 3.5), indicating that the 
animals were not cachectic (p=n.s.) and no apparent oedema was observed. Animals 
undergoing either laparotomy (3.37±0.14) or air laparoscopy (2.73±0.11) had 
significantly (p<0.001) higher metastatic burden than anaesthetic controls (1.32±0.12). 
Animals undergoing C 02 laparoscopy, where air is excluded had a metastatic burden 
similar to controls (1.94±0.42, p=n.s.) (Fig. 3.6).
3.2.5 Effect of surgery on mitosis and apoptosis within lung metastases
As it is ultimately the balance between proliferating cells and dying cells within 
metastases which govern their growth, the mitotic and apoptotic index within the 
metastases was determined. Similar trends were observed to those seen for metastatic 
burden. Figure 3.7A and 3.7B are representative sections showing mitotic and apoptotic 
cells, respectively. Animals undergoing either laparotomy (8.33±0.21) or air laparoscopy 
(7.99±0.09) had significantly (p<0.001) higher mitotic indices than anaesthetic controls 
(4.39±0.63) or C 0 2 laparoscopy (4.71±0.15) groups (Fig. 3.8). Laparotomy (1.31±0.13) 
or laparoscopy with air (1.33±0.42) resulted in significantly (p<0.01) lower apoptotic 
indices compared with controls (4.46±1.13). In contrast, mitotic (4.39±0.63) and 
apoptotic (3.17±0.76) indices in animals undergoing laparoscopy with C 0 2 were similar 
to controls (p=n.s.) (Fig. 3.8 and 3.9, respectively).
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As net tumour growth is determined by the relative numbers of proliferating and 
apoptotic tumour cells, the ratio o f mitosis : apoptosis, MI/AI was calculated as described 
in section 2.8. Laparotomy (6.20±0.35) or laparoscopy with air (6.35±1.00) resulted in 
significantly (p<0.01) higher ratios compared with either C 0 2 laparoscopy (1.54±0.19) or 
control (1.02±0.15) groups (Figure 3.10).
3.2.6 Effect of surgery on plasma endotoxin levels
It has previously been reported that surgery results in the translocation of endotoxin, 
across the gut into the abdominal cavity and systemic circulation (Watson et al, 1995). 
In that study, the levels of endotoxin peaked at 4 hours post-operatively. The levels of 
plasma endotoxin were therefore measured 4 hours post surgery using the LAL assay, as 
described in section 2.10. Laparotomy (1.22±0.18 EU/ml) and air laparoscopy 
(0.50±0.15 EU/ml) groups had significantly higher levels of circulating LPS than 
controls (0.13±0.19 EU/ml). Animals which underwent laparoscopy with air exclusion 
(C 02 laparoscopy) had levels o f LPS comparable to controls (0.19±0.14 EU/ml, p=n.s. vs 
control). (Fig. 3.11)
3.2.7 Effect of surgery on serum VEGF levels
The levels o f serum VEGF were measured by ELISA at 5 days after surgery, at the time 
of sacrifice. Laparotomy (77.92±5.00 pg/ml) and air laparoscopy (61.97±7.14 pg/ml) 
groups had significantly higher post-operative levels of circulating VEGF compared 
with either control (14.28±5.44 pg/ml) or C 0 2 laparoscopy groups (28.41±13.70 pg/ml) 
(Fig. 3.12). No significant difference was observed between the control and C 02 
laparoscopy group (p=n.s.). The presence of high levels o f this pro-angiogenic factor in 
the circulation following surgery suggests that an angiogenic mechanism may be
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involved in the enhanced metastatic tumour growth observed in the surgical groups 
exposed to air. The relationship between serum VEGF at the time o f sacrifice and the 
levels o f circulating endotoxin in the immediate post-operative period were examined. A 
significant positive correlation (Pearson Product Moment, r=0.966) was observed 
between circulating VEGF and LPS levels, when all surgical groups were examined in 
parallel (Fig. 3.13).
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Fig. 3.5: Body weights of mice following surgery. Surgery was performed two weeks 
after tail-vein injection of 105 4T1 mammary adenocarcinoma cells. 5 days later animals 
were weighed before sacrifice. Statistical analysis was by ANOVA, with Scheffe post- 
hoc correction (mean ± S.E.M., n=8/group). No significant differences in body weights 
was observed between any of the groups (p=n.s.).
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Fig. 3.6 : Metastatic burden in mice following surgery. Surgical procedures were
performed two weeks after tail-vein injection of 105 4T1 mammary adenocarcinoma 
cells. 5 days later animals were sacrificed and lungs removed and weighed. Tumour 
burden is expressed as lung weight/body weight x 100 (mean ± S.E.M., n=8/group). 
Statistical analysis was by ANOVA, with Scheffe post-hoc correction. A significant 
increase in metastatic growth was observed following laparotomy and air laparoscopy 
compared to controls * (pO.OOOl) or C 0 2 laparoscopy # (pO.OOl).
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Fig. 3.7 : Mitosis and apoptosis within lung métastasés following surgery. A. Mitotic cells 
in lung métastasés. Arrow indicates cell during metaphase with linear chromosome 
alignment (original magnification X 400). B. Apoptotic cells in lung métastasés. Arrow 
indicates apoptotic cell following TUNEL staining as described in section 2.8.2 (original 
magnification X  400).
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Fig. 3.8 : Mitotic index within metastases following surgery. Surgical procedures were 
performed two weeks after tail-vein injection o f 105 4T1 cells. 5 days later animals were 
sacrificed, lungs were removed and processed for histology. Mitotic index is expressed as 
the average number o f mitotic cells counted over 10 fields in a 1 mm3 grid, counting an 
average of 500 cells per grid (mean ± S.E.M., n=8/group). Statistical analysis was by 
ANOVA, with Scheffe post-hoc correction. A significant increase in mitotic indices was 
observed following laparotomy and air laparoscopy compared to controls or C 0 2 
laparoscopy *(p<0.001).
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Fig. 3.9: Apoptotic index within metastases following surgical treatment. Apoptotic 
cells within metastases were identified by TUNEL staining. The apoptotic index is 
expressed as the average number o f positively stained cells counted over 10 fields in a 1 
mm3 grid, counting an average of 500 cells per grid (mean ± S.E.M., n=8/group). 
Statistical analysis was by ANOVA, with Scheffe post-hoc correction. A significant 
reduction in apoptosis was observed following laparotomy or air laparoscopy compared 
to controls or C 02 laparoscopy *(p<0.01).
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Fig. 3.10: Mitosis : Apoptosis ratios within metastases following surgery. The number 
of mitotic and apoptotic cells (mean o f ten fields) were estimated for each group and the 
ratio calculated. Data represent the mean ± S.E.M (n=8 / group). A significant increase in 
mitosis : apoptosis ratios was observed following laparotomy or air laparoscopy * 
(p<0.01) compared to controls or C 02 laparoscopy. There was no significant difference 
between the controls and C 0 2 laparoscopy groups (p=n.s.)
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Fig. 3.11 *. Plasma endotoxin levels following surgery. Blood was collected by cardiac 
puncture and LPS levels were examined 4 h post-surgery by the LAL. Data represent 
mean ± S.E.M. (n=8 / group). Laparotomy * (p<0.001) and air iaparoscopy # (p<0.03) 
both resulted in significantly elevated levels o f circulating LPS compared to the controls 
receiving anaesthesia alone. No significant difference was observed between the control 
and C 0 2 laparoscopy groups (p=n.s.)
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Fig. 3.12: Serum VEGF in mice following surgery. 5 days post-operatively, blood was 
obtained by cardiac puncture and VEGF was assessed by quantitative ELISA. Data 
represent mean ± S.E.M. (n=8 / group). A significant increase in circulating levels of 
VEGF was observed following laparotomy and air laparoscopy compared to controls * 
(pO.OOl) or C 02 laparoscopy groups # (p<0.01).
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Fig. 3.13: Circulating VEGF in relation to plasma LPS levels (n=20). The relationship 
between serum VEGF and plasma LPS levels was examined by Pearson Product 
Moment correlation. A strong positive correlation (r=0.966) was observed between 
serum VEGF at 5 days and plasma LPS levels 4 h post-surgery.
20 rt*
An experimental model of pulmonary metastasis with no primary tumour was established 
to examine the effect o f surgeiy on post-operative metastatic tumour growth in mice. 
Laparotomy, or open surgery, resulted in increased metastatic tumour growth compared 
to controls receiving anaesthesia only. It has been known for many years that major 
surgical trauma induces profound immunosuppression (Lennard et al., 1985; Arai et al.,
1992). As various forms of anaesthesia have also been implicated in post-operative 
immuno-suppression (Vose and Moudgil, 1976; Cullen, 1976; Lundy et al., 1978), the 
control group received halothane anaesthesia for the same period of time to correct for 
any effects of anaesthesia on tumour growth. These results are in agreement with other 
recent reports, indicating that open surgical procedures result in significantly higher post­
operative tumour growth than minimally invasive techniques (Allendorf et al., 1998; Da 
Costa et al., 1998). To examine the effect of minimally invasive surgery on metastatic 
tumour growth, two groups receiving laparoscopy with air or C 0 2 insufflation of the 
peritoneum were included. Mice which received laparoscopy with sterile C 0 2, where air 
is excluded from the peritoneum, had a metastatic burden comparable to controls. 
However, when the laparoscopy procedure was performed using room air, which 
contains endotoxin, significant increases in metastastic growth was observed. The level 
of metastatic growth was, in fact, comparable to that o f mice which underwent open 
laparotomy, implicating an airborne factor in the increased metastatic tumour growth 
observed in this group.
The removal of a primary tumour (and consequently the anti-angiogenic factors it 
produces) has been implicated in postoperative tumour metastatic growth (O’Reilly et 
al., 1994; O ’Reilly et al., 1997). In the model used here there was no primary tumour 
established. Therefore, the increased metastatic tumour growth observed in animals
3.3 Discussion
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exposed to air during the surgical procedure cannot be attributed to the removal of anti- 
angiogenic factors derived from primary tumours. As tumour growth is controlled at the 
cellular level by the balances between cellular proliferation and apoptotic death within 
cell populations, the extent o f mitosis and apoptosis was examined 
immunohistochemically within metastases. The increases in metastatic burden coincided 
with significantly higher tumour cell mitosis and lower apoptosis within lung metastases 
of both laparotomy and air laparoscopy groups. With both sides of the balance altered in 
favour of tumour cell expansion, metastases grew rapidly and significant increases in 
tumour burden were observed after 5 days. Mitotic cells were identified morphologically 
in haematoxylin and eosin stained tissues. Although this method identified significant 
differences between groups, reports suggest that staining metastases for antigens 
associated with cellular proliferation (such as Ki67 or proliferating cell nuclear antigen 
PCNA) may detect up to 3 times the amount o f proliferating cells (Huang et al., 1994). It 
is therefore possible that the ratio of mitosis : apoptosis within these surgical groups is an 
under-estimate, and if  PCNA or Ki67 staining were performed a much higher ratio may 
be observed. However, other reports have also suggested that these methods grossly 
over-exaggerate the proliferating fraction of cell populations (Scott et al., 1991)
It has been suggested that the effect of open surgery on distant tumour growth 
could be due to the spill over of wound factors, such as sVEGF, into the circulation post- 
operatively. In this study it is unlikely that this is the case, as similar responses were 
observed in groups which contained a significant wound (laparotomy) and in the group 
receiving laparoscopy with air, in which no significant wound was present. These effects 
indicate that systemic factors were responsible for the alterations in tumour growth. Both 
laparotomy and air contamination of the peritoneum have previously been shown to 
result in bacterial translocation across the gut, and the release of endotoxin into the
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peritoneal cavity and systemic circulation (Watson et al., 1995). In that study levels of 
endotoxin peaked 4 hours post-operatively. Plasma endotoxin levels were therefore 
measured 4 h post surgery in this study. Significantly higher levels o f plasma endotoxin 
were observed in animals which underwent either laparotomy or laparoscopy with air 
compared to controls. However, when circulating endotoxin levels were examined in the 
C 02 laparoscopy group, there was no difference to that o f controls. Endotoxin is present 
ubiquitously in the air at concentrations of approximately 1 ^g / m3 (Rylander et al.,
1989). It is also a major component of endogenous gut bacteria. A possible mechanism 
responsible for the increased metastatic tumour growth observed in this study is through 
quantities of endotoxin introduced into the peritioneal cavity following laparotomy or 
laparoscopy with air, which in combination with intestinal agitation, could result in the 
translocation of endotoxin from gut flora into the systemic circulation. Having entered 
the circulation, endotoxin could effect the growth of distant metastases. Indeed, it has 
been directly implicated in cellular proliferation and differentiation, possibly through the 
phosphorylation and activation of several protein kinases (Weinstein et al., 1992; Shapira 
et al., 1994).
Vascular endothelial growth factor (VEGF) is the most potent angiogenic factor 
identified to date (Peters et al., 1993). It's production is regulated by a range of effector 
molecules and cytokines. It has recently been shown that endotoxin upregulates VEGF 
expression by human pulp cells through a soluble CD 14 mediated mechanism 
(Matsushita et al., 1999). Angiogenesis is critical for the growth of metastases and its 
suppression results in tumour dormancy (Holmgren et al., 1995). VEGF expression has 
been shown to correlate with the level of metastases in experimental melanomas 
(Claffey et al., 1996). Therefore levels of circulating VEGF were estimated by ELISA. 
Open surgery or air laparoscopy resulted in significantly elevated levels of circulating
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serum VEGF compared with either the C 0 2 laparoscopy group or controls. As increased 
metastatic burden was observed in these groups, it is possible that the increases in VEGF 
could simply be a consequence of the increased tumour volume. However, separate 
studies in our laboratory have found increased VEGF expression within tumour nodules 
from endotoxin treated mice compared to tumour nodules from untreated mice (Harmey, 
un-published observations). When the levels o f plasma endotoxin were compared with 
circulating VEGF in all groups, a strong positive correlation was observed. This suggests 
that in addition to promoting tumour growth, the surgical introduction o f endotoxin 
induced the release o f the pro-angiogenic cytokine VEGF.
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Chapter 4
Endotoxin and Anti-Endotoxin Therapies in 
Metastatic Tumour Growth
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It has been reported that infection, and its associated inflammation, are risk factors in 
many forms of cancer (Correa, 1992; Schiller, 1988; Kantor, 1984). Increased tumour 
growth and capillary proliferation into the tumour stroma has been reported in a rat 
model of bladder cancer following infection with killed E.coli (Yamamoto et al., 1992), 
supporting the theory that bacteria, or components thereof, are angiogenic in the tumour 
microenvironment. With rcspect to bladder cancer, other investigators have reported the 
tumour enhancing effect of urinary tract bacterial infections, and these have been 
attributed to lipopolysaccharide (LPS) / endotoxin (Kawai et al., 1993; Johansson et al., 
1987). These studies also reported increased angiogenesis in the tumour stroma, and 
endotoxin has been shown to be angiogenic in a number o f in vivo model systems, 
inducing angiogenesis in the corneal implant model in rabbits (Li et al., 1991; BenEzra et 
al., 1993) and also in the rat mesentery (Mattsby-Baltzer et al., 1994).
Bacterial endotoxin has a wide range of biological effects on a number of cells 
and organs in the host (Morrison and Ryan., 1979; Raetz et al., 1991). There are a 
number of mechanisms through which it may exert its angiogenic and tumour enhancing 
effects. Stimulation of macrophages and other cells to release cytokines such as TNF-a  , 
IL-1, IL-6 and bFGF are possible pro-tumour effector molecules (Austgulen & Nissen- 
Meyer, 1988, Motro et al., 1990; Fajardo et al., 1992). These cytokines have been 
suggested to be involved in the pathogenesis of psoriasis, which is characterised by 
increased angiogenesis in the skin and increased proliferation o f keratinocytes (Nickoloff 
et al., 1991; Kupper, 1988). The cytokine network induced by LPS plays a significant 
role in cellular proliferation in inflammation-induced urothelial hyperplasia (Kawai et al.,
1993). Inflammation induces short lived effects on host vasculature, such as increased
4.1 Introduction
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permeability and activation o f endothelium, as well as chronic effects such as extensive 
mitosis of the endothelium resulting in the remodeling o f capillaries and venules 
(Thurston et al., 1998). Indeed, recently LPS has been shown to increase VEGF 
expression by human pulp cells (Matsushita et al., 1999), which could account for these 
observations. It is likely that inflammation influences metastasis which is facilitated by 
hyperpermeability and increased proliferation of blood vessels (see section 1.3).
Endogenous gut bacteria are a major source o f endotoxin, which can be released 
following bacterial cell division or upon lysis of the bacterial cell. Significant 
translocation of endotoxin into the peritoneal cavity and systemic circulation occurs 
following open surgery or laparoscopy with air-sufflation within as little as 2-4 hours 
(Watson et al., 1995). Subsequent observations on laparotomy-induced growth of the 
murine B16 flank tumour suggested that, in addition to post-operative 
immunosuppression, exposure of the peritoneal cavity to air, and the minute quantities of 
LPS in this air, are causal factors in this tumour growth (DaCosta et al., 1998).
As there is accumulating evidence to suggest that LPS, either directly or 
indirectly through the induction of inflammatory cytokines, is a possible regulator of 
tumour growth and angiogenesis, strategies which neutralise LPS or block the production 
or biological effects of LPS-induced cytokines, may be useful in cancer therapy. 
Physiologically, the body has developed regulatory mechanisms to deal with, and control 
our response to bacterial infection. The polymorphonuclear leukocytes (PMN) play a 
central role in the host defense against gram negative bacteria. Bactericidal/permeability 
increasing protein (BPI) is a 55-kDa cationic protein localised in the azurophilic granules 
of mature neutrophils that specifically kills gram negative bacteria (Weiss et al., 1978). 
This protein was first purified by Weiss et al. in 1978 and has been isolated from both 
human and rabbit neutrophils. In a similar way to LPS binding protein (LBP), BPI
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interacts with LPS to form high affinity complexes. The binding of LPS by BPI prevents 
binding by LBP, and the subsequent binding to the cellular receptor CD 14, therefore 
neutralising the inflammatory cascade associated with LPS (Marra et al., 1990; Marra et 
al., 1992).
The LPS binding property of BPI has been localised to its N-terminal fragment 
(Abrahamson et al., 1997) and a 25-kDa recombinant form of BPI, termed rBPI21 has 
been developed (Ooi et al., 1987). Essentially, rBPI21 is the proteolytic N-terminal 193 
amino acids of the holoprotein BPI produced from engineered Chinese Hamster Ovary 
(CHO) cells in culture, with a single amino acid change at position 132 with cysteine 
being substituted with alanine (communication with Dr. R. Dedrick, Xoma, Ca., US). 
BPI binds to a region close to lipid A, however minimal binding is observed to 
monophosphoryl lipid A (Jahr et al., 1995). Results from Jahr and co-workers (1995) 
indicate that rBPI21 has a considerably higher neutralising activity on LPS with long 
polysaccharide chains compared to LPS which contains only 2-keto-3-deoxyoctane 
(KDO) sugars (see Fig. 1.3). Differential TNF-a  production, in response to different LPS 
molecules and BPI, led the authors to suggest that rBPI21 may have a higher affinity for 
smooth LPS than for the lipid A moiety and that therefore rBPI2, may interact with the 
polysaccharide part of the LPS molecule. Elsbach et al. (1994) compared the inhibitory 
effect of BPI with rBPI21 on bacterial growth and found that BPIs inhibitory effects 
diminished with increasing polysaccharide chain length (Elsbach et al., 1994). It was 
suggested that long hydrophilic polysaccharide chains impede BPI binding to the lipid A 
region which is embedded in the outer membrane of the gram-negative bacterial 
envelope and that the smaller 25-kDa rBPI fragment penetrated more easily. These 
observations suggest that LPS and lipid A may use different mechanisms to stimulate 
monocyte TNF-a  production, and implies that CD 14 may bind polysaccharide parts of
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LPS as well as lipid A. They may also explain why anti-endotoxin therapies, such as the 
E5 anti-lipid A murine monoclonal antibody, designed to neutralise the lipid A moiety of 
the LPS molecule, failed to have satisfactory endotoxin-neutralising activity in vivo 
(Baumgartner et al., 1991 ; Marra et al., 1994).
The aim of this chapter was to investigate the effect o f endotoxin exposure on 
metastatic tumour growth. Metastatic burden, mitosis and apoptosis within the lung 
métastasés were assessed. Circulating levels o f serum VEGF were also measured post- 
LPS injection to examine if LPS induced the release o f this pro-angiogenic factor into the 
circulation. The use of the novel anti-endotoxin agent rBPI2] was investigated in 
comparison to the monoclonal anti-lipid A antibody E5 in blocking LPS induced 
alterations in tumour growth. A separate group was included which received a control 
peptide the same size as rBPI21, thaumatin, which has no anti-LPS activity. Finally, the 
use of these anti-endotoxin agents in the post-operative period was investigated, to 
examine if anti-endotoxin strategies could reduce surgically induced tumour growth and 
angiogenesis.
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4.2 Results
4.2.1 Dose response for endotoxin injection
Endotoxin / lipopolysaccharide (LPS) has been shown to be angiogenic. As angiogenesis 
is critical for the growth of both primary and metastatic tumours, the effect o f LPS on 
metastatic growth was examined. An initial set of experiments was carried out to 
establish a clinically relevant dose without associated morbidity or toxicity in mice. 
Experimental lung metastases were established by tail vein injection of 4T1 mammary 
adenocarcinoma cells. 14 days after injection animals received an intra-peritoneal 
injection of LPS (0, 1 ng, 10 ng, 100 ng, 1 ^g, 10 ^g, 100 ^g) in saline. These 
concentrations reflect the clinical setting where plasma concentrations of 2 ng/ml - 20 
l^g/'ml have been reported and shown to be angiogenic (Mattsby-Baltzer et al., 1994). 
Animals were sacrificed 5 days later and a lung to body weight ratio calculated as before. 
10 jjg LPS/animal (2.063+0.287) and 100 ^g LPS/animal (2.193+0.285) resulted in 
significantly (p<0.02) increased metastatic burden compared to control animals receiving 
a saline injection (0.597+0.023) (Figure 4.1). The higher dose of 100 ng, however, was 
outside the clinically relevant dose previously reported and had an associated mortality 
rate of 40% by day 4 post-injection. Therefore, a dose o f 10 ^g/animal was chosen to 
further investigate the effect o f LPS on other parameters involved in tumour growth.
4.2.2 Effect of LPS on metastatic tumour burden, mitosis and apoptosis within lung 
metastases
There was no significant difference between body weights of animals receiving 10 ^g 
LPS and saline controls (Fig. 4.2.A), indicating that the animals were not cachectic 
(p=n.s.) and no apparent oedema was observed. As in the dose-response experiment, 10 
l^g of endotoxin (2.84±0.20) resulted in a significantly (p<0.001) higher metastatic
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from each group are shown in Figure 4.2.C demonstrating increased macroscopic
metastases in mice which received endotoxin injection relative to controls. Mitosis and
apoptosis within the lung metastases were assessed by counting mitotic figures and
TUNEL stained cells respectively, and calculating the number of cells per grid of 500
cells. The higher metastatic burden was accompanied by a significantly (p<0.05) higher
mitotic index in the endotoxin injection group (7.68+0.24) compared to the saline
injection group (4.74+0.99), (Fig. 4.3.A). In addition, a significantly (p<0.05) lower
apoptotic index was observed in the endotoxin group (1.27+0.11) compared to the saline
group (2.98+0.53) (Fig. 4.3.B). As it is ultimately the balance between mitosis and
apoptosis that governs net tumour growth, a ratio o f mitosis : apoptosis within the
metastases was calculated. The MI/AI ratio in the endotoxin injection group (6.18+0.64) 
was significantly (p<0.02) higher than the ratio observed following saline injection
(2.02+0.88), (Fig. 4.3.C). This represented a 3-fold increase in MI/AI ratio in the 
endotoxin treated animals.
4.2.3 Effect of LPS on circulating levels of serum VEGF
As VEGF is the most potent angiogenic factor identified and LPS has been shown to 
increase its expression by certain cell types (Matsushita et al., 1999), the levels o f serum 
VEGF were measured by ELISA. The endotoxin injection group (207.85±42.74 pg/ml) 
was found to have significantly (p<0.003) higher levels o f circulating VEGF compared 
with the saline treated group (33.88±7.34 pg/ml) (Fig. 4.4). This represents a six-fold 
increase in circulating VEGF following LPS injection, demonstrating that LPS has a pro- 
angiogenic effect, which could contribute to the increased metastatic tumour growth 
observed in mice following endotoxin injection.
burden compared with the saline controls (1.99±0.10), (Fig. 4.2.B). Photographs o f lungs
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Fig 4.1 : Effect of LPS on experimental lung metastases. 14 days after tail vein injection 
o f 105 4T1 cells, mice (n=3) received an injection of saline or LPS. 5 days later mice 
were sacrificed and a lung : body weight index calculated. Data represents mean ± 
S.E.M. * p<0.05 (ANOVA with Scheffe post-hoc correction).
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Fig. 4.2 : Effect o f LPS on metastatic tumour growth. 14 days after tail vein injection of 
105 4T1 cells, mice (n=8/group) received an i.p injection of saline or 10 mg LPS. 5 days 
later mice were sacrificed. Data represents mean + S.E.M. Statistical analysis was by 
students t-test. A. Body weight p=n.s. B. Lung metastatic burden * (p<0.001). C. 
Representative lungs.
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Fig. 4.3 : Mitosis and Apoptosis within lung metastases in histological sections. In each 
case an average o f 500 cells/mnr grid were scored in 10 fields/section. Mitotic cells were 
estimated by counting mitotic figures and apoptosis by counting cells stained positive by 
TUNEL. Data is represented as mean + S.E.M (n=8). Statistical analysis was by students 
t-test. A. Mitotic Index within lung metastases, * p<0.04. B. Apoptotic index within lung 
metastases, * p<0.05.
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Fig. 4.3: D. Mitosis : Apoptosis ratio within lung metastascs, * p<0.02.
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Fig 4.4 : Serum VEGF in tumour bearing mice following endotoxin injection. On the day 
of sacrifice, blood was obtained by cardiac puncture and VEGF assessed by ELISA. Data 
represent mean ± s.e.m. (n=8 / group). Statistical analysis was by students t-test, 
*(p<0.003).
113
4.2.4 Effect of anti-endotoxin rBPI2i on LPS induced metastatic growth.
Having demonstrated that intra-peritoneal injection of LPS increases metastatic tumour 
growth in the murine model of breast cancer, the efficacy o f anti-endotoxin treatments in 
attenuating this increased growth was evaluated. A novel recombinant bactericidal 
permeability-increasing protein (BPI), named rBPI21, and a control peptide of the same 
size, thaumatin, were gifts from Xoma Corporation, CA. US. Mice were injected with 
105 4T1 cells via the lateral tail vein as previously described. Two weeks later the mice 
received an intra-peritoneal injection o f either sterile saline or 10 ^g LPS, in combination 
with the dose regime of rBPI21, thaumatin or formulation buffer outlined in section 2.7.5. 
Five days after LPS or saline injection animals were sacrificed and a lung / body weight 
index recorded. LPS injection (1.81+0.12) resulted in a significantly (p<0.001) higher 
metastatic burden compared to saline injected controls (0.83+0.80). However, when 
rBPI21 treatment was injected with LPS (0.804+0.12) the LPS-induced increase in 
metastatic burden was significantly (p<0.001) attenuated (Figure 4.5.A). rBPI21 
completely blocked LPS-induced metastatic growth, with metastatic burden in these 
animals comparable to saline controls. The control peptide, thaumatin had no effect on 
LPS induced metastatic growth (1.869+0.089). Representative lungs taken from each of 
the six groups clearly show the effect of rBPI21 treatment on LPS-induced lung 
metastatic growth (Figure 4.5.B).
The altered growth kinetics observed in these experiments relative to previous groups of 
mice (Section 4.1 and 4.2) is due to the fact that a different batch of 4T1 cells was 
obtained from another laboratory (Fred Miller, Duke University) following the loss of all 
cell culture stocks, due to liquid nitrogen failure within our facility. Factors such as the 
source of cells, their preparation, and the length of time between injections, all contribute
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to the inter-batch variations observed between experiments. Although there are 
differences between metastatic burden, mitotic index (MI) and apoptotic index (AI) 
between experiments, there is a clear trend reflected in all the groups. Higher Mis are 
observed in groups with high metastatic burdens, and correspondingly lower AIs are also 
observed in these groups. Increased metastatic burden was observed in mice receiving 
LPS relative to controls, demonstrating the validity of the model with the newly obtained 
cells. A table of the various batches of mice from different experiments is shown in Table 
4.1. These data clearly demonstrate the relationship between net tumour growth and the 
proliferation / apoptotic balance.
4.2.5 Effect of rBPI21 on mitosis and apoptosis within metastases.
The mitotic and apoptotic index within the metastases was examined histologically. A 
similar trend was observed to that seen in the lung/body weight ratios. Endotoxin 
injection (4.90±0.26 cells/grid) resulted in significantly (p<0.001) higher mitotic indices 
compared to saline controls (1.47±0.29). However, when mice were treated with rBPI21 
following LPS injection (1.46+0.355) the mitotic index was significantly (p<0.001) 
reduced to the level of saline controls (Fig.4.6 A). rBPI completely blocked LPS induced 
increases in mitotic index compared to saline controls. Thaumatin treatment (4.70+0.336) 
had no effect on LPS induced increases in mitotic indices.
When apoptosis was examined, LPS injection (1.58+0.067) resulted in significantly 
(p<0.001) reduced numbers of apoptotic cells within metastases compared to saline 
injected mice (4.36+0.467). rBPI2] treatment (3.79+0.043) significantly prevented LPS 
mediated inhibition o f tumour cell apoptosis (p<0.003 vs LPS), while thaumatin 
treatment (1.13+0.043) had no effect (Fig. 4.6 B). There was almost a complete
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inhibition in LPS-induced reduction in apoptosis following treatment with rBPI. The 
MI/AI ratio was calculated as described in section 2.8. LPS injection (3.436+0.337) 
resulted in significantly higher ratios compared to saline injected mice (0.365+0.108, 
p<0.002) or mice receiving LPS with rBPI21 treatment (0.467+0.059, p<0.005) (Figure
4.6 C). Thaumatin had no effect on LPS induced MI:AI indices (4.121+0.681 vs 
3.436+0.337, p=n.s). It is clear that rBPI21 blocks the stimulation of tumour growth by 
LPS by inhibiting it's effect on apoptosis and mitosis, the opposing processes governing 
tumour growth.
4.2.6 Effect of rBPI21 on LPS induced serum VEGF.
Intra-peritoneal injection of LPS was previously shown to increase circulating levels of 
VEGF (4.2.3), therefore serum VEGF levels were examined in mice following LPS 
injection and rBPI21 treatment to establish whether rBPI2] could prevent the pro- 
angiogenic effect o f LPS. LPS injection (292.4+65.94 pg/ml) resulted in higher 
circulating VEGF than saline injected controls (86.07+1.64 pg/ml) as before. Treatment 
with rBPI21 following LPS injection (144.48+79.9 pg/ml) did not significantly reduce 
LPS-induced circulating VEGF (p=n.s, vs LPS only), although an apparent reduction in 
the levels of VEGF was observed (Fig. 4.7). Treatment with the control peptide 
thaumatin (191.3+87.64 pg/ml) did not effect LPS induced VEGF. The effect of rBPI21 
may not have reached statistical significance because o f the small numbers of bloods 
analysed in the study (n=4) and considerable variation in the levels of VEGF production 
between mice. Nevertheless the data suggests a trend toward rBPI blocking VEGF 
induction.
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Fig. 4.5 Effect o f rBPI21 on LPS induced metastatic growth. Mice received 1 x 105 4T1 
tumour cells by tail vein injection, followed 14 days later by either saline or endotoxin 
(10 ^g/animal) i.p., with or without rBPI21 or thaumatin as indicated. Mice were 
sacrificed 5 days after intra-peritoneal injection and their lungs excised. A: Tumour 
burden is expressed as lung weight/body weight x 100. Data is expressed as mean ± 
S.E.M. (n=4). Statistical analysis was by ANOVA with Scheffe post-hoc correction * 
(pO.OOl vs control), # (p<0.001 vs LPS). B: Representative lungs.
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Experimental Metastatic Mitotic Index Apoptotic M I/ AI
Group Burden (MI) Index (Al)
Section 3.2
Control 1.32+0.12 4.39+0.63 4.46+1.13 1.02+0.15
C 0 2 Laparoscopy 1.94+0.42 4.71+0.63 3.17+0.76 1.54+0.19
Air Laparoscopy 2.73+0.12 7.99+0.09 1.33+0.42 6.35+1.00
Laparotomy 3.37+0.14 8.33+0.21 1.31+0.13 6.20+0.35
Section 4.2
Saline Injection 1.99+0.10 4.74+0.99 2.98+0.53 2.02+0.64
LPS Injection 2.84+0.20 7.68+0.24 1.27+0.11 6.18+0.64
Section 4.2
Control 0.83+0.80 1.47+0.29 4.36+0.047 0.365+0.108
LPS 1.81+0.12 4.90+0.26 1.58+0.067 3.436+0.337
LPS + rBPI21 0.804+0.12 1.46+0.355 3.79+0.043 0.467+0.059
LPS + thaumatin 1.869+0.089 4.70+0.336 1.13+0.043 4.121+0.681
Table 4.1 Comparison o f metastatic burden, mitotic indices, apoptotic indices and 
MI/AI index between experimental groups.
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Fig. 4.6 Effect of rBPI21 on mitosis and apoptosis within lung métastasés following LPS 
injection. Data is expressed as mean + S.E.M. (n=4). Statistical analysis is by ANOVA 
with Scheffe post-hoc correction A: Mitotic index within métastasés *(p<0.001 vs 
controls) #(p<0.001 vs LPS injection). B: Apoptotic index within métastasés *(p<0.001 
vs controls) #(p<0.003 vs LPS injection). C. Mitosis : Apoptosis ratios within 
métastasés *(p<0.002 vs controls) #(p<0.005 vs LPS injection).
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Fig 4.7 : Serum VEGF in mice following endotoxin injection and rBPI21 treatment. 5 days 
after injection blood was obtained by cardiac puncture and VEGF assessed by ELISA. 
Data represent mean ± S.E.M. (n=4 / group). Statistical analysis is by ANOVA with 
Scheffe post-hoc correction (p=n.s. between all groups).
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Section 3.2.6 showed elevated plasma LPS in mice following surgery with a tight 
correlation between serum VEGF and LPS (section 3.2.7). Having demonstrated that 
LPS increases metastatic burden in mice and the anti-endotoxin agent rBPI21 blocks this 
effect, the effect o f rBPI2I on surgically-enhanced metastatic tumour growth was 
investigated. rBPI2] and the control peptide thaumatin, were used as before. The 
efficiency of rBPI21, which binds to a region on / or close to the lipid A moiety and the 
anti-Lipid A murine monoclonal antibody, E5, obtained from Xoma Corporation (CA. 
US) were compared. Mice were injected with 1 x 105 cells via the lateral tail vein as 
before. Two weeks later the mice received a mid-line laparotomy with intestinal agitation 
or anaesthesia alone for a period of 30 min (described in section 2.7.3), in combination 
with the treatment schedule of rBPI21, thaumatin , E5 or formulation buffer as described 
(section 2.7.5). 5 days later the animals were sacrificed, their lungs removed and a lung / 
body weight index recorded (Fig. 4.8). Surgery (1.135+0.124) resulted in a significantly 
(p<0.001) higher metastatic burden compared to saline injected controls (0.674+0.026). 
rBPI21 treatment significantly reduced surgically enhanced metastatic tumour growth 
(0.637+0.018 vs 1.135+0.124, p<0.002). The metastatic burden in rBPI treated animals 
was comparable to control animals which did not receive a surgical insult. Treatment 
with the anti-Lipid A antibody E5 had no effect on surgically induced metastatic growth 
(0.994+0.127 vs 1.135+0.124, p=n.s.) Similarly, the control peptide, thaumatin 
(1.13+0.152) had no protective effect.
These results implicate LPS as a causative factor in surgically enhanced tumour growth, 
as the anti-LPS agent rBPI is capable of preventing this enhanced growth. The results 
also indicate that rBPI is far more effective at blocking LPS and surgically induced
4.2.7 Effect of rBPI2] or E5 on surgically-induced metastatic burden.
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metastatic growth than the monoclonal antibody E5. E5 is no longer in production by 
Xoma Corp., and it was for this reason that there was only a limited supply available to 
use in this one study.
4.2.8 Effect of rBPI21 and E5 on mitosis and apoptosis within surgically-induced 
metastases.
The mitotic and apoptotic indices within lung metastases was calculated to determine the 
numbers o f proliferating and apoptotic cells within metastases. Open surgery 
(5.29+0.226) resulted in significantly (p<0.001) higher mitotic indices compared to 
anaesthesia controls (1.44±0.131). However, when mice were treated with rBPI21 
following surgery (1.61+0.205) the mitotic index was significantly (p<0.001) reduced to 
that observed in lung metastases of anaesthetic controls (Fig.4.9 A). Treatment with 
either the monoclonal antibody E5 (4.57+0.327) or thaumatin (5.20+0.20) had no effect 
on surgically-induced increases in mitotic indices.
When apoptosis was examined, surgery (1.12+0.128) significantly (p<0.001) reduced the 
number of apoptotic cells within metastases compared to mice undergoing anaesthesia 
alone (4.37+0.288). rBPI21 treatment (4.44+0.396) prevented the reduction in apoptosis 
observed in the lung metastases of animals following surgery (p<0.001 vs Surgery) with 
levels comparable to controls, while E5 (1.28+0.061) or thaumatin treatment 
(1.28+0.182) had no effect (Fig. 4.9 B). The ratio of mitotic : apoptotic cells (MI/AI) was 
calculated as described in section 2.8. Open surgery (5.048+0.717) resulted in 
significantly (p<0.001) higher ratios compared to anaesthetic controls (0.341+0.049). 
rBPI21 treatment (0.364+0.042) prevented this increase with a similar MI/AI to control 
mice (p<0.001 vs Surgery) (Figure 4.9 C). Neither E5 (3.637+0.369), nor thaumatin
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(4.482+0.735) had any effect on the increased MI/A1 observed in mice which received 
laparotomy. In each case, as before, the MI/AI reflects the metastatic burden, with a high 
MI/AI in those groups with a high metastatic burden.
4.2.9 Effect of anti-endotoxin rBPI21 and E5 on surgically induced serum VEGF.
Chapter 3 showed that laparotomy increased circulating levels o f VEGF and this increase 
was associated with increased circulating LPS in the plasma. The levels o f VEGF 
following surgery and rBPI21, E5 or thaumatin treatment were examined. Open surgery 
(213.56+39.2 pg/ml) resulted in significantly (p<0.01) higher circulating VEGF than in 
animals receiving anaesthesia alone (21.14+6.69 pg/ml). Treatment with rBPI21 following 
surgery (39.69+10.18 pg/ml) significantly (p<0.02) reduced circulating levels o f VEGF, 
compared to animals undergoing surgery (Fig. 4.10). However, this level was still twice 
that observed in the control groups, so rBPI2, does not appear to completely block 
surgically induced VEGF. Thaumatin (184.87+23.22 pg/ml) or E5 (180.80+13.56) failed 
to reduce circulating VEGF levels following surgery. This indicates that blocking the 
lipid-A moiety alone is not sufficient to block the angiogenic response to LPS in tumour 
bearing mice, whereas rBPI which can also bind regions outside of the lipid A moiety 
can.
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Fig. 4.8 : Effect of endotoxin blockade on surgically-induced metastatic growth. Mice 
(n=5/group) received 105 4T1 cells by tail vein injection. 14 days later mice underwent a 
laparotomy or laparotomy combined with the anti-endotoxin agents rBPI, E5 or 
thaumatin control peptide. Control mice received anaesthetic only. Mice were sacrificed 
5 days later and the lung:body weight index recorded. Data is expressed as mean + 
S.E.M. Statistical analysis is by ANOVA with Scheffe post-hoc correction * (pO.OOl vs 
control) # (p<0.002 vs Laparotomy).
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Fig. 4.9. Mice (n=5/group) received 105 4T1 cells by tail vein injection. 14 days later 
mice underwent a laparotomy or laparotomy combined with the anti-endotoxin agents 
rBPI, E5 or thaumatin control peptide. Control mice received anaesthetic only. Data is 
expressed as mean ± S.E.M (n=5/group). Statistical analysis is by ANOVA with Scheffe 
post-hoc correction. A: Mitotic index within metastases * (p<0.001 vs control) # 
(p<0.001 vs Laparotomy). B: Apoptotic index within metastases * (p<0.001 vs control) # 
(p<0.001 vs Laparotomy). C. Mitosis : Apoptosis ratios within metastases * (p<0.001 vs 
control) # (p<0.001 vs Laparotomy).
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Fig 4.10: Effect of endotoxin blockade on surgically-induced serum VEGF. 5 days post- 
operatively, blood was obtained by cardiac puncture and VEGF assessed by ELISA. Data 
represent mean ± S.E.M. (n=5 / group). Statistical analysis is by ANOVA with Scheffe 
post-hoc correction * (p<0.01 vs control) # (p<0.02 vs Laparotomy).
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The data presented in this chapter show that endotoxin injection into the peritoneal cavity 
results in enhanced growth of established metastases in the lungs of mice. Following a 
dose response experiment, a concentration of 10 jjg LPS / mouse was shown to result in 
significantly higher metastatic burden compared to saline controls, reflected by increased 
lung / body weight indices. This dose was well tolerated in mice, with no associated 
cachexia, and was within the clinically relevant doses described in previous reports (2 ng- 
20 j^g/ml) (Mattsby-Baltzer et a l, 1994). In addition, this dose is within the range of 
those previously reported to induce angiogenesis in the mesentery window assay and 
increase bladder tumourigenesis in vivo (Mattsby-Baltzer el a l, 1994; Kawai et a l, 
1993). The enhanced tumour growth in response to LPS was reflected by increased 
proliferation and also by decreased apoptosis within the lung metastatic deposits. The 
consequence of these effects tip the balances governing tumour growth in favour of 
tumour expansion, resulting in a 50% increase in metastatic burden in mice following 
LPS injection.
There are many possible mechanisms accounting for the tumour-enhancing effect 
of LPS. Endotoxin has previously been shown to increase the incidence of tumours in the 
bladders of rats pre-treated with /V-mcthyl-iV-nitrosourea (Kawai et al., 1993). In this 
study the enhanced effects were associated with increased oxidative stress by the reactive 
oxygen species H20 2 in the bladder lumen, and a proliferative response of the 
carcinogen-exposed urothelium to the inflammatory stimulation. LPS may also increase 
the proliferation of the tumour cells directly, through the phosphorylation and activation 
of several protein kinases such as protein tyrosine kinase (PTK) and protein kinase C 
(PKC), which have been implicated in cellular proliferation and differentiation 
(Weinstein et al., 1992; Shapira et al., 1994). It is also possible that the increased
4.3 Discussion
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proliferation observed in these tumour métastasés is a consequence o f cytokines 
produced in response to LPS. LPS can induce the release o f cytokines such as IL-1, IL-6 
and TNF-a , which have been shown to be involved in the proliferation o f keratinocytes 
and subsequent pathogenesis of psoriasis (Nickoloff et al., 1991; Kupper, 1988). Indeed, 
TNF-a has been associated with increased tumour métastasés in murine and human 
tumour models (Malik et a l, 1990; Orosz et a l,  1993). In addition, the cytokines elicited 
by LPS, such as TNF-a  may be angiogenic and result in marked vascular proliferation in 
the stroma of tumours (Leibovich et al., 1987).
In this study, injection o f LPS resulted in a six-fold increase in circulating levels 
of the potent pro-angiogenic cytokine VEGF. In addition a strong positive correlation 
between post-operative levels of LPS and serum VEGF was identified in previous 
experiments, described in chapter 3. Taken together these data suggest that LPS has a 
pro-angiogenic effect in 4T1 lung métastasés through the induction of VEGF. On the 
other hand, levels of circulating VEGF may simply reflect the increased tumour burden 
observed in mice following LPS injection. However, the fact that a six-fold increase was 
observed in circulating levels, compared to only a 50% increase in metastatic burden, 
would suggest that tumour bulk alone is not responsible for the elevated levels of this 
angiogenic factor. These observations, coupled with the knowledge that LPS induces 
VEGF expression in human pulp cells (Matsushita et al., 1999) suggest that LPS may 
regulate VEGF production by certain cell types that could influence tumour growth.
The cascade of biological events induced by LPS is composed of a large number 
o f mediators interacting within a complex network. A number o f therapeutic treatments 
targeted against LPS have sought to neutralise one or a combination of the cytokine 
mediators induced by LPS. Antibodies to TNF-a  have been shown to protect mice from
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the lethal effects of lipopolysaccharide and bacterial administration (Beutler et al., 1985; 
Tracey et al., 1987). It is clear that a more complete effect might be seen by averting the 
harmful effects of LPS through the blockade o f lipopolysaccharide itself, preventing the 
initiation o f the cytokine cascade. The potential value o f the novel anti-LPS agent, rBPI2I, 
in preventing LPS-induced tumour growth was evaluated. Previous studies have reported 
that the 25-kDa N-terminal portion o f BPI possesses essentially all of BPI’s LPS- 
neutralising activity (Ooi et a l, 1987), inhibiting LPS-induced cytokine release and 
oxygen free-radical generation from whole human blood (Mezaros et a l, 1993), as well 
as nitric oxide release from human macrophages (Betz-Corradin et a l, 1994). As all of 
these factors are potential mechanisms whereby LPS may influence tumour growth and 
angiogenesis, therefore rBPI21, a recombinant form of BPI, was considered a strong 
candidate for the prevention o f LPS-induced tumour growth. In the model o f metastatic 
disease used in these studies, rBPI21 therapy was capable o f completely blocking LPS- 
induced metastatic tumour burden, at least in part by inhibiting LPS-induced proliferation 
within metastases and LPS-induced reductions in apoptosis within the same metastases. 
Treatment with rBPI2] markedly reduces the pathological effects o f LPS in endotoxemia 
and septic shock (Ammons et al., 1996), however the data described here indicate that 
rBPI21 is also capable of inhibiting the biological effects of LPS on tumour growth. To 
ensure that the observations made were specific for LPS-blockade, a group receiving 
therapy at each time point with a control peptide of similar size to rBPI21, thaumatin, was 
included in each experiment. No protective effects were observed in any o f the 
parameters examined relating to tumour growth, namely metastatic burden, mitosis or 
apoptosis within metastasis, In vivo, in addition to its bactericidal activity, BPI can also 
neutralise LPS released from bacteria. LPS-binding proteins such as LBP and BPI have 
been shown to function as a receptor/receptor-antagonist system to regulate the hosts
response to LPS (Marra et al., 1992), as described in Fig. 1.4. The therapeutic 
administration of recombinant BPI should enhance the natural ability to control the 
bodies responses to endotoxin.
Previous data (described in chapter 3) demonstrated that surgery resulted in increased 
metastatic tumour growth. In these experiments elevated plasma endotoxin levels were 
detected in mice following surgery, with the highest levels detected in mice having 
received laparotomy with intestinal agitation as compared to anaesthetic controls. 
Abdominal contamination with airborne factors during surgery has been shown to result 
in immunological alterations and bacterial translocation in mice (Watson et a l, 1995). 
Treatment with rBPI2I peri-operatively and post-operatively at 4 h intervals over a further 
24 h blocked the surgically-induced metastatic growth observed following laparotomy. 
The effectiveness of the specific anti-LPS agent in blocking tumour growth clearly 
indicates that LPS is a major contributing factor to increased tumour growth observed 
following open surgery.
The lipid-A domain of endotoxin is thought to be the active component of the 
molecule (Galanos et al., 1984). Antibodies directed against lipid A, such as the murine 
monoclonal antibody E5, have been developed and used in studies and clinical trials for 
sepsis. Although survival rates in some patients with gram-negative bacteremia and 
septic shock was reported, these studies failed to demonstrate adequate efficacy to 
warrant approved use because o f insufficient binding potency of the antibodies 
(Greenman et al., 1991; Schedel et al., 1991; Greenberg et al., 1992). There is also the 
added complication o f allergic reactions to murine antibody therapy in some patients. In 
this study, therapy with E5 failed to show any protective effect against surgically-induced 
tumour growth. The likely reason for its lack of efficacy is through insufficient binding 
of LPS as previously described. There is another possible reason why rBPI21 is more
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effective at neutralising LPS-induced tumour growth than E5. It has been reported that 
BPIs inhibitory effects on bacterial cell growth diminished with increasing 
polysaccharide chain length (Jahr et al., 1995). Long hydrophilic polysaccharide chains 
may impede access of the bulky BPI protein to the lipid A site that is embedded in the 
outer membrane of the gram-negative bacterial envelope, while the smaller recombinant 
BPI (21 KD) fragment can possibly penetrate more easily. The larger E5 antibody may 
also encounter steric hindrance preventing access binding to the lipid A site in endotoxin 
derived from endogenous bacteria. The failure of the E5 therapy in this study could 
therefore be as a result of the inability o f the antibody to reach and neutralise the lipid A 
moiety of the bacteria. There is also the potential that the antibodies were cleared by the 
murine host defenses, which would be unlikely to occur following rBPI treatment 
because the protein is naturally occurring in the host.
It was also reported in the same study, that BPI binds to a site close to lipid A, with 
minimal binding observed to monophosphoryl lipid A (Jahr et al., 1995). Results 
indicated that rBPI had more neutralising activity on LPS with long polysaccharide 
chains and that it may have a higher affinity for smooth LPS than for the lipid A region, 
indicating that it may possibly interact with the polysaccharide part of the molecule. If 
this is the case, then anti-lipid A antibodies may be o f little effect in controlling LPS 
induced tumour growth as the mechanisms controlling these effects may not be solely 
due to the lipid A region of the molecule.
rBPI21 therapy also prevented increased serum VEGF levels in response to open 
surgery, and appeared to lower VEGF levels following LPS injection. In the case of mice 
receiving LPS injection, rBPI21 failed to significantly reduce VEGF levels. However, 
treatment with rBPI21 resulted in a 50% reduction in serum VEGF and it is highly likely 
that the failure to reach significance is due to the lower numbers o f mice in the study,
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compared to other experiments. This is confirmed by the fact that injection of 10 of 
LPS failed to significantly increase serum VEGF in this experiment, while the same 
treatment led to significance with more numbers. Endotoxin has previously been reported 
to be angiogenic in a number of experimental models (Li et al., 1991; BenEzra et al., 
1993; Mattsby-Baltzer et al., 1994). Increased angiogenesis within tumour stroma has 
also been reported in bladder tumorigenesis associated with endotoxin-induced urinary 
tract infection (Johansson el al., 1987; Kawai et al., 1993). By reducing VEGF, rBPI21 
may act as a potential anti-angiogenic agent by blocking LPS-induced induction of 
angiogenic cytokines in the post-operative period. E5 therapy failed to reduce surgically 
induced serum VEGF levels.
In clinical situations many patients undergo extensive antibiotic therapy in 
response to severe bacterial infections. Anti-LPS agents such as rBPI21 could be most 
beneficial in these patients because, although antibiotics kill the organisms, the bacteria 
destroyed during such therapy release breakdown products that include 
lipopolysaccharide that could influence tumours that would otherwise be in a state of 
clinical dormancy. Similarly, it may be used in the post-operative treatment o f patients to 
prevent the pro-metastatic and pro-angiogenic environment that is created in response to 
LPS released from endogenous bacteria or introduced from air.
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Chapter 5
Regulation of VEGF and angiogenesis by LPS.
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Tumours are composed o f a heterogenous population o f both host and tumour cells. In 
addition to endothelial cells, which form the basic unit o f blood vessels within tumours, 
there are other host cells present including fibroblasts and a variety o f immune cells. 
These host cells may actually contribute to the growth o f the tumour through the release 
o f factors which regulate proliferation and angiogenesis within the tumour.
Macrophages form a major component of the immune infiltrate of many solid 
tumours, and in the case of breast tumours they may account for up to 50% of the tumour 
mass (O’Sullivan and Lewis, 1994). Macrophages can mediate tumour cytotoxicity but 
many tumour cells are capable o f suppressing this effect through the secretion o f factors 
such as TGF-pl, interleukin-10 (IL-10) and prostaglandin E2 (PGE2) (Elgert et al., 1998). 
Macrophages have also been associated with multiple steps in the metastatic process, 
forming aggregates with tumour cells in the circulation they could enable the cells to 
avoid immune recognition and aid invasion (Van Netten et al., 1993). They can also 
stimulate angiogenesis through their secretory activity (Leibovich et al., 1987; 
Sunderkotter et al., 1991; Sunderkotter et al., 1994). Conditioned medium of tumour 
associated macrophages, isolated from experimental murine fibrosarcomas, induced 
endothelial cell proliferation in vitro and angiogenesis in vivo (Polverini and Leibovich, 
1984). Furthermore, experimental murine fibrosarcomas were shown to be less 
vascularised when mice were depleted of monocytes (Evans, 1977). The angiogenic 
activity of macrophages requires the specific activation o f the cells. Lipopolysaccharide 
(LPS) or endotoxin is the most potent stimulator of macrophages known, inducing the 
release of a number of factors with potential angiogenic activity including TNF-a , TGF-
p, IL-6 and bFGF (O’Sullivan et al., 1993; Leibovich et al., 1987; Lewis et al., 1995;
5.1 Introduction
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Koch., 1998). Endotoxin has been reported to be angiogenic and it has been suggested 
that its angiogenic activity may be mediated through monocyte activation and cytokine 
production (Mattsby-Baltzer el al., 1994).
Macrophages may also regulate angiogenesis through the production of 
angiogenesis inhibitors. They are the source of metalloelastase which cleaves 
plasminogen into the anti-angiogenic fragment angiostatin (Dong et al., 1997). LPS 
stimulation of macrophages suppresses the release o f metalloelastase, resulting in 
reduced production of angiostatin (Kumar et al., 1996; Dong et al., 1997). By reducing 
anti-angiogenic molecules, LPS may tip the balance in favour of angiogenesis. In 
addition to downregulating anti-angiogenics, LPS stimulates VEGF production by a 
variety of cell types including human pulp cells, ventricular myocytes, 
polymorphonuclear leukocytes and 4T1 murine tumour cells (Matsushita et al., 1999; 
Sugishita et al., 2000; Scapini et al., 1999; McCourt et al., 1999; Pidgeon et al., 1999). 
In endometriosis patients, LPS stimulation of peritoneal macrophages increased VEGF 
secretion by these cells (McLaren et al., 1996). A similar effect, namely increased VEGF 
secretion in response to LPS, has also been reported in macrophages isolated from 
cirrhotic patients (Perez-Ruiz, 1999). More recently, a separate study reported that LPS 
activation of monocytes from healthy volunteers increased VEGF mRNA, but not bFGF 
expression (Torisu et al., 2000). This study also reported that anti-TNF-a  monoclonal 
antibodies inhibited LPS-induced VEGF expression by monocytes, suggesting that in 
this case, the effects of LPS are mediated by TNF-a . There is also evidence that 
macrophage mediated angiogenesis is due, at least in part, to TNF-a  production by these 
cells (Leibovich et al., 1987).
LPS could potentially stimulate angiogenesis by acting directly on the endothelial 
cells. It is known that endotoxin, and its associated cytokines, have profound effects on
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the vascular endothelium during sepsis, resulting in vascular injury and 
hyperpermeability (Morrison and Ryan, 1987; Pober and Cotran, 1990). Whereas LPS 
mediates its effects on monocytes, macrophages and neutrophils through the CD 14 
receptor (Wright et al., 1990), endothelial cells do not express the CD 14 receptor on their 
surface. LPS induced vascular endothelial cell injury and activation, an effect that could 
be blocked by the anti-endotoxin agent rBPI (Arditi et al., 1994). A recent study reported 
that LPS enhanced VEGF production by human endothelial cells (Marx et al., 1999). 
Thus LPS has multiple effects on host cells, inducing macrophage and neutrophil 
mediated angiogenesis, suppressing the production o f angiogenesis inhibitors and 
altering the host vasculature.
From the literature, it was unclear whether the angiogenic effect o f LPS was 
mediated directly or indirectly through its repertoire of cytokines. The aim of this chapter 
was to investigate the mechanisms through which LPS exerts its angiogenic activity. As 
macrophages are the major immune infiltrate in human tumours, the effect o f LPS on the 
expression of the angiogenic factors, VEGF, bFGF and TGF-p was examined. As LPS 
has been shown to be angiogenic in a number o f model systems, the direct effect o f LPS 
on endothelial cell proliferation and apoptosis was investigated. The effect of LPS on 
tumour cell proliferation was also examined. An in-vivo M atrigefrM  model of 
angiogenesis was used to establish whether LPS is directly angiogenic.
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5.2.1 LPS upregulates VEGF and TGF-P mRNA in human monocyte-derived 
macrophages (MDMs).
Monocytes isolated from healthy volunteers were matured to macrophages, activated with 
interferon-y and treated with LPS (1 ng/ml, 10 ng/ml, 50 ng/ml, 100 ng/ml and 200 ng/ml) 
for 18 h. VEGF, TGFb-1 and bFGF expression were examined by reverse transcriptase 
PCR (RT-PCR) with commercial PCR primers. RT-PCR resulted in a 204 bp product 
from all VEGF isoforms. LPS treatment resulted in a dose dependent increase in VEGF 
expression by macrophages (lane 7 - 4) compared to untreated controls shown in lane 8 
(Fig. 5.1A). VEGF expression is increased above the dose of 10 ng/ml (lane 6), while 
treatment with 1 ng/ml (lane 7) has little effect. The absence of a band in lane 3 indicates 
that amplification o f this sample didn’t occur, due to the omission o f PCR primers, p-actin 
was also amplified by PCR to serve as a control on loading differences (Fig. 5.ID). VEGF 
mRNA levels were normalised against the constitutively expressed P-actin and expressed 
as the ratio between VEGF and P-actin PCR products (Fig 5. IE). Treatment with LPS also 
resulted in a dose dependent increase in TGF-P (Fig 5.IB), however the increase was not 
as strong as that noted with VEGF. No increase in bFGF expression was noted in response 
to LPS treatment in human macrophages (Fig. 5.1C).
5.2.2 Effect of LPS on VEGF protein expression in human MDMs.
The effect o f LPS on VEGF protein production by human monocyte-derived macrophages 
was examined by ELISA (n=4). MDMs were activated with interferon-y and treated with 
LPS (1 ng/ml, 10 ng/ml, 100 ng/ml, 1 (ag/ml and 10 pg/ml) for 24h. As observed at the 
mRNA level, LPS resulted in a statistically significant increase in VEGF protein
5.2 Results
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producton by macrophages at concentrations o f 1 pg/ml (42.66±2.91 pg/pg protein) and 
10 pg/ml (64.91±5.79 pg/pg protein) compared to untreated cells (13.61 ±2.83 pg/pg 
protein, p<0.05) (Fig 5.2).
5.3.3 Effect of LPS on tumour cell proliferation.
As LPS increased metastatic tumour growth in the in-vivo 4T1 tumour model (chapter 4), 
the direct effect o f LPS on the proliferation o f both 4T1 and the human mammary 
adenocarcinoma MDA-MB-231 cells was examined. Two proliferation assays were used 
and compared in 4T1 cells, described in section (2.2.12). The results from both assays 
were similar with LPS causing a dose-dependent increase in tumour cell proliferation 
relative to untreated controls. This increase in proliferation was statistically significant at 1 
pg/ml LPS (114%±2.98) or 10pg/ml LPS (133.65%±3.60) relative to controls (p<0.01) 
with the BrdU based assay (Fig. 5.3A). Similarly, in the tétrazolium dye-based 
proliferation assay (MTT) concentrations o f 1 pg/ml LPS (109%±0.71) or 10 pg/ml LPS 
(124.68%±1.96) resulted in significantly higher proliferation relative to controls (p<0.01) 
(Fig. 5.3B).
As the metabolic based proliferation assay was more economical and provided similar 
results, it was used for all subsequent proliferation assays. In human MDA-MB-231 cells, 
LPS also increased cell proliferation reaching statistical significance at 100 ng/ml (116.2 ± 
4.16%), 1 pg/ml (121.1±0.645%) and 10 pg/ml LPS (128.8±0.484%) (P<0.05, Fig. 5.4).
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Fig. 5.1. VEGF, TGF-b and bFGF expression in MDMs in response to LPS. Cells were 
incubated for 18 h and expression assessed by RT-PCR. Lane 1 shows molecular weight 
markers <|)X174DNA digested with HaeJR, lane 2 is a negative control; lanes 3-8 are 200, 
100, 50, 10, 1 and 0 ng/ml LPS respectively. Positions o f PCR products are indicated. A. 
VEGF mRNA expression. B. TGF-p mRNA expression. C. bFGF mRNA expression. D. 
p-Actin mRNA expression. E. Densitometric analysis of VEGF relative to p-actin.
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Fig. 5.2 VEGF protein levels in human macrophages exposed to LPS. Human monocytes 
were isolated, matured to macrophages, activated with IFNy and stimulated with LPS (1 
ng/ml-10 jig/ml) for 24h. VEGF protein production was assayed by ELISA and total cell 
protein by the BCA assay. Results are expressed as pg VEGF/ mg total protein and 
shown as mean + S.E.M (n=4). Statistical analysis is by ANOVA with scheffe post-hoc 
correction * (p<0.05, vs control)
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A number of studies suggest that LPS may mediate its tumourigenic effect, inducing 
angiogenesis, via the induction o f TNF-a  (Leibovich et al., 1987; Torisu et al., 2000). To 
examine if  increased tumour cell proliferation in response to LPS could be due to TNF-a  
secretion, the effect of TNF-a  (100 pg/ml - 1 ^g/ml) on proliferation o f the MDA-MB- 
231 cells was examined (n=4). These levels of TNF-a  are within the physiological levels 
observed in Balb/C mice (1522±97.1 pg/ml) following LPS injection induced by LPS 
(unpublished observations, Harmey). In direct contrast to LPS stimulation of 
proliferation, TNF-a  resulted in a dose-dependent decrease in proliferation at 100 ng/ml 
(89±3.0%) or 1 (j,g/ml (79±3.7%) (p<0.02) relative to untreated controls (Fig. 5.5). This 
reduction in cell numbers may be due to the cytotoxic effects associated with TNF-a  
rather than a reduction in the proliferation rate o f the cells per se, as the metabolic based 
tetrazolium dye assay does not distinguish between a reduction in proliferation and 
cytotoxicity. This is supported by the fact that the cells looked stressed at these 
concentrations, losing their characteristic morphology.
5.3.4 Effect of TNF-a on tumour cell proliferation.
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Fig. 5.3 Effect of LPS on 4T1 cell proliferation. Cells were stimulated with LPS (100 
pg/ml-lO^g/ml) for 48 h. Tumour cell proliferation was assessed by a metabolic 
tétrazolium dye assay (A) and a BrdU based assay (B). Data is representative of 4 
independent experiments and expressed as mean + S.E.M where control cells are taken as 
100%. Statistical analysis is by ANOVA with scheffe post-hoc correction * (p<0.05 vs 
control).
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Fig. 5.4 Effect o f LPS on proliferation o f MDA-MB-231 cells. Cells were stimulated 
with LPS (100 pg/ml-lO^g/ml) for 48 h. Tumour cell proliferation was assessed by the 
metabolic tetrazolium dye assay. Data is representative o f 4 independent experiments and 
expressed as mean ± S.E.M where control cells are taken as 100%. Statistical analysis is 
by ANOVA with scheffe post-hoc correction * (p<0.05 vs control).
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Fig. 5.5 Effect of TNF-a  on proliferation of MDA-MB-231 cells. Cells were treated with 
TNF-a  (100 pg/ml-1 jig/ml) for 48 h. Tumour cell proliferation was assessed by the 
metabolic tétrazolium dye assay. Data is representative o f 4 independent experiments and 
expressed as mean + S.E.M where control cells are taken as 100%. Statistical analysis is 
by ANOVA with scheffe post-hoc correction * (p<0.02 vs control).
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5.3.5 Effect of LPS on HUVEC proliferation.
LPS has been shown to be angiogenic in a number o f animal experimental model 
systems (Mattsby-Baltzer et al., 1994; Li et al., 1991). Like tumour growth, the growth 
of blood vessels is governed by both the rate o f proliferation and cellular death 
(apoptosis) o f the endothelial cells (Duke et al., 1996). Human umbilical vein endothelial 
cells (HUVECs) were freshly isolated, grown in 96-well plates and treated with various 
concentrations o f LPS (100 pg/ml - 10 ^g/ml) for 48 h. Thereafter the percentage 
proliferation relative to untreated control cells was examined using the tetrazolium dye 
assay based on metabolic activity o f the cells. Treatment with 10 ^g/ml (125.8±2.82 %) 
resulted in significantly higher proliferation compared to controls (p<0.02) (Fig. 5.6). 
This result indicates that LPS induces the proliferation o f human endothelial cells over a 
48 h period, either directly or through the release of other cytokines by the cells.
5.3.6 Effect of LPS on HUVEC apoptosis.
Having illustrated that LPS increases proliferation of HUVECs, the effect of LPS on the 
other side of the balance governing cell numbers, namely apoptosis, was examined by 
TUNEL staining. HUVEC cells were freshly isolated, grown in culture chamber slides 
and treated with various concentrations of LPS (100 ng/ml, 1 ^.g/ml and 10 jjg/ml) for 18 
h, and stained thereafter. Treatment with 1 ^g/ml (19.68±1.7%) and 10 ^g/ml 
(16.41±1.7%) significantly reduced HUVEC apoptosis relative to controls (p<0.01, 
44.46±2.2%) (Fig. 5.7) indicating that LPS confers a survival advantage on endothelial 
cells, which would contribute to the angiogenic nature o f LPS. Thus LPS is directly pro- 
angiogenic, affecting both sides of the balance, increasing proliferation and decreasing 
apoptosis of endothelial cells.
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OFig. 5.6 Effect o f LPS on proliferation of HUVECs. Cells were stimulated with LPS 
(100 pg/ml-10 j^g/ml) for 48 h and proliferation assessed by the metabolic tétrazolium 
dye assay. Data is representative of 4 independent experiments and expressed as mean + 
S.E.M. Statistical analysis is by ANOVA with scheffe post-hoc correction * (p<0.02 vs 
control).
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Fig 5.7 Effcct ofLPS on HUVBC apoptosis on culture chamber slides. Cells were treated 
with LPS for 18 h  and apoptosis was assessed in situ by TUNEL staining Data is 
representative of 3 independent experiments and expressed as mean + s.c.m. Statistical 
analysis is by ANOVA with scheffe post-hoc corrcction * (p<0.01).
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5.3.7 Effect of TNF-a  on HUVEC proliferation.
A number of reports have suggested that much o f the angiogenic effects o f LPS have
been attributed to its induction of TNF-a  secretion (Torisu et al., 2000). There have also
been reports that macrophage mediated angiogenesis is mediated by TNF-a  (Leibovich
et al., 1987). To examine if the proliferative effect of LPS on endothelial cells is
mediated by TNF-a  secretion, the effect o f treatment with TNF-a  (100 pg/ml - 1 ^g/ml)
on proliferation of HUVECs was examined (n=4). TNF-a  had no effect on HUVEC
proliferation at any of the doses tested (Fig. 5.8). Unlike the results observed for tumour
cells, there was no cytotoxic effect or growth inhibition observed at any dose. This
indicates that TNF-a  does not mediate LPS-induced proliferation of HUVEC or tumour 
cells but can inhibit the growth of MDA-MB-231 cells at high levels. The effect o f TNF-
a  on HUVEC or tumour cell apoptosis was not examined because TNF-a , as its name 
suggests, causes death by necrosis and not by apoptosis, which is the mode of death 
favoured by tumour cells.
5.3.8 Effect of LPS on HUVEC and tumour cell proliferation in the absence of 
FCS.
It is recognised that LPS mediates most of its biological effects through its binding to 
LPS binding protein (LBP) and the binding of the resulting complex to the CD 14 
receptor on the cell surface (Tobias et al., 1989). To establish if  the proliferative effect of 
LPS on tumour cells was mediated by a serum factor such as LBP, the effect of LPS on 
MDA-MB-231 and HUVEC proliferation in the absence of Fetal Calf Serum (FCS) was 
examined (n=4). MDA-MB-231 cells were cultured in 96-well plates and then treated for 
48 h with various concentrations of LPS (10 ng/ml - 10 jjg/ml) in the absence of FCS.
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Although 1 ^g and 10 ^g LPS/ml stimulated the proliferation o f MDA-MB-231 cells 
(see Fig. 5.4), this stimulatory effect was lost in the absence of FCS (Fig. 5.9A).
To examine the effect o f LPS on endothelial cell proliferation in the absence of serum 
factors, HUVECs were grown in medium containing endothelial growth factor (EGF) 
only, with various concentrations of LPS (10 ng/ml - 10 |j,g/ml) in the absence o f FCS. 
Similarly, although 10 ^g LPS/ml stimulated the proliferation o f endothelial cells 
previously (see Fig. 5.6), this stimulatory effect was not observed when FCS was omitted 
from the medium (Fig. 5.9B). These data implicate a serum factor, most likely LBP, in 
LPS-induced proliferation o f tumour cells and endothelial cells.
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Fig. 5.8 Effect of TNF-a  on proliferation of HUVECs. Cells were stimulated with TNF-
a  (100 pg/ml-1 ^ g/ml) for 48 h. HUVEC proliferation was assessed by the metabolic 
tétrazolium dye assay. Data is representative o f 4 independent experiments and expressed 
as mean + S.E.M. Statistical analysis was by ANOVA with Scheffe post-hoc correction 
(p=n.s).
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Fig. 5.9 Effect o f LPS on proliferation o f MDA-MB-231 cells (A) and HUVECs (B) in 
the absence of FCS. Cells were treated with LPS (10 ng/ml-lO^g/ml) for 48 h in medium 
containing no FCS. Data is representative of 4 independent experiments, expressed as 
mean ± S.E.M where proliferation of control cells is taken as 100%. Statistical analysis 
was by ANOVA with Scheffe post-hoc correction (p=n.s).
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In the earlier half of this decade a number of investigators reported that endotoxin was 
angiogenic in many different animal models (Li ei al., 1991; BenEzra el a l, 1993; 
Mattsby-Baltzer el al., 1994). In none of these reports was the mechanism of LPS- 
induced angiogenesis elucidated. To establish whether LPS was directly angiogenic in 
BALB/c mice, a subcutaneous MatrigehM model was used. With no tumour present, 
matrigel impregnated with sterile PBS (negative control), VEGF (100 ng/ml, positive 
control) or LPS (10 |j,g/ml) were implanted subcutaneously in mice (n=3). 5 days later 
the gels were excised and infiltrating endothelial cells and vessels stained by 
PECAM/CD31 specific immunostaining. The number o f positively stained cells or 
vessels in various regions of the gel was examined by counting 5 high power fields of 
vision (magnification X 400).
Gels containing VEGF (35.72±2.02) had significantly (p<0.004) more endothelial cells at 
the edge o f the gel compared to those containing PBS (7.87±1.18), showing that VEGF 
impregnated matrigels stimulated angiogenesis (Fig.5.10). Similarly, gels containing LPS 
(25.08±4.92) contained significantly (p<0.004) higher numbers o f endothelial cells 
compared to the PBS controls. There was no difference in the numbers of infiltrating 
non-endothelial cells at the edge o f the gel between any groups, however gels containing 
LPS (28.62±5.35) showed a trend toward more of these cells compared to either the PBS 
gels (11.58±3.87) or VEGF gels (15.83±4.73) (Fig. 5.11). An increase in immune cell 
infiltrate would be anticipated due to the pro-inflammatory agent LPS in the gels. Failure 
to reach significance is likely due to the small numbers used in the study (n=3). 
Representative sections from the edge of the gel in each group are shown in panels (A-E) 
in Fig. 5.12.
It has been suggested that a more accurate measure o f angiogenesis is observed by taking
5.3.9 Effect of LPS on angiogenesis in vivo in a matrigel model.
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the endothelial cell counts at the centre o f the gels. These counts represent cells that have 
migrated inward. Gels containing VEGF (35.42±2.38) and LPS (25.47±2.74) resulted in 
significantly higher numbers of endothelial cells at the centre o f the gels compared to 
gels containing PBS (6.36±1.18; p<0.001 vs VEGF, p<0.007 vs LPS). The number of 
formed blood vessels (containing a lumen) was also examined, and gels containing 
VEGF (10.7±0.25) or LPS (4.97±0.49) contained significantly higher numbers of blood 
vessels compared to PBS gels (1.03±0.4; p<0.001 vs VEGF, p<0.05 vs PBS) (Fig. 5.15). 
This would indicate that LPS appears to be directly angiogenic, inducing the infiltration 
of endothelial cells at the edge o f the gels and also the migration of the cells to the centre 
of the gels to form blood vessels.
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Fig. 5.10 Numbers of infiltrating endothelial cells at the edge of impregnated matrigels. 
Matrigel containing PBS, VEGF (100 ng/ml) or LPS (10 ^g/ml) were implanted 
subcutaneously. 5 days later gels were recovered and endothelial cells were stained with 
CD31. The numbers o f positively stained cells were averaged in 5 high power fields (X 
400) for each gel. Data is representative of 3 mice/groups, expressed as mean number of 
cells + S.E.M. Statistical analysis is by ANOVA with Scheffe post-hoc correction * 
(p<0.004 vs PBS gel).
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Fig. 5.11 Numbers o f other cells infiltrating the edge o f matrigels. Non-endothelial cells 
stained with haemotoxylin in CD31/pecam sections and were averaged over 5 fields o f 
vision (X 400). Data is representative o f  3 mice/groups, expressed as mean number o f  
ee ls  ± S.E.M. Statistical analysis is by ANOVA with Scheffe post-hoc corrcction 
(p=n.s).
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Fig. 5.12 Representative sections from the edge o f matrigels stained for the endothelial- 
cell-specific CD31 marker and counterstained with haemotoxylin and eosin (X 400) 
Immune cells (CD-31 negative) stain blue and endothelial cells (CD31-positive) stain 
brown and are indicated by the arrow in panel B. Panels are as follows: A. PBS gel, B. 
VEGF gel, C. LPS gel.
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Fig. 5.13 Numbers of endothelial cells in the centre of impregnated matrigels. 
Endothelial cells were stained with CD31 and the numbers o f positively stained cells 
were averaged in 5 high power fields (X 400) for each gel. Data is representative of 3 
mice/groups, expressed as mean number of cells ± S.E.M. Statistical analysis is by 
ANOVA with Scheffe post-hoc correction *0 (p<0.001 vs PBS gel), # (P<0.007 vs PBS
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Fig. 5.14 Numbers of stained blood vessels in the centre of impregnated matrigels. . 
Endothelial cells were stained with CD31 and the numbers o f positively stained cells were 
averaged in 5 high power fields (X 400) for each gel. Data is representative of 3 
mice/groups, expressed as mean number of cells ± SEM. Statistical analysis is by 
ANOVA with Scheffe post-hoc correction * (pO.OOl vs PBS gel), # (p<0.05 vs PBS gel).
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Fig. 5.15 Representative sections from the centre o f matrigels stained for the endothelial­
cell-specific CD31 marker and counterstained with haemotoxylin (X 400). F.ndothelial cells 
(CD31-positive) stain brown and a formed vessel is indicated by the arrow. Panels are as 
follows: A. PBS gel, B. VEGF gel, C. LPS gel.
As VEGF plays a central role in tumour growth promoting angiogenesis and facilitating 
metastasis by increasing vessel permeability, factors regulating its production and cells 
secreting it are therefore critical in disease progression. There is much controversy as to 
the prognostic significance o f tumour infiltrating macrophages, which appears to depend 
on the tumour type. However, with respect to breast tumours, there is overwhelming 
evidence that the infiltration of immune cells supports tumour growth. Previous chapters 
demonstrated increased LPS in the circulation following surgery; it is therefore possible 
that LPS stimulates the release of VEGF from host macrophages contributing to 
angiogenesis at a distant site. The data presented in this chapter shows that LPS 
upregulates VEGF expression in human macrophages at both the mRNA and protein 
level. LPS also resulted in increased expression of TGF-p mRNA, though to a lesser 
extent than VEGF. However, TGF-p can also increase the production o f VEGF from 
both macrophages and tumour cells (Harmey et al., 1998; Donovan et al., 1997).
LPS has been implicated in cellular proliferation and differentiation, possibly 
through the phosphorylation and activation of several protein kinases (Weinstein et al., 
1992; Shapira et al., 1994). In vivo, LPS increased the mitotic index in experimental 
metastases (Pidgeon et al., 1999). LPS increased the proliferation of both tumour cells 
(murine 4T1 and human MDA-MB-231 cells) and endothelial cells (HUVECs) in vitro. 
At the highest concentration used (10 ^g/'ml), proliferation o f the cells was increased by 
24.7% in 4T1 cells and by 28.8% in MDA-MB-231 cells relative to controls. When 
HUVEC or MDA-MB-231 cells were treated with LPS in the absence of FCS, no 
proliferative effect was observed. This implicates a serum factor in LPS-mediated cell 
proliferation. In macrophages and other cells expressing CD14, the serum factor LPS- 
binding protein (LBP) is required for the interaction o f the LPS molecule with the
5.3 Discussion
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receptor. It would appear that in this tumour cell line a similar mechanism is necessary to 
allow LPS to interact with the cells.
A potent cytokine produced by macrophages upon activation with LPS is tumour 
necrosis factor alpha. TNF-a  has been implicated in tumorigenic activities related to LPS 
(Torisu et al., 2000, Leibovich et a l, 1987). In contrast to the results observed when cells 
were treated with LPS, TNF-a  significantly inhibited tumour cell proliferation in a dose- 
dependent manner. At the highest concentration used (1 ^g/ml) proliferation was 
inhibited by 21%. At the lower doses, which are more physiologically relevant, TNF-a  
had no effect on tumour cell proliferation. This clearly indicates that TNF-a  secretion is 
not responsible for the increased cellular proliferation in response to LPS. There is 
evidence that TNF-a  plays a role in macrophage mediated angiogenesis in response to 
LPS (Leibovich et al., 1987) and anti-TNF-a  monoclonal antibodies blocked LPS 
induced VEGF expression in monocytes (Torisu et al., 2000). It therefore appears that 
LPS-induced VEGF and cell proliferation occur by independent mechanisms.
Endotoxin has been reported to induce de-novo angiogenesis in adult, 
mammalian, normally vascularised tissues at doses (20 ng/ml - 20 ^g/ml) that appear 
realistic in the clinical setting (Mattsby-Baltzer et a l, 1994). The majority of 
investigators suggest that the angiogenic effects observed following LPS treatment are 
probably mediated by cytokines released by macrophages (Li et al., 1991; Mattsby- 
Baltzer et al., 1994). LPS resulted in a dose-dependent increase in HUVEC proliferation; 
10 jjg LPS/ml resulted in a 25.8% increase in proliferation relative to controls. At the 
same dose, LPS inhibited HUVEC apoptosis from 44.5% in control cells to 16.4%. 
Therefore LPS affects both proliferation and apoptosis o f the endothelial cells, altering 
the balance on both sides to favour blood vessel growth. It is possible that LPS mediates
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these effects on endothelial cells through VEGF production. It has previously been 
reported that LPS induces the expression of VEGF in human endothelial cells at the 
concentrations used in this study (Marx et al., 1999). In that study apoptosis was rarely 
seen following LPS treatment, but simultaneous treatment with anti-VEGF antibodies 
resulted in increased apoptosis. It has also been shown that VEGF acts as a survival 
factor for endothelial cells by inhibiting apoptosis (Alon et al., 1995; Nor et al., 1999). It 
is therefore possible that the inhibition of HUVEC apoptosis by LPS increased VEGF 
production, which acted as a survival factor for the cells.
The in vivo angiogenesis assay used in this study demonstrated that LPS is 
directly angiogenic at the concentration tested (10 ng/ml). Although the angiogenic 
response was not as dramatic as that seen with VEGF implants, LPS gels contained 
significantly more endothelial cells at both the edge o f the gels and in the centre o f the 
gels, suggesting that LPS stimulated cell migration. VEGF and LPS also resulted in 
increased numbers of blood vessels, which were denoted by an intact lumen. Within the 
assay there was some degree of inflammation and endothelial cell infiltrate in gels 
impregnated with PBS control probably due to an inflammatory reaction caused at the 
site o f the injection. During an inflammatory response, cells migrate toward the source of 
inflammation. Indeed, there was a high degree of non-endothelial cell infiltrate in all gels 
at the edge. Gels containing LPS had significantly higher amounts of these non- 
endothelial cells, supporting the fact that these cells were most probably immune 
infiltrates in response to inflammation. This is in agreement with the findings by other 
investigators, that in the models of angiogenesis used, namely corneal implant and 
mesentery window, induction of angiogenesis is secondary to an inflammatory reaction 
(Li et al., 1991; Mattsby-Baltzer et al., 1994).
Taken together this data clearly shows that LPS is directly angiogenic, inhibiting
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endothelial cell apoptosis, increasing the proliferation of the cells, and increasing 
endothelial cell migration into matrigel and the subsequent formation of vessels.
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Chapter 6
LPS and VEGF as Survival Factors in Tumour Cells
Submitted : Pidgeon G. P., Barr M.P., Harmey J.H., Foley D.A. and Bouchier-Hayes 
D.J. (2000) Vascular endothelial growth factor (VEGF) upregulates Bcl-2 
and inhibits apoptosis in human and murine adenocarcinoma cells. Br. J. 
Cancer.
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Under normal physiological conditions, a delicate balance between cellular proliferation 
and cell death ensures that the overall numbers of cells are maintained within an 
appropriate range (Reed, 1997). Cancer progression may result from disturbances to 
either of these mechanisms, such as a relative increase in cell proliferation or a decrease 
in cell death, and in extreme cases both mechanisms may be effected (Thompson, 1995). 
The selective process whereby cells are discretely removed from populations without 
affecting surrounding cells is termed apoptosis or ‘programmed cell death’. Disturbances 
to this process may confer a growth advantage to neoplastic tissues, resulting in clonal 
expansion o f the tumour (Reed, 1994; Thompson, 1995).
The Bcl-2 family o f apoptosis-regulating proteins function to either promote or 
suppress cell death (Oltvai et al., 1993). The function o f several members o f the Bcl-2 
family is regulated by their ability to form homo- and heterodimers with each other 
(Oltvai et al., 1993; Sato et a l, 1994). Some of the pro-apoptotic Bcl-2 family members 
preferentially form dimers with subsets of the pro-survival members, in which apoptosis 
proceeds. For instance, the pro-apoptotic protein Bax will preferentially dimerise with the 
anti-apoptotic protein Bcl-2 to form a heterodimer, rather than with a second Bax protein 
to form a homodimer. These differences in dimerisation partners suggests that the 
expression of various members of the Bcl-2 family is important in the regulation of 
apoptosis or proliferation within a cell at any time. Increased expression of Bcl-2 has 
been reported in many cancers and is associated with a reduction in the level of apoptosis 
(Lipponen et a l, 1999). Paradoxically, some reports suggest that increased expression of 
Bcl-2 is a good prognostic indicator in breast cancer correlating with response to therapy 
and overall survival (Shabaik et a l, 1994; Krajewski et al., 1999). A possible explanation 
for this paradoxical finding in breast cancer may be that Bcl-2 is induced by estrogen and
6.1 Introduction
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as such may represent a marker of less aggressive or poorly differentiated tumours 
(Krajewski et al., 1999). Alternatively the anti-proliferative effect o f Bcl-2 may be 
involved (Bomer, 1996).
The induction of anti-apoptotic proteins is a possible mechanism whereby tumour 
cells escape the cytotoxic effects of many chemotherapeutic and radiation regimes. 
Indeed, in the case of one neoadjuvant chemotherapy trial in breast cancer, a long-term 
treatment benefit was observed in patients whose tumours displayed features favouring 
apoptosis, ie. no or weak Bcl-2 expression, and Bax overexpression (Diadone et al.,
1999). In this case Bcl-2 and Bax expression predicted the cellular response to genotoxic 
damage. Overexpression of another of the anti-apoptotic members of the Bcl-2 family, 
Bcl-XL, suppressed chemotherapy induced apoptosis o f mammary tumours in a murine 
model (Liu et al., 1999).
Angiogenesis, the development of new blood vessels, is an essential requirement 
for both primary and metastatic tumour growth (Morgan et al., 1996). It is well 
documented that in the absence of angiogenesis, tumours are restricted to a limited size 
of 1-2 mm3 in a dormant-like state (Folkman., 1994). The ability o f tumours to stimulate 
neovascularisation is governed by the net balance of angiogenic stimulators and 
inhibitors in the tumour micro-environment (Hanahan and Folkman, 1996). Tumours 
secrete or mobilise a variety of angiogenic factors that tip the balance in favour of 
angiogenesis.
By inducing blood vessels within tumours, the angiogenic factor, VEGF facilitates 
metastasis by providing an escape route for metastatic tumour cells. Recently, it has been 
shown that VEGF acts as a survival factor for endothelial cells by inhibiting apoptosis 
(Alon et al., 1995; Nor et al., 1999). In one of these studies, VEGF protected endothelial 
cells from apoptosis induced by growth factor withdrawal by up-regulating Bcl-2
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expression (Nor et a l, 1999). Furthermore, VEGF has been shown to protect leukemia 
cells and haematopoetic stem cells from radiation induced apoptosis (Katoh et a l,  1995). 
In MCF human breast cancer cells, bcl-2 and hypoxia acted synergistically to modulate 
the expression of VEGF in bcl-2 transfected cells, and tumours transfected with bcl-2 
produced more VEGF and were more highly vascularised than controls (Birroccio et al.,
2000). Therefore there is a growing body of evidence to suggest an inter-relationship 
between VEGF and the anti-apoptotic protein, bcl-2.
In the experimental metastasis model used in this thesis, LPS exposure resulted in 
elevated circulating VEGF and decreased apoptosis with lung metastases relative to 
control mice (Pidgeon et al., 1999). Increased expression o f VEGF in response to LPS 
has also been reported in human pulp cells (Matsushita et al., 1999).
The aim of this chapter was to examine the effect o f VEGF and LPS as survival 
factors for tumour cells. The effect of LPS treatment on VEGF protein expression by 
human MDA-MB-231 and murine 4T1 mammary carcinoma cells was examined in 
vitro. As Bcl-2 has previously been shown to be upregulated in response to VEGF, the 
effect of VEGF or LPS treatment on Bcl-2 expression in both cell lines was examined. 
LPS was used to stimulate VEGF in this set of experiments and anti-VEGF antibodies 
were used to specifically block VEGF. As it is alterations in these proteins that ultimately 
regulate tumour cell apoptosis, the effect of these treatments on tumour cell apoptosis 
was investigated.
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6.2 Results
6.2.1 LPS upregulates VEGF production by 4T1 and MDA-MB-231 tumour cells.
4T1 and MDA-MB-231 cells were treated with LPS (lng/m l, 10ng/ml, 100ng/ml, 
l^g/m l and lO^g/ml) and VEGF protein expression was analysed by ELISA (n=3). 
VEGF production was expressed as pg VEGF/^g total cell protein. LPS significantly 
(*p<0.05, **p<0.01 v ’s control) up-regulated VEGF protein at a concentration of 
10ng/ml (89.06+14.98 pg/^g protein), 100ng/ml (93.27+9.07 pg/^g protein), l^g/m l 
(95.94+9.9 pg/jj,g protein) and lO^g/ml (117.22+11.89 pg/^g protein) o f LPS in the 
4T1 tumour cells and at 10^g/ml (28.32+2.05 pg/^g protein) in the MDA tumour (Fig.
6.1 A and Fig. 6. IB respectively).
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Fig. 6.1. LPS upregulation o f VEGF protein. 4T1 (A) and MDA (B) cell cultures were 
stimulated with LPS (1 ng/ml-10pg/ml) for 24 h. VEGF protein was assayed by ELISA 
and total cell protein by the BCA assay. VEGF levels were significantly increased 
relative to controls at a concentration of lOng/ml, lOOng/ml, 1 pg/ml and lOpg/ml o f 
LPS in the 4T1 tumour cells and at lOpg/ml in the MDA tumour cells 
(*p<0.05,**p<0.01 vs controls).
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6.2.2 Effect of VEGF, LPS and anti-VEGF antibodies on Bcl-2 protein 
expression.
The level of Bcl-2 protein expression was examined by Western Blot analysis 
following treatment with LPS, VEGF and/or anti-VEGF antibodies (n=3). Total 
protein was isolated and separated on denaturing polyacrylamide gels before transfer to 
nitrocellulose membranes. Fig. 6.2 shows coomassie stained SDS-PAGE o f cell lysates 
demonstrating the integrity of the proteins and equal loading. VEGF (100 ng/ml) (lane 
5) and LPS (10 Llg/ml) (lane 2) resulted in increased Bcl-2 expression in both cell lines 
examined relative to controls (lane 1) (Fig. 6.3A for 4T1, and Fig. 6.4A for MDA-MB- 
231). p-actin expression was examined to control for loading differences (Fig. 6.3B 
and Fig. 6.4B respectively). Densitometry confirmed that relative Bcl-2 expression by 
4T1 and MDA-MB-231 cells was significantly increased following treatment with 
either LPS (4T1, 140+7.5%; MDA-MB-231, 138+13.4%) or VEGF (4T1, 136+7.6%; 
MDA-MB-231, 166+31.2%) compared to controls (p<0.02, Fig. 6.3C and p<0.05, Fig. 
6.4C respectively). Neutralising anti-VEGF antibody (l^g/m l) (lane 4) decreased Bcl-2 
protein expression in both cell lines (4T1, 46+10.2%; MDA-MB-231, 18+3.5% 
relative to controls). In this case, the antibody is blocking basal VEGF expressed by 
the tumour cells. Densitometric analysis illustrated that this blockade o f endogenous 
VEGF was significant relative to controls (p<0.03). Anti-VEGF antibodies also 
blocked LPS-induced Bcl-2 expression (lane 3), resulting in a significant decrease in 
Bcl-2 protein levels relative to LPS treated cells (4T1, 51+11.1%; MDA-MB-231, 
48+6.6%) (p<0.03). These data demonstrate that anti-VEGF antibodies reduce 
endogenous and LPS-induced Bcl-2 expression in both 4T1 and MDA-MB-231 cells.
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Having shown that LPS or VEGF upregulate the expression o f the anti-apoptotic 
protein, Bcl-2, in human and murine tumor cells and that Bcl-2 expression can be 
blocked with anti-VEGF antibodies, we studied their effect on tumor cell apoptosis 
directly by TUN EL staining on culture chamber slides. Due to the low basal rate of 
apoptosis in tumor cells, apoptosis was induced to a level o f 10.33+1.41 % in 4T1 and 
8.4±0.47% in MDA-MB-231 cells by growth factor withdrawal (Fig. 6.5A and 6.6A, 
respectively). Treatment with LPS (4T1, 5.39±0.66%; MDA-MB-231, 3.4±0.18%) or 
VEGF (4T1, 4.07±0.44%; MDA-MB-231, 4.2±0.39%) resulted in a significant decrease 
in the rate o f apoptosis compared to untreated cells (4T1, 10.33±1.41%; MDA-MB-231, 
8.4±0.47%) (P<0.05, Fig. 6.5A and 6.6A, respectively).
Treatment o f cells with anti-VEGF antibodies resulted in a significant increase in the 
level o f apoptosis in both cell lines (24.2+0.90%, p<0.01 in 4T1 cells and 22±2.84%, 
p<0.02 in MDA-MB-231 cells) compared to controls. In both cell lines, treatment with 
anti-VEGF antibodies prevented LPS-mediated inhibition o f apoptosis compared to 
cells treated with LPS alone (15.12+1.98% v ’s 5.39±0.66%, p<0.01 in 4T1) and 
(11.8+2.23% v ’s 3.4+0.18%, p<0.005 in MDA-MB-231).
Typical stained MDA-MB-231 cells from each treatment are shown in Fig. 6.6B. 
Increased numbers of TUNEL-positive cells are clearly visible in samples treated with 
anti-VEGF (panel IV) relative to untreated controls (panel I), where endogenous VEGF 
is active. Blocking either endogenous VEGF produced by tumour cells (panel IV), or 
exogenous (in this case induced by LPS exposure) (panel III) leads to increased 
apoptosis, indicating that VEGF increases tumour cell survival by inhibiting apoptosis.
6.3.3 Effect of VEGF, LPS and anti-VEGF antibodies on tumor cell apoptosis.
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Treatment with either LPS (panel II) or recombinant VEGF (panel V) decreases 
apoptosis in both cell lines.
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Fig. 6.2 Total proteins isolated from 4T1 (A) and MDA-MB-231 (B) cells and separated 
on 12% denaturingpolyacrylamide gels by electrophoresis.
179
A.
LPS +
Control LPS anti-VEGF anti-VEGF VEGF 
1 2 3 4 5
Bcl-2 (26 Kda) ------------ ►
B .
ß-Actin (42 K da)------------ ►
Fig. 6.3 Expression o f Bcl-2 in 4T1 cells by western blot analysis. Blots shown are 
representative o f 3 independent experiments. (A) Bcl-2 protein expression in 4T1 cells. 
Position o f Bcl-2 is indicated by arrow. (B) B-actin expression. Position o f b-actin 
indicated by arrow. (C) Densitometrie analysis of Bcl-2 protein relative to B-actin. 
Values are expressed as expression relative to control cells (100%). * (p<0.02 vs 
control), # (p<0.003 vs LPS), ^  (p<0.03 vs control).
180
c.
% E xpression  
rela tive  to Control
160
140 I I
120
100
80
60
40
20
Control LPS LPS+AbVEGF AbVEGF VEGF
181
LPS +
Control LPS anti-VEGF anti-VEGF VEGF 
1 2 3 4 5
Bcl-2 (26 Kda) -------^
Fig. 6.4 Expression of Bcl-2 in MDA-MB-231 cells by western blot analysis. Blots 
shown are representative of 3 independent experiments. (A) Bcl-2 protein expression 
in 4T1 cells. Position o f Bcl-2 is indicated by arrow. (B) B-actin expression. Position 
o f b-actin indicated by arrow. (C) Densitometrie analysis o f Bcl-2 protein relative to B- 
actin. Values are expressed as expression relative to control cells (100%). * (p<0.05 vs 
control), # (p<0.01 vs LPS), ^  (p<0.02 vs control).
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Fig 6.5 Levels o f apoptosis in 4T1 cells were examined in chamber slides by TUNEL 
staining (n=3). Apoptosis was induced to a level of 10.04% in control cells by growth 
factor depletion. Percentage apoptosis in treatment groups * (p<0.03 vs control) 
#(p<0.05 vs control).
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Fig 6.6 Levels o f apoptosis in MDA-MB-231 cells were examined in chamber slides 
by TUNEL staining (n=3). Apoptosis was induced to a level o f 8.4% in control cells by 
growth factor depletion. A. Percentage apoptosis in treatment groups * (p<0.03 vs 
control) #(p<0.05 vs control) B. Representative MDA-MB-231 cells from culture 
chamber slides following treatment as follows: (A) untreated controls, (B) 10^g/ml 
LPS, (C) 10^g/ml LPS and l^g/m l VEGF neutralising antibody, (D) l^g/m l VEGF 
neutralising antibody, (E) lOOng/ml rhVEGF.
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A number o f studies have shown that anti-angiogenic strategies result in increased 
tumour cell apoptosis (Holmgren et al., 1995; Parangi et al., 1996; O ’Reilly et al., 1997). 
To date, this effect has been attributed to blood vessel regression. However, the 
angiogenic factor VEGF inhibits radiation and chemotherapy induced apoptosis of 
haematopoeitic cells, the latter effect being achieved by the induction o f MCL1, a 
member of the Bcl-2 family (Katoh et al., 1998; Gorski et al., 1999), showing that it 
may mediate effects in other non-endothelial cells. VEGF is known to act as a survival 
factor for endothelial cells, inducing the expression of the anti-apoptotic protein Bcl-2 
(Nor et al., 1999). We previously showed that LPS increased circulating VEGF and 
decreased tumour cell apoptosis in the 4T1 murine model of experimental metastases 
(Pidgeon et al., 1999). In that study, groups with high levels of circulating VEGF 
displayed lower levels of apoptosis within experimental tumour metastases, and 
subsequently higher ratios of mitosis/apoptosis.
The potent inflammatory mediator endotoxin / lipopolysaccharide (LPS) has been 
shown to be angiogenic in a number of experimental systems (Mattsby-Baltzer et al., 
1994; Li et al., 1991; Kenyon et al., 1996). However, the mechanism whereby LPS 
induces angiogenic activity has to date, remained unknown. Treatment o f human or 
murine metastatic breast carcinoma cell lines with 10 ^g/ml endotoxin resulted in 
increased VEGF expression relative to controls. This observation demonstrates that LPS 
directly upregulates VEGF and is in agreement with previous work that demonstrated a 
strong positive correlation between post-operative plasma LPS and serum VEGF levels 
in 4T1 tumour bearing mice (Chapter 3).
LPS has been shown to upregulate the expression of VEGF in human pulp cells
6.3 Discussion
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at similar concentrations, via a soluble CD 14 mechanism (Matsushita et a l, 1999). The 
link between LPS and VEGF expression has not been fully characterised. However, 
TNF-a , an important inflammatory mediator induced by LPS, has been shown to 
strongly enhance VEGF rnRNA in a glioma cell line (Ryuto et a l,  1996). This has been 
attributed to the transcription factor SP-1. LPS activates a number o f MAP kinases such 
as c-Jun and c-Fos (Paul et a l, 1997), resulting in the over-expression of the transcription 
factors AP-1, AP-2 and SP-l. The VEGF promoter contains binding sites for these 
transcription factors (Shima et a l, 1996). Thus, the induction of these factors by LPS 
could result in increased VEGF transcription. These suggestions are supported by the fact 
that LPS increased the expression of the transcription factors AP-1, SP-1 and NF-KB in 
pulp cells (Matsushita et a l, 1999). Inhibitors to AP-1 were capable o f blocking LPS 
induced VEGF expression, while inhibiting SP-1 or NF-KB were inactive. In this study 
it was also observed that the protein synthesis inhibitor, cycloheximide, was capable o f 
blocking the VEGF protein accumulation in response to LPS, indicating that de novo 
protein synthesis is required for this induced VEGF expression. It would appear that at 
least in pulp cells, VEGF induction by LPS is mediated by an ongoing synthesis of c-jun 
and c-fos protein which produce AP-1. This is not to say that VEGF production by other 
cell types may be regulated by different factors, as in the case of TNF-a  and SP-1.
In this chapter the link between LPS-induced VEGF and LPS-mediated inhibition 
of tumour cell apoptosis was investigated. VEGF has previously been shown to induce 
the expression of the anti-apoptotic protein, Bcl-2, in endothelial cells. This set of 
experiments demonstrates a similar effect in murine and human metastatic tumour cells. 
Following stimulation with either LPS or VEGF, tumour cell expression of Bcl-2 was 
increased in both the human and murine tumour cells. Inclusion of a neutralising
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antibody to VEGF resulted in a marked reduction in LPS-induced Bcl-2 protein 
expression. The data demonstrates that LPS induced Bcl-2 expression in tumour cells is 
via a VEGF mediated mechanism.
Folkman and co-workers have shown that anti-angiogenic therapy inhibits the 
growth o f tumours through increased tumour cell apoptosis in the absence of alterations 
in tumour cell growth rates (Holmgren et al., 1995; Parangi et al., 1996; O’Reilly et al.,
1997). In these studies, the induction of apoptosis within the tumours had been attributed 
to vessel regression and consequent depletion of nutrients. The data presented in this 
chapter showed that LPS or VEGF inhibited apoptosis o f tumour cells in-vitro, 
detennined by TUNEL immunostaining. As the basal rate o f apoptosis was very low in 
both cell lines (<4%) apoptosis was induced by growth factor withdrawal. This induction 
of apoptosis was most probably mediated through alterations in Bcl-2, as serum depletion 
potentiates the effects of VEGF on Bcl-2 transcription in endothelial cells (Gerber et al.,
1998). Treatment of tumour cells with anti-VEGF antibodies resulted in almost a three­
fold increase in the rates of apoptosis in both 4T1 and MDA-MB-231 tumour cells, 
presumably due to blocking endogenous VEGF production by the tumour cells. This 
result alone, indicates that the removal of VEGF from tumour cells results in increased 
tumour cell death directly. Anti-VEGF antibodies also blocked LPS-induced reductions 
in tumour cell apoptosis, providing further evidence that the LPS-induced survival effect 
on tumour cells is mediated through VEGF. There is a growing body of evidence to 
support these observations. VEGF null fibrosarcomas were found to have an 8.5-fold 
increase in apoptosis compared to VEGF +/+ tumours (Grunstein et al., 1999). The 
results in this chapter suggest that loss o f VEGF, or its blockade in certain tumour types 
inhibits tumour growth in part by affecting tumour cell survival. Therefore, in addition to
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its direct angiogenic effects on endothelial cells, VEGF has a role as a survival factor in 
tumour cells.
The signalling pathway through which VEGF acts on tumour cells remains to be 
clarified. Flowever, recently a novel third receptor, neuropilin 1, specific for VEGF165, 
has been identified on a number of tumour cells including MDA-MB-231 (Soker et al.,
1998). In previous studies in our laboratory, western blot analysis has failed to identify 
either KDR/Flk-1 or F lt l, the VEGF receptors expressed by endothelial cells, in 4T1 or 
MDA-MB-231 cells (unpublished observations, Siobhan Griffen). A role for VEGF in 
preventing tumour cell apoptosis is further supported by recent reports that 
overexpression o f soluble neuropilin 1 (sNRPl), which prevents VEGF165 binding to 
cell surface receptors, in tumour cells was associated with increased prostate tumour cell 
apoptosis in vivo (Gagnon et al., 2000). These authors also demonstrated that sNRPl 
prevented VEGF 165 binding to rat prostate carcinoma cells, although the consequences 
o f VEGF binding to these tumour cells was unknown. VEGF has been shown to 
upregulate the expression of the KDR receptor on endothelial cells, which may be a 
positive feedback mechanism for VEGF action (Shen et al., 1998). Thus strategies that 
block VEGF activity may reduce VEGF receptor expression. Decreased VEGF receptor 
expression may therefore lead to an overall reduction in VEGF expression.
Anti-angiogenic therapy has received a lot of attention in the last decade and has 
resulted in a number of promising results (Baillie et al., 1995; Parangi et al., 1996; 
O’Reilly et al., 1998). The results presented here suggest that anti-angiogenics, in 
particular, those directed against VEGF, may have multiple anti-tumour effects. Firstly, 
they inhibit endothelial cell growth, inducing endothelial cell apoptosis and vessel 
regression. Secondly, by blocking or reducing angiogenic molecules they may have a
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direct anti-tumour effect by increasing tumour cell apoptosis. It would suggest that anti- 
VEGF strategies, as part o f combination therapy, may improve the efficacy of 
conventional treatments aimed at inducing tumour cell apoptosis, such as chemotherapy 
and/or radiation therapy.
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Chapter 7
Concluding Discussion
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In these studies a number o f factors critical in regulating tumour growth were 
examined, including the balance of mitosis and apoptosis within tumours and VEGF as 
an index of angiogenesis. The results presented demonstrate that open surgery results 
in the increased growth of lung metastases in a murine model of experimental 
metastasis. Metastatic burden was increased following an open laparotomy compared 
to animals which received anaesthetic alone. The increase in tumour burden was 
associated with increased proliferation and decreased apoptosis within lung metastases. 
The tumour enhancing effect of surgery has been demonstrated previously, however 
the mechanisms underlying the effect have not been fully elucidated. It has been 
suggested that the surgical removal of a primary tumour may lead to the rapid 
recurrence o f the disease, as a consequence o f removing anti-angiogenic factors 
produced by the primary (O’Reilly et al., 1994; O ’Reilly et al., 1997). In this series of 
experiments there was no primary tumour present, therefore the increased tumour 
growth observed could not be attributed to a similar effect. Open surgery had 
previously been shown to induce the translocation of endotoxin from the peritoneum 
into the systemic circulation. Endotoxin has been implicated in bladder tumour growth 
and shown to be angiogenic in the corneal implant and rat mesentery models of 
angiogenesis. Circulating levels o f endotoxin were therefore examined post-operatively 
and were found to be elevated following open surgery or laparoscopy with air. More 
significantly, these levels correlated with post-operative VEGF levels, which were an 
indication o f angiogenesis within the tumours.
Interestingly, when laparoscopy was performed with sterile C 0 2, containing no 
endotoxin, the critical parameters governing tumour growth, namely metastatic burden, 
mitosis, apoptosis and serum VEGF, were comparable to those o f mice receiving 
anaesthesia alone. However, when the procedure was performed with room air, which
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does contain endotoxin, a similar response to that of an open surgical procedure was 
observed. This implicated some air-borne factor in the tumour growth. The fact that the 
air laparoscopy procedure resulted in similar findings to open surgery implied that the 
laparotomy wound was not the causative factor in the tumour growth observed. This is 
supported by the fact that the tumour growth was observed 5 days post-operatively, 
while it has been reported that wound factors peak between 1 and 2 weeks after 
surgery. Therefore it may be o f interest to extend the study to examine the growth of 
the tumours over a longer period o f time.
As endotoxin was elevated following surgery and correlated with serum 
VEGF, the effect o f endotoxin injection on metastatic tumour growth was examined. 
Endotoxin resulted in a similar response to that observed following open surgery, 
increasing metastatic burden, tumour cell proliferation and decreasing apoptosis. Intra- 
peritoneal injection of endotoxin also resulted in increased circulating levels of VEGF. 
These experiments confirmed the findings of the surgical experiments, and suggests 
that endotoxin, introduced into the circulation during the surgical procedure augments 
metastatic tumour growth by altering the balances governing tumour expansion and 
angiogenesis. These findings may be of particular relevance to patients with a previous 
history of cancer undergoing surgery for an unrelated complaint, as it would appear 
that LPS may stimulate the growth of previously dormant cells, possibly leading to 
recurrence.
There have been many anti-endotoxin strategies designed to limit the effect of 
LPS, and most o f these have been designed as therapeutic strategies in the treatment of 
sepsis. Of all of the strategies reviewed to date, the most promising agents appear to be 
the BPI proteins. Recombinant BPI (rBPI21) has been shown to prevent, in a dose- 
dependent manner, a) the LBP-mediated binding and internalisation of LPS to
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monocytes and b) LPS-induced TNF-a release from monocytes (Heumann et al., 
1993). Therefore, the effect ofrB P I21 on endotoxin-induced metastatic tumour growth 
was investigated in-vivo. Treatment with rBPI21 during and after LPS injection 
inhibited LPS-induced metastatic tumour growth. This was reflected in the balances 
governing tumour expansion, with proliferation and apoptosis ratios similar to mice 
receiving a saline injection. More importantly, peri-operative rBPI2l blocked 
surgically-induced metastatic tumour growth, and decreased circulating levels of 
VEGF observed following surgery. This is the first study to demonstrate that 
administration of an anti-endotoxin agent following surgery blocks metastatic tumour 
growth. The monoclonal antibody E5 was ineffective at blocking surgically-induced 
tumour growth. This is most probably due to weaker binding of the monoclonal 
antibody to LPS, and the fact that rBPI21 binds to both smooth and rough LPS, as well 
as the lipid-A moiety o f the LPS molecule.
These results indicate that the endotoxin-neutralising activity o f rBPI21 may be of 
therapeutic benefit in many other endotoxin-related disorders, such as SIRS and 
MODS. It would also be of interest to examine the usefulness o f this agent in limiting 
other LPS-induced effects, such as vascular injury, permeability and angiogenesis, all 
o f which create a favourable environment for tumour growth. Although encouraging, 
these experiments were by no means conclusive that rBPI21 will work in the clinical 
setting. Further study over a longer period would be necessary to examine the effect of 
the compound at inhibiting tumour recurrence, when other factors such as wound 
elements would come into play. However, the study does highlight a potential 
therapeutic window in the peri- and early post-operative period for reducing a risk 
factor that may be inadvertently imposed upon every surgical / oncology patient.
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As LPS was found to be elevated in mice following surgery, and LPS induced 
tumour growth in vivo, the mechanism whereby LPS enhanced tumour growth was 
investigated. A number of cell types, both host and tumour derived are involved in 
tumour progression. Thus, the effect of LPS on macrophages, endothelial cells and 
tumour cells was investigated. LPS increased macrophage VEGF expression at both 
the mRNA and protein levels. However, higher levels o f VEGF protein were induced 
in murine tumour cells following treatment with LPS. This would suggest that the 
majority of circulating VEGF found in tumour bearing mice following surgery or 
endotoxin injection is most probably derived from the tumour metastases. This is 
supported by the fact that serum VEGF was highest in groups with larger tumour bulk. 
However, whether increased VEGF is responsible for the increase in tumour bulk, or 
simply a consequence of it, remains to be determined. As increased proliferation and 
decreased apoptosis was observed in the metastases of mice following open surgery or 
endotoxin injection, the direct effect o f LPS on proliferation and apoptosis o f tumour 
and endothelial cells was examined. LPS increased proliferation o f both murine and 
human mammary adenocarcinoma cells as well as HUVECs. This effect was not 
observed when cells were grown in the absence of FCS, indicating that a serum factor, 
probably LBP was required for LPS binding and activation o f the cells. Future work 
could focus on the mechanisms regulating proliferation in response to LPS. As 
endotoxin induces the secretion of a large number of cytokines from a variety o f cell 
types, it would be o f interest to examine whether any o f these factors could be 
responsible for the increased proliferation observed in these experiments. TNF-a is one 
of the most potent factors secreted in response to the stimulation of cells with LPS, and 
has been implicated as an angiogenic factor in-vivo. However, TNF-a was not 
responsible for the increased proliferation of tumour cells observed in response to LPS,
and was in fact, cytotoxic to the cells at doses above 100 ng/ml. As it is likely that the 
effects o f LPS are mediated through its binding to its cell surface receptor, it would be 
interesting to investigate the effect o f using anti-CD 14 antibodies to block the 
biological effects of LPS. In a similar manner, examination of the downstream 
activation o f different protein kinases or signalling molecules in response to LPS could 
provide more information into the mechanism whereby LPS induces VEGF production 
and proliferation in cells.
Endotoxin has been reported to be angiogenic in a number o f systems. 
However, the mechanism has not been elucidated. In an in vivo matrigel model of 
angiogenesis, LPS was directly angiogenic, inducing endothelial cell infiltration at 
both the edge and centre o f the gel, as well as the formation o f blood vessels at the gel 
core. Further investigations could prove useful in determining whether LPS is 
angiogenic through the stimulation of other cytokines, using gels impregnated with a 
variety o f factors elicited in response to LPS. However, the evidence presented in this 
thesis suggests that the angiogenic effect o f LPS observed in the matrigel model is a 
direct effect.
Tumour dormancy is a major clinical concern in cancer patients. Dormant 
metastases provide a constant risk o f recurrence throughout a patient’s life-time. 
Interestingly the growth of metastasis following the removal o f primary tumours has 
been attributed to alterations in apoptosis levels in tumours and not in their 
proliferation. As VEGF has been shown to be a survival factor for endothelial cells, 
and decreased apoptosis was observed in the metastases o f mice with elevated serum 
VEGF, the effects of VEGF and LPS on tumour cell apoptosis were examined in-vitro. 
VEGF and LPS were found to increase the expression o f the anti-apoptotic protein bcl- 
2 in both the murine and human breast cancer cell lines examined. Furthermore, anti-
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VEGF antibodies were capable o f blocking LPS-induced bcl-2 expression, indicating 
that the induction of bcl-2 was via a VEGF mechanism. This is similar to the situation 
reported in endothelial cells, where VEGF is a survival factor by inducing bcl-2. Since 
VEGF and LPS were shown to induce bcl-2, the effect o f these treatments on tumour 
cell apoptosis was investigated. Either LPS or VEGF resulted in a decrease in tumour 
cell apoptosis, and again anti-VEGF antibodies blocked LPS-mediated inhibition in 
apoptosis. These experiments suggest that VEGF is not solely an angiogenic factor, but 
perhaps more importantly is also a survival factor for tumour cells through the 
upregulation o f bcl-2. Therefore, it implies that VEGF may make tumour cells resistant 
to chemotherapy and radiotherapy, and that blocking VEGF in combination with 
chemotherapy may prove useful in the treatment o f cancer.
Collectively, this thesis has examined the role o f endotoxin in many aspects of 
metastatic disease. It has shown that LPS regulates VEGF production by a number of 
cell types, and is directly angiogenic in vivo. It highlights a serious issue with regard to 
tumour recurrence following surgery, and provides direct evidence that LPS is at least 
partly responsible for this effect. Furthermore, a potentially promising therapeutic 
approach for the limitation o f post-operative metastatic disease was investigated. 
Further study is required to examine the mechanisms involved in these LPS-mediated 
effects and the long-term usefulness o f anti-endotoxin therapy, with the ultimate goal 
o f producing more therapeutic agents that may inhibit tumour growth.
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Appendix I - Representative Standard curves
VEGF (pg/ml)
Representative standard curve from ELISA used for human VEGF measurements in 
conditioned medium. Regression coefficient, r*= 0.997.
232
1.4
570 nm
VEGF (pg/nil)
Representative standard curve from ELISA used for murine VEGF measurements in 
conditioned medium. Regression coefficient, r2^  0.999.
233
Protein (ug/ml)
Representative standard curve from BCA assay used for protein measurements in 
conditioned medium and cell lysates. Regression coefficient, r  = 0.997.
234
1.6 T
0.2
0 .
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LPS (EU/nil)
0.25 0.3
Representative standard curve from LAL assay used for endotoxin measurements in 
murine plasma samples. Regression coefficient, rz= 0.993.
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